{
    "questions": [
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17264330"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17264330",
                    "offsetInBeginSection": 410,
                    "offsetInEndSection": 564,
                    "text": "Concomitant treatments included atropine for cholinergic symptoms, loperamide for diarrhea at the first liquid stool, and preventive antiemetic treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17264330",
                    "offsetInBeginSection": 1001,
                    "offsetInEndSection": 1202,
                    "text": "The most common grade 3/4 toxicities were neutropenia (46%), abdominal pain or cramping (17%), cholinergic syndrome (14%), nausea/vomiting (11%), anemia (11%), thrombocytopenia (9%), and diarrhea (6%).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are the indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan?",
            "type": "list",
            "id": "662fc44b187cba990d000015",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26040720",
                "http://www.ncbi.nlm.nih.gov/pubmed/31930741",
                "http://www.ncbi.nlm.nih.gov/pubmed/37273064",
                "http://www.ncbi.nlm.nih.gov/pubmed/29233873",
                "http://www.ncbi.nlm.nih.gov/pubmed/35253652",
                "http://www.ncbi.nlm.nih.gov/pubmed/37043189",
                "http://www.ncbi.nlm.nih.gov/pubmed/35795666",
                "http://www.ncbi.nlm.nih.gov/pubmed/30559329",
                "http://www.ncbi.nlm.nih.gov/pubmed/35436985",
                "http://www.ncbi.nlm.nih.gov/pubmed/37794057"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26040720",
                    "offsetInBeginSection": 416,
                    "offsetInEndSection": 613,
                    "text": "Here we show that members of the FAM134 reticulon protein family are ER-resident receptors that bind to autophagy modifiers LC3 and GABARAP, and facilitate ER degradation by autophagy ('ER-phagy').",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26040720",
                    "offsetInBeginSection": 614,
                    "offsetInEndSection": 777,
                    "text": "Downregulation of FAM134B protein in human cells causes an expansion of the ER, while FAM134B overexpression results in ER fragmentation and lysosomal degradation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26040720",
                    "offsetInBeginSection": 1079,
                    "offsetInEndSection": 1236,
                    "text": "Therefore, selective ER-phagy via FAM134 proteins is indispensable for mammalian cell homeostasis and controls ER morphology and turnover in mice and humans.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31930741",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 106,
                    "text": "Degradation of endoplasmic reticulum (ER) by selective autophagy (ER-phagy) is crucial for ER homeostasis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31930741",
                    "offsetInBeginSection": 235,
                    "offsetInEndSection": 465,
                    "text": "Here, we show that oligomerization of ER-phagy receptor FAM134B (also referred to as reticulophagy regulator 1 or RETREG1) through its reticulon-homology domain is required for membrane fragmentation in vitro and ER-phagy in vivo.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37273064",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 159,
                    "text": "Family with sequence similarity 134, member B (FAM134B), also known as Reticulophagy regulator 1 (RETREG1), is an ER-phagy receptor involved in ER homeostasis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29233873",
                    "offsetInBeginSection": 682,
                    "offsetInEndSection": 901,
                    "text": "We will focus on the recently discovered selective autophagy pathway for ER, ER-phagy, with particular emphasis on the structure and function of known mammalian ER-phagy receptors, namely FAM134B, SEC62, RTN3 and CCPG1.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35253652",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 152,
                    "text": "ER-phagy is a selective endoplasmic reticulum (ER) autophagy mediated by ER-localized receptors, which ensures proper cellular homeostasis under stress.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35253652",
                    "offsetInBeginSection": 1086,
                    "offsetInEndSection": 1210,
                    "text": "During this process, the ER-phagy receptor FAM134B anchors and fragments ER, and then binds with LC3 to form autophagosomes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37043189",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 178,
                    "text": "Macroautophagy (autophagy) utilizes a serial of receptors to specifically recognize and degrade autophagy cargoes, including damaged organelles, to maintain cellular homeostasis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the function of FAM134B (also called JK-1, RETREG1)?",
            "type": "summary",
            "id": "662cf81b187cba990d000001",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16473618",
                "http://www.ncbi.nlm.nih.gov/pubmed/1385396",
                "http://www.ncbi.nlm.nih.gov/pubmed/9286278",
                "http://www.ncbi.nlm.nih.gov/pubmed/10579793",
                "http://www.ncbi.nlm.nih.gov/pubmed/16899552",
                "http://www.ncbi.nlm.nih.gov/pubmed/7659087",
                "http://www.ncbi.nlm.nih.gov/pubmed/7536744",
                "http://www.ncbi.nlm.nih.gov/pubmed/1321717",
                "http://www.ncbi.nlm.nih.gov/pubmed/10711702",
                "http://www.ncbi.nlm.nih.gov/pubmed/8199204"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16473618",
                    "offsetInBeginSection": 416,
                    "offsetInEndSection": 886,
                    "text": "We used two methods to characterize the direct binding between Rab5 in various nucleotide-bound states and the p85 protein. In the first assay, the ability of p85 to bind to Rab5 is measured using an enzyme-linked immunosorbent assay (ELISA). The second assay is a glutathione S-transferase (GST) pull-down approach in which GST-Rab5 proteins in various nucleotide-bound states are allowed to bind p85. In both instances, bound p85 is detected using anti-p85 antibodies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1385396",
                    "offsetInBeginSection": 988,
                    "offsetInEndSection": 1261,
                    "text": "Immunoprecipitation with anti-p85 antibodies and phosphotyrosine immunoblotting revealed no tyrosine phosphorylation of PI 3-kinase, but demonstrated co-precipitation of tyrosine-phosphorylated IRS-1, as well as another phosphotyrosine protein of approximately 135-140 kDa.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9286278",
                    "offsetInBeginSection": 806,
                    "offsetInEndSection": 1039,
                    "text": "Immunoblot analysis showed the presence of 85 and 110 kDa proteins in ROS. PI 3-kinase immunoprecipitated by anti-p85 antibody converted PI to PI-3-P and PI-4-P to PI-3,4-P2, as determined by HPLC analysis of the deacylated products.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10579793",
                    "offsetInBeginSection": 274,
                    "offsetInEndSection": 516,
                    "text": "Tyrosine phosphorylation of p85, the regulatory subunit of PI-3 kinase, in the human prostate cancer cell lines LNCaP and PC-3 was assessed by sequential immunoprecipitation with anti-p85 antibody and immunoblotting with anti-phosphotyrosine.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16899552",
                    "offsetInBeginSection": 636,
                    "offsetInEndSection": 759,
                    "text": "Cell lysates were immunoprecipitated with p85 antibody and blotted with either phosphotyrosine or phosphoserine antibodies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7659087",
                    "offsetInBeginSection": 350,
                    "offsetInEndSection": 506,
                    "text": "In intact cells, insulin increased tyrosine phosphorylation of both the IR and IRS-1. Both of these proteins were immunoprecipitated with antibodies to p85.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7536744",
                    "offsetInBeginSection": 994,
                    "offsetInEndSection": 1252,
                    "text": "The tyrosine-phosphorylated c-Kit was co-immunoprecipitated with anti-MATK and anti-p85 antibodies in KL/SCF-stimulated CMK cells, but not in granulocyte-macrophage colony stimulating factor or interleukin-6-stimulated cells, suggesting receptor specificity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1321717",
                    "offsetInBeginSection": 396,
                    "offsetInEndSection": 712,
                    "text": "To analyze possible interactions of the enzyme with cellular proteins, immunoprecipitations with the following antibodies were performed: (a) anti-phosphotyrosine antibodies, (b) two antibodies to the 85-kDa subunit of PtdIns-3-kinase (p85) and (c) an antibody to the 185-kDa major insulin receptor substrate (p185).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10711702",
                    "offsetInBeginSection": 405,
                    "offsetInEndSection": 566,
                    "text": "PI-3K activity in capsule-epithelium and fiber cell layers was determined after immunoprecipitation with antibodies against p85, the regulatory subunit of PI-3K.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8199204",
                    "offsetInBeginSection": 1260,
                    "offsetInEndSection": 1858,
                    "text": "To examine the involvement of PtdIns 3-kinase, which is believed to play an important role in 3-phosphorylated phosphoinositide synthesis, we studied tyrosine phosphorylation and the association with tyrosine-phosphorylated proteins of the p85 alpha subunit of PtdIns 3-kinase in thrombin-stimulated platelets. We did not detect tyrosine-phosphorylated protein by Western blotting where p85 alpha was located. Similarly, when platelet lysates were precipitated with anti-p85 alpha antibodies and then blotted with anti-phosphotyrosine antibodies, tyrosine-phosphorylated p85 alpha was undetectable.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the use of P85-Ab?",
            "type": "summary",
            "id": "65cfae831930410b13000015",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/33773923",
                "http://www.ncbi.nlm.nih.gov/pubmed/30913173"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33773923",
                    "offsetInBeginSection": 363,
                    "offsetInEndSection": 508,
                    "text": "Vaccines safe to be administered to all pregnant ladies are tetanus toxoid (TT; tetanus, diphtheria, acellular pertussis (Tdap) and Flu vaccines.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30913173",
                    "offsetInBeginSection": 812,
                    "offsetInEndSection": 979,
                    "text": "Influenza and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines are routinely recommended for all pregnant women in the United States.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30913173",
                    "offsetInBeginSection": 474,
                    "offsetInEndSection": 652,
                    "text": "In general, inactivated vaccines are considered safe for pregnant women and their fetuses, whereas live vaccines are avoided owing to the theoretical potential risk to the fetus.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30913173",
                    "offsetInBeginSection": 980,
                    "offsetInEndSection": 1234,
                    "text": "Seasonal inactivated influenza vaccine is recommended for all pregnant women in any trimester of pregnancy, mainly to protect the mother, but there is growing evidence that infants benefit from passive antibody protection against influenza complications.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33773923",
                    "offsetInBeginSection": 747,
                    "offsetInEndSection": 869,
                    "text": "Flu vaccine can be given to all mothers at any gestation, and if not offered during pregnancy, it can be given postpartum.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30913173",
                    "offsetInBeginSection": 1235,
                    "offsetInEndSection": 1458,
                    "text": "The Tdap vaccine is recommended during the third trimester of each pregnancy to provide optimal protection to infants who are at particularly high risk of pertussis complications and mortality in the first 3 months of life.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33773923",
                    "offsetInBeginSection": 659,
                    "offsetInEndSection": 746,
                    "text": "All pregnant mothers should receive TT and Tdap vaccination during the third trimester.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Which vaccines are safe to be administered for all pregnancies?",
            "type": "list",
            "id": "66300f53187cba990d00001d",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36920778",
                "http://www.ncbi.nlm.nih.gov/pubmed/37897645",
                "http://www.ncbi.nlm.nih.gov/pubmed/32101256",
                "http://www.ncbi.nlm.nih.gov/pubmed/36630140",
                "http://www.ncbi.nlm.nih.gov/pubmed/33350863",
                "http://www.ncbi.nlm.nih.gov/pubmed/36994947",
                "http://www.ncbi.nlm.nih.gov/pubmed/37195407",
                "http://www.ncbi.nlm.nih.gov/pubmed/29353026",
                "http://www.ncbi.nlm.nih.gov/pubmed/37318750"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36920778",
                    "offsetInBeginSection": 2043,
                    "offsetInEndSection": 2212,
                    "text": "In the induction period of two phase 3 trials, 16 weeks of treatment with lebrikizumab was effective in adolescents and adults with moderate-to-severe atopic dermatitis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36920778",
                    "offsetInBeginSection": 375,
                    "offsetInEndSection": 710,
                    "text": "Eligible patients with moderate-to-severe atopic dermatitis (adults [18 years of age] and adolescents [12 to <18 years of age, weighing 40 kg]) were randomly assigned in a 2:1 ratio to receive either lebrikizumab at a dose of 250 mg (loading dose of 500 mg at baseline and week 2) or placebo, administered subcutaneously every 2 weeks.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37897645",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "text": "Lebrikizumab and dupilumab are monoclonal antibodies approved for treating moderate-to-severe atopic dermatitis (AD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32101256",
                    "offsetInBeginSection": 2769,
                    "offsetInEndSection": 2989,
                    "text": "During 16 weeks of treatment, lebrikizumab provided rapid, dose-dependent efficacy across a broad range of clinical manifestations in adult patients with moderate to severe AD and demonstrated a favorable safety profile.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36630140",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 262,
                    "text": "Lebrikizumab (LEB), a high-affinity monoclonal antibody targeting interleukin (IL)-13, demonstrated efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD) during 16 weeks of monotherapy in a phase 2b trial, and two 52-week phase 3 trials.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33350863",
                    "offsetInBeginSection": 614,
                    "offsetInEndSection": 1004,
                    "text": "A placebo-controlled phase 2b clinical trial evaluating the efficacy and safety of lebrikizumab, an IL-13 inhibitor, in AD demonstrated that, at 16 weeks, Eczema Area and Severity Index (EASI) 75 and Investigator's Global Assessment (IGA) 0/1 were achieved by 60.6% and 44.6% of patients taking lebrikizumab at its highest dose (vs 24.3% and 15.3% of patients taking placebo, respectively).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36994947",
                    "offsetInBeginSection": 106,
                    "offsetInEndSection": 332,
                    "text": "To evaluate the efficacy and safety of lebrikizumab monotherapy in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD) over 52 weeks of treatment in ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37195407",
                    "offsetInBeginSection": 160,
                    "offsetInEndSection": 299,
                    "text": "To report integrated safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis from phase 2 and 3 studies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29353026",
                    "offsetInBeginSection": 126,
                    "offsetInEndSection": 268,
                    "text": "We investigated the efficacy and safety of lebrikizumab, an IL-13 monoclonal antibody, as an add-on to topical corticosteroid (TCS) treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37195407",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 159,
                    "text": "Lebrikizumab is a monoclonal antibody that binds with high affinity to interleukin (IL)-13, thereby blocking the downstream effects of IL-13 with high potency.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the use of lebrikizumab?",
            "type": "factoid",
            "id": "65d36e761930410b13000044",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23199955",
                "http://www.ncbi.nlm.nih.gov/pubmed/29037457",
                "http://www.ncbi.nlm.nih.gov/pubmed/25964524",
                "http://www.ncbi.nlm.nih.gov/pubmed/20307840",
                "http://www.ncbi.nlm.nih.gov/pubmed/27672265",
                "http://www.ncbi.nlm.nih.gov/pubmed/34661888",
                "http://www.ncbi.nlm.nih.gov/pubmed/22021967",
                "http://www.ncbi.nlm.nih.gov/pubmed/21616117",
                "http://www.ncbi.nlm.nih.gov/pubmed/18847554",
                "http://www.ncbi.nlm.nih.gov/pubmed/25455637"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23199955",
                    "offsetInBeginSection": 473,
                    "offsetInEndSection": 660,
                    "text": "HPV infection has been identified as a definite human carcinogen for six types of cancer: cervix, penis, vulva, vagina, anus and oropharynx (including the base of the tongue and tonsils).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29037457",
                    "offsetInBeginSection": 129,
                    "offsetInEndSection": 310,
                    "text": "High-risk HPV types are not only responsible for virtually all cervical cancer cases but also for a fraction of cancers of the vulva, vagina, penis, anus, and head and neck cancers.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25964524",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "text": "Human papillomavirus (HPV) is associated with cancer of the cervix uteri, penis, vulva, vagina, anus and oropharynx.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20307840",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 185,
                    "text": "Human papillomavirus (HPV) infection is a necessary cause of cervical cancer, and is etiologically associated with a subset of cancers of the anus, oropharynx, penis, vagina, and vulva.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27672265",
                    "offsetInBeginSection": 400,
                    "offsetInEndSection": 640,
                    "text": "The International Agency for Research on Cancer has found that the following cancer sites have a strong causal relationship with HPV: cervix uteri, penis, vulva, vagina, anus and oropharynx, including the base of the tongue and the tonsils.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34661888",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 157,
                    "text": "Human Papillomavirus (HPV) is the causative agent in the majority of anal, head and neck, oral, oropharyngeal, penile, vaginal, vulvar, and cervical cancers.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34661888",
                    "offsetInBeginSection": 230,
                    "offsetInEndSection": 403,
                    "text": "Of all diagnosed human malignant neoplasms, approximately 4.5% are attributable to HPV, including cervical, anal cancers, vaginal, vulvar, penile, and oropharyngeal cancers.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22021967",
                    "offsetInBeginSection": 418,
                    "offsetInEndSection": 567,
                    "text": "HPV infection is considered to contribute to almost 100% cervical cancers and at least 80% of anal and 40-60% of vulvar, vaginal, and penile cancers.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20307840",
                    "offsetInBeginSection": 186,
                    "offsetInEndSection": 402,
                    "text": "Current data indicate that HPV infection is potentially associated with 90%-93% of anal cancers, 12%-63% of oropharyngeal cancers, 36%-40% of penile cancers, 40%-64% of vaginal cancers, and 40%-51% of vulvar cancers.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21616117",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 269,
                    "text": "Human papillomavirus (HPV) infection is associated with a range of diseases and cancers at different anatomical sites. In addition to its role as a necessary cause of cervical cancer, HPV is also associated with cancers of the vulva, vagina, anus, penis, head and neck.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What cancers are associated with human papilloma virus?",
            "type": "list",
            "id": "661688cefdcbea915f000053",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12789289",
                "http://www.ncbi.nlm.nih.gov/pubmed/18443366",
                "http://www.ncbi.nlm.nih.gov/pubmed/10721491",
                "http://www.ncbi.nlm.nih.gov/pubmed/9632718",
                "http://www.ncbi.nlm.nih.gov/pubmed/9810513",
                "http://www.ncbi.nlm.nih.gov/pubmed/31772149",
                "http://www.ncbi.nlm.nih.gov/pubmed/30768589",
                "http://www.ncbi.nlm.nih.gov/pubmed/19671168",
                "http://www.ncbi.nlm.nih.gov/pubmed/29610526",
                "http://www.ncbi.nlm.nih.gov/pubmed/37083077"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12789289",
                    "offsetInBeginSection": 320,
                    "offsetInEndSection": 483,
                    "text": "For instance, the transcription factor AP-2 plays a tumor suppressor-like role in melanoma progression by regulating genes involved in tumor growth and metastasis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12789289",
                    "offsetInBeginSection": 484,
                    "offsetInEndSection": 690,
                    "text": "Previously, we have shown that the progression of human melanoma to the metastatic phenotype is associated with loss of AP-2 expression and deregulation of target genes such as MUC18/MCAM, c-KIT, and MMP-2.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12789289",
                    "offsetInBeginSection": 1509,
                    "offsetInEndSection": 1757,
                    "text": "We propose that loss of AP-2 results in increased expression of the thrombin receptor, which subsequently contributes to the metastatic phenotype of melanoma by upregulating the expression of adhesion molecules, proteases, and angiogenic molecules.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18443366",
                    "offsetInBeginSection": 462,
                    "offsetInEndSection": 647,
                    "text": "Down-modulation of AP-2 expression in tumor cells by RNA interference (RNAi) led to enhanced tumor growth and reduced chemotherapy-induced cell death, as well as migration and invasion.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721491",
                    "offsetInBeginSection": 828,
                    "offsetInEndSection": 1104,
                    "text": "Since AP-2 also regulates other genes that are involved in the progression of human melanoma such as E-cadherin, MMP-2, p21WAF-1, HER-2, BCL-2, and insulin like growth factor receptor-1, we propose that loss of AP-2 is a crucial event in the development of malignant melanoma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9632718",
                    "offsetInBeginSection": 447,
                    "offsetInEndSection": 599,
                    "text": "Here we show that up-regulation of MCAM/MUC18 expression in highly metastatic cells correlates with loss of expression of the transcription factor AP-2.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9632718",
                    "offsetInBeginSection": 1231,
                    "offsetInEndSection": 1474,
                    "text": "These results indicate that the expression of MCAM/MUC18 is regulated by AP-2 and that enforced AP-2 expression suppresses tumorigenicity and metastatic potential of human melanoma cells, possibly by down-regulating MCAM/MUC18 gene expression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9632718",
                    "offsetInBeginSection": 1475,
                    "offsetInEndSection": 1707,
                    "text": "Since AP-2 also regulates other genes that are involved in the progression of human melanoma such as c-KIT, E-cadherin, MMP-2, and p21(WAF-1), we propose that loss of AP-2 is a crucial event in the development of malignant melanoma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9810513",
                    "offsetInBeginSection": 1251,
                    "offsetInEndSection": 1395,
                    "text": "We found that both genes, c-KIT and MCAM, are regulated by the transcription factor AP-2 and that metastatic melanoma cells do not express AP-2.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9810513",
                    "offsetInBeginSection": 1396,
                    "offsetInEndSection": 1497,
                    "text": "We therefore propose that loss of AP-2 might be a crucial event in the progression of human melanoma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the role of the transcription factor activator protein 2 (AP-2) alpha (TFAP2A) in tumor formation and metastasis?",
            "type": "summary",
            "id": "662fdb1e187cba990d000019",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35258723",
                "http://www.ncbi.nlm.nih.gov/pubmed/37698547",
                "http://www.ncbi.nlm.nih.gov/pubmed/25552807",
                "http://www.ncbi.nlm.nih.gov/pubmed/36169798",
                "http://www.ncbi.nlm.nih.gov/pubmed/16079934",
                "http://www.ncbi.nlm.nih.gov/pubmed/10971876",
                "http://www.ncbi.nlm.nih.gov/pubmed/16344620",
                "http://www.ncbi.nlm.nih.gov/pubmed/37901234",
                "http://www.ncbi.nlm.nih.gov/pubmed/29433114",
                "http://www.ncbi.nlm.nih.gov/pubmed/37916482"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35258723",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 157,
                    "text": "Cryoglobulinemic vasculitis (CV) is a rare immune complex disease of small vessels (capillaries, venules or arterioles) with detection of cryoglobulins (CG).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37698547",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 145,
                    "text": "Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is a systemic vasculitis that affects small blood vessels.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25552807",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 168,
                    "text": "Cryoglobulinemic vasculitis is a small vessel vasculitis that has been associated with chronic infections and autoimmune, lymphoproliferative, and neoplastic disorders.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36169798",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 224,
                    "text": "Cryoglobulinemic vasculitis (CV) or mixed cryoglobulinemic syndrome (MCS) is a systemic small-vessel vasculitis characterized by the proliferation of B-cell clones producing pathogenic immune complexes, called cryoglobulins.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16079934",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 107,
                    "text": "Cryoglobulinemic vasculitis is an immune complex-mediated vasculitis predominantly affecting small vessels.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10971876",
                    "offsetInBeginSection": 1108,
                    "offsetInEndSection": 1234,
                    "text": "main distinctions of cryoglobulinemic vasculitis are immune deposits consisting of cryoglobulins in the wall of small vessels.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16344620",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 115,
                    "text": "Cryoglobulinemic vasculitis is an immune-complex-mediated systemic vasculitis involving small-medium-sized vessels.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37901234",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "Cryoglobulinemic vasculitis is a type of small vessel vasculitis diseases that can cause dysfunction in multiple organs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29433114",
                    "offsetInBeginSection": 106,
                    "offsetInEndSection": 203,
                    "text": "HCV-induced cryoglobulinemic vasculitis primarily affects small-sized vessels of systemic organs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37916482",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "text": "Cryoglobulinemic vasculitis (CV) is an immune complex mediated small vessel vasculitis characterized by the presence of cryoglobulins in serum",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "is Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), a systemic vasculitis that affects large blood vessels.",
            "type": "yesno",
            "id": "662cf888187cba990d000002",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19048626",
                "http://www.ncbi.nlm.nih.gov/pubmed/23182509",
                "http://www.ncbi.nlm.nih.gov/pubmed/19261464",
                "http://www.ncbi.nlm.nih.gov/pubmed/20369905",
                "http://www.ncbi.nlm.nih.gov/pubmed/17156139",
                "http://www.ncbi.nlm.nih.gov/pubmed/20664028",
                "http://www.ncbi.nlm.nih.gov/pubmed/27194458",
                "http://www.ncbi.nlm.nih.gov/pubmed/30659991",
                "http://www.ncbi.nlm.nih.gov/pubmed/18612821",
                "http://www.ncbi.nlm.nih.gov/pubmed/29927637"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19048626",
                    "offsetInBeginSection": 977,
                    "offsetInEndSection": 1289,
                    "text": "For CTC to gain similar life-years as colonoscopy screening every 10 years, it should be offered every 5 years with referral of polyps >or=6 mm. For this strategy to be as cost-effective as colonoscopy screening, the costs must not exceed $285 or 43% of colonoscopy costs (range in sensitivity analysis: 39-47%).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23182509",
                    "offsetInBeginSection": 444,
                    "offsetInEndSection": 565,
                    "text": "CTC needs to achieve a higher attendance rate or cost less than colonoscopy to be cost-effective relative to colonoscopy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19261464",
                    "offsetInBeginSection": 537,
                    "offsetInEndSection": 916,
                    "text": "The incremental cost-effectiveness ratios of colonoscopy and CT-colonography versus no screening remained under 20,000 euro and 30,000 euro per life year gained, respectively. Although, both screening modalities were cost-effective according to most international thresholds, in most of the economic evaluations colonoscopy seemed more cost-effective than colonography screening.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20369905",
                    "offsetInBeginSection": 1036,
                    "offsetInEndSection": 1323,
                    "text": "CTC remained cost effective under a range of assumptions in the univariate sensitivity analysis. However, in the probabilistic sensitivity analysis, CTC dominated FOBT in only 5.9% of simulations and was cost effective at a threshold of pound30,000 per QALY gained in 48% of simulations.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17156139",
                    "offsetInBeginSection": 1278,
                    "offsetInEndSection": 1485,
                    "text": "CT colonography can be reasonably cost-effective when the diagnostic accuracy of CT colonography is high, as with primary 3-dimensional technology, and if costs are about 60% of those of optical colonoscopy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20664028",
                    "offsetInBeginSection": 2209,
                    "offsetInEndSection": 2476,
                    "text": "CTC could be a cost-effective option for colorectal cancer screening among Medicare enrollees if the reimbursement rate per scan is substantially less than that for colonoscopy or if a large proportion of otherwise unscreened persons were to undergo screening by CTC.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27194458",
                    "offsetInBeginSection": 1464,
                    "offsetInEndSection": 1678,
                    "text": "CTC and MRC have potential for CRC screening, compared with no screening and compared with three rounds of 10-yearly colonoscopy screening. When taking FIT screening as the reference, imaging is not cost-effective.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30659991",
                    "offsetInBeginSection": 1745,
                    "offsetInEndSection": 1907,
                    "text": "In an updated review, we found that common CRC screening strategies and computed tomographic colonography continued to be cost effective compared to no screening.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17156139",
                    "offsetInBeginSection": 325,
                    "offsetInEndSection": 416,
                    "text": "CT colonography every 5 or 10 yr was effective and cost-effective relative to no screening.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23182509",
                    "offsetInBeginSection": 303,
                    "offsetInEndSection": 443,
                    "text": "CTC is cost-effective compared with no screening, indicating that it represents an attractive test noncompliance with the available options.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is CT colonography a cost-effective test for colorectal cancer screening?",
            "type": "yesno",
            "id": "662fc981187cba990d000018",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26362532",
                "http://www.ncbi.nlm.nih.gov/pubmed/23153306",
                "http://www.ncbi.nlm.nih.gov/pubmed/23927571",
                "http://www.ncbi.nlm.nih.gov/pubmed/25275652",
                "http://www.ncbi.nlm.nih.gov/pubmed/28840803",
                "http://www.ncbi.nlm.nih.gov/pubmed/21943222",
                "http://www.ncbi.nlm.nih.gov/pubmed/25658839",
                "http://www.ncbi.nlm.nih.gov/pubmed/11791969",
                "http://www.ncbi.nlm.nih.gov/pubmed/20477964",
                "http://www.ncbi.nlm.nih.gov/pubmed/16598178"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26362532",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 106,
                    "text": "Japanese encephalitis virus (JEV) isolates from India phylogenetically belong to two genotypes, III and I.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23153306",
                    "offsetInBeginSection": 1104,
                    "offsetInEndSection": 1268,
                    "text": "Phylogenetic analysis based on complete envelope gene sequences of 13 isolates showed the emergence of JEV genotype I (GI), co-circulating with genotype III (GIII).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23927571",
                    "offsetInBeginSection": 1194,
                    "offsetInEndSection": 1341,
                    "text": "Phylogenetic analysis based on complete E gene sequences of JEV isolates showed the co-circulation of JEV genotype I (GI) with genotype III (GIII).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25275652",
                    "offsetInBeginSection": 928,
                    "offsetInEndSection": 1251,
                    "text": "A phylogenetic analysis of the JEV envelope gene sequences isolated from the captured mosquitoes demonstrated that the predominant JEV genotype has shifted from genotype III to genotype I (GI), providing evidence for transmission cycle maintenance and multiple introductions of the GI strains in Taiwan during 2008 to 2012.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28840803",
                    "offsetInBeginSection": 1149,
                    "offsetInEndSection": 1402,
                    "text": "Phylogenetic analyses revealed that JEV detected in Cambodia belonged to genotype I and clustered in two clades: genotype I-a, mainly comprising strains from Thailand, and genotype I-b, comprising strains from Vietnam that dispersed northwards to China.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21943222",
                    "offsetInBeginSection": 485,
                    "offsetInEndSection": 768,
                    "text": "Two regions of the JEV genome were sequenced from 19 pools; the envelope gene and the nonstructural protein 5 (NS5)/3'-untranslated region (UTR). Eighteen pools of Culex tritaeniorhynchus and one pool of Cx. bitaeniorhynchus were positive for genotype I and genotype V, respectively.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25658839",
                    "offsetInBeginSection": 913,
                    "offsetInEndSection": 1149,
                    "text": "A total of six JEV-positive pools were detected from Culex orientalis and Culex pipiens caught in the Gangwon-do and Gyeonngi-do provinces. All the detected JEVs were revealed as genotype V by phylogenetic analysis of the envelope gene.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11791969",
                    "offsetInBeginSection": 475,
                    "offsetInEndSection": 865,
                    "text": "Nucleotide sequencing and phylogenetic analyses of the premembrane and envelope genes were performed which showed that both the pig and mosquito JE virus isolates (TS00 and TS4152, respectively) clustered in genotype I, along with northern Thai, Cambodian, and Korean isolates. All previous Australasian JE virus isolates belong to genotype II, along with Malaysian and Indonesian isolates.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20477964",
                    "offsetInBeginSection": 849,
                    "offsetInEndSection": 953,
                    "text": "Phylogenetic analysis of the E sequence of isolated strain classified it within genotype III of the JEV.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16598178",
                    "offsetInBeginSection": 318,
                    "offsetInEndSection": 425,
                    "text": "The isolated JEV was classified into genotype I by nucleotide sequence analysis of the viral envelope gene.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are the genotypes of Japanese Encephalitis Virus (JEV)?",
            "type": "list",
            "id": "662e29f9187cba990d00000a",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28370966",
                "http://www.ncbi.nlm.nih.gov/pubmed/29080429",
                "http://www.ncbi.nlm.nih.gov/pubmed/30384472",
                "http://www.ncbi.nlm.nih.gov/pubmed/32830420",
                "http://www.ncbi.nlm.nih.gov/pubmed/27690200",
                "http://www.ncbi.nlm.nih.gov/pubmed/30191558",
                "http://www.ncbi.nlm.nih.gov/pubmed/29127595",
                "http://www.ncbi.nlm.nih.gov/pubmed/29476066",
                "http://www.ncbi.nlm.nih.gov/pubmed/27960197",
                "http://www.ncbi.nlm.nih.gov/pubmed/37549143"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28370966",
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 396,
                    "text": "One of the main concerns about ZIKV exposure during pregnancy is abnormal brain development, which results in microcephaly in newborns.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29080429",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 217,
                    "text": "The 2015 Zika virus (ZIKV) epidemic in the Americas led to the discovery that ZIKV causes congenital abnormalities including microcephaly, intrauterine growth restriction, and eye disease that can result in blindness.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30384472",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 216,
                    "text": "Zika virus (ZIKV) emerged suddenly in the Americas in 2015 and was associated with a widespread outbreak of microcephaly and other severe congenital abnormalities in infants born to mothers infected during pregnancy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32830420",
                    "offsetInBeginSection": 220,
                    "offsetInEndSection": 357,
                    "text": "Zika virus spread rapidly throughout the Americas, and in 2016 was identified as a cause of microcephaly and other serious birth defects.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32830420",
                    "offsetInBeginSection": 581,
                    "offsetInEndSection": 796,
                    "text": "Although postnatal Zika virus infection typically causes mild or no symptoms, effects on infants born to prenatally infected mothers can be severe and include structural birth defects and neurodevelopmental effects.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32830420",
                    "offsetInBeginSection": 797,
                    "offsetInEndSection": 1070,
                    "text": "The risk of a structural birth defect among infants born to mothers with confirmed or suspected Zika virus infection during pregnancy has ranged from 5 to 10%. The timing of Zika infection during pregnancy affects risk, with higher risks with the first-trimester infection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690200",
                    "offsetInBeginSection": 220,
                    "offsetInEndSection": 569,
                    "text": "The link with brain defect, which has been detected mainly in some areas of Brazil, is supported by the following evidence: (1) ZIKV transmission from infected pregnant women to their fetuses; (2) the potential of ZIKV to determine a specific congenital fetal syndrome characterized by abnormalities involving primarily the developing brain and eye.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690200",
                    "offsetInBeginSection": 721,
                    "offsetInEndSection": 881,
                    "text": "Among brain defects, microcephaly, brain calcifications, and ventriculomegaly are the most frequent abnormalities of the central nervous system detected so far.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30191558",
                    "offsetInBeginSection": 792,
                    "offsetInEndSection": 892,
                    "text": "The effects of ZIKV infection during pregnancy are potentially devastating to the fetus and newborn.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29127595",
                    "offsetInBeginSection": 340,
                    "offsetInEndSection": 561,
                    "text": "Zika virus, an arbovirus, is a new TORCH member that leads to congenital infection through vertical transmission and harms the developing brain, disrupting synaptogenesis, and causing other central nervous system lesions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Consequences for the newborn of infection by Zika virus during pregnancy.",
            "type": "list",
            "id": "66155e7dfdcbea915f00004c",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [],
            "snippets": [],
            "body": "What medication were tested in the TRICOTEL trial?",
            "type": "list",
            "id": "65d373151930410b13000048",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23645448",
                "http://www.ncbi.nlm.nih.gov/pubmed/33014208",
                "http://www.ncbi.nlm.nih.gov/pubmed/34591282",
                "http://www.ncbi.nlm.nih.gov/pubmed/21073634",
                "http://www.ncbi.nlm.nih.gov/pubmed/29477912",
                "http://www.ncbi.nlm.nih.gov/pubmed/29491579",
                "http://www.ncbi.nlm.nih.gov/pubmed/23710764",
                "http://www.ncbi.nlm.nih.gov/pubmed/24450414",
                "http://www.ncbi.nlm.nih.gov/pubmed/30650279",
                "http://www.ncbi.nlm.nih.gov/pubmed/26559497"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23645448",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 285,
                    "text": "Development of drug resistance after standard chemotherapy for glioblastoma multiforme (GBM) with temozolomide (TMZ) is associated with poor prognosis of GBM patients and is at least partially mediated by a direct DNA repair pathway involving O6-methylguanine methyltransferase (MGMT).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23645448",
                    "offsetInBeginSection": 775,
                    "offsetInEndSection": 1076,
                    "text": "We also tested for an effect of treatment on MGMT expression and important upstream regulators of the latter, including nuclear factor kappa B (NFB), p44/42 mitogen-activated protein kinase (MAPK), p53, signal transducer and activator of transcription 3 (STAT3) and hypoxia-inducible factor 1 (HIF-1).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23645448",
                    "offsetInBeginSection": 1223,
                    "offsetInEndSection": 1452,
                    "text": "Maximal efficacy was associated with downregulation of MGMT, reduced IB-mediated proteasome-dependent nuclear accumulation of NFB, attenuation of p44/42 MAPK, AKT and STAT3 activation, and stabilization of p53 and inactive HIF-1.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33014208",
                    "offsetInBeginSection": 322,
                    "offsetInEndSection": 737,
                    "text": "This high severity is dependent on a cytokine storm, most likely induced by the interleukin-6 (IL-6) amplifier, which is hyper-activation machinery that regulates the nuclear factor kappa B (NF-B) pathway and stimulated by the simultaneous activation of IL-6-signal transducer and activator of transcription 3 (STAT3) and NF-B signaling in non-immune cells including alveolar epithelial cells and endothelial cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34591282",
                    "offsetInBeginSection": 664,
                    "offsetInEndSection": 887,
                    "text": "Glioblastoma cells stimulated by IL-1 induced the production of IL-6 and CXCL8, which synergistically promoted glioblastoma growth via signal transducer and activator of transcription-3 and nuclear factor-kappa B signaling.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21073634",
                    "offsetInBeginSection": 639,
                    "offsetInEndSection": 897,
                    "text": "Furthermore, corosolic acid inhibited the proliferation of glioblastoma cells, U373 and T98G, and the activation of signal transducer and activator of transcription-3 (STAT3) and nuclear factor-kappa B (NF-B) in both human macrophages and glioblastoma cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29477912",
                    "offsetInBeginSection": 290,
                    "offsetInEndSection": 414,
                    "text": "It inhibited the activation of nuclear factor kappa B (NF-B) and signal transducer and activator of transcription 3 (STAT3).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29491579",
                    "offsetInBeginSection": 686,
                    "offsetInEndSection": 857,
                    "text": "Two important transcription factors implicated in chronic inflammatory diseases are nuclear factor kappa B (NF-B) and signal transducers and activators of transcription 3.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23710764",
                    "offsetInBeginSection": 190,
                    "offsetInEndSection": 493,
                    "text": "It has been well documented that the deregulated activation of the archetypal pro-inflammatory and oncogenic transcription factors nuclear factor-kappa B (NF-B) and signal transducer and activator of transcription (STAT)3 is a common feature of GI cancers that invariably correlates with poor prognosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24450414",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 194,
                    "text": "Constitutive activation of the signal transducer and activator of transcription 3 (STAT3) or the nuclear factor-B (NF-B) pathway occurs frequently in cancer cells and contributes to oncogenesis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Which are the key transcription factors known to drive glioma progression and therapy resistance?",
            "type": "list",
            "id": "66302090187cba990d00002a",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23560833",
                "http://www.ncbi.nlm.nih.gov/pubmed/24821824",
                "http://www.ncbi.nlm.nih.gov/pubmed/31195212",
                "http://www.ncbi.nlm.nih.gov/pubmed/24623990",
                "http://www.ncbi.nlm.nih.gov/pubmed/26045027",
                "http://www.ncbi.nlm.nih.gov/pubmed/23610528",
                "http://www.ncbi.nlm.nih.gov/pubmed/24980770",
                "http://www.ncbi.nlm.nih.gov/pubmed/26327919",
                "http://www.ncbi.nlm.nih.gov/pubmed/30323618",
                "http://www.ncbi.nlm.nih.gov/pubmed/34522132"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23560833",
                    "offsetInBeginSection": 539,
                    "offsetInEndSection": 698,
                    "text": "Common side effects include asthenia/tiredness, loss of appetite, hand-foot skin syndrome, diarrhea, mucositis, weight loss, infections, hypertension and rash.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24821824",
                    "offsetInBeginSection": 839,
                    "offsetInEndSection": 1150,
                    "text": "The most common adverse events of regorafenib include dermatologic and mucosal toxicities (especially hand-foot skin reaction, rash, and oral mucositis), constitutional symptoms (e.g., fatigue, nausea, and weight loss), vascular effects (especially hypertension), and gastrointestinal symptoms (e.g., diarrhea).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31195212",
                    "offsetInBeginSection": 471,
                    "offsetInEndSection": 646,
                    "text": "Fatigue, diarrhoea, hand-foot skin reaction, nausea, vomiting, decreased appetite, hypertension and weight loss are among the most common AEs experienced with these four TKIs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24623990",
                    "offsetInBeginSection": 1079,
                    "offsetInEndSection": 1382,
                    "text": "In this review, we highlight regorafenib's mechanism of action, present key efficacy data from the CORRECT trial, and discuss how to proactively manage common adverse events (eg, hand-foot skin reaction, hypertension, oral mucositis, diarrhea, and fatigue) experienced by patients receiving regorafenib.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26045027",
                    "offsetInBeginSection": 558,
                    "offsetInEndSection": 802,
                    "text": "Commonly reported adverse events specifically associated with regorafenib include hand-foot skin reaction and hypertension, whereas others such as fatigue, diarrhea, and liver dysfunction may occur during both targeted and cytotoxic treatments.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23610528",
                    "offsetInBeginSection": 778,
                    "offsetInEndSection": 943,
                    "text": "The most frequent adverse events of grade 3 or higher related to regorafenib were hand-foot skin reaction, fatigue, diarrhea, hypertension, and rash or desquamation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24980770",
                    "offsetInBeginSection": 244,
                    "offsetInEndSection": 362,
                    "text": "The most common drug-related adverse events with regorafenib are hypertension, hand-foot skin reactions, and diarrhea.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26327919",
                    "offsetInBeginSection": 837,
                    "offsetInEndSection": 967,
                    "text": "The most common grade 3-4 adverse reactions with the drug are hand foot skin reactions (HFSR), diarrhea, hypertension and fatigue.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30323618",
                    "offsetInBeginSection": 1180,
                    "offsetInEndSection": 1365,
                    "text": "Results showed that hand-foot skin reaction (HFSR; 54%), diarrhea (33%), fatigue (32%), hypertension (31%), oral mucositis (28%), and anorexia (23%) were the most frequent clinical AEs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34522132",
                    "offsetInBeginSection": 1062,
                    "offsetInEndSection": 1221,
                    "text": "Additionally, the most frequent adverse reactions during regorafenib treatment were hand-foot syndrome (HFS; 52.1%), hypertension (38.5%), and fatigue (33.3%).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are the most frequent side effects of regorafenib?",
            "type": "list",
            "id": "66214ff0b9f8b89d7e000006",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37861890"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37861890",
                    "offsetInBeginSection": 272,
                    "offsetInEndSection": 538,
                    "text": "Although the association of intellectual disability with the dystrophinopathies Duchenne (DMD) and Becker muscular dystrophy (BMD) has been long established, their association with ASD is more recent, and the dystrophin genotype-ASD phenotype correlation is unclear.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37861890",
                    "offsetInBeginSection": 1272,
                    "offsetInEndSection": 1543,
                    "text": "Whole exome sequencing in these ASD-DMD/BMD individuals together with the literature suggest, although based on preliminary data, a complex and heterogeneous genetic architecture underlying ASD in dystrophinopathies, that include rare variants of large and medium effect.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is there an association between specific genotypes and the risk of ASD for Duchenne Muscular Dystrophy?",
            "type": "yesno",
            "id": "6630211d187cba990d00002d",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24247042",
                "http://www.ncbi.nlm.nih.gov/pubmed/28398635",
                "http://www.ncbi.nlm.nih.gov/pubmed/27751727",
                "http://www.ncbi.nlm.nih.gov/pubmed/26344077",
                "http://www.ncbi.nlm.nih.gov/pubmed/32489361",
                "http://www.ncbi.nlm.nih.gov/pubmed/27054127",
                "http://www.ncbi.nlm.nih.gov/pubmed/27178891",
                "http://www.ncbi.nlm.nih.gov/pubmed/28219384",
                "http://www.ncbi.nlm.nih.gov/pubmed/27725167",
                "http://www.ncbi.nlm.nih.gov/pubmed/28929787"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247042",
                    "offsetInBeginSection": 356,
                    "offsetInEndSection": 628,
                    "text": "Periostin is an extracellular matrix protein that is induced by interleukin (IL)-4 and IL-13 in airway epithelial cells and lung fibroblasts. It has proven to be an important biomarker of TH2-associated airway inflammation and a potential predictor of airway eosinophilia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28398635",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 111,
                    "text": "Periostin has been suggested as a novel, phenotype-specific biomarker for asthma driven by type 2 inflammation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27751727",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 218,
                    "text": "Periostin is being investigated as a potential biomarker for T-helper-2 (Th2)-driven asthma or eosinophilic inflammation and may help to identify patients more likely to benefit from interleukin-13-targeted treatments.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26344077",
                    "offsetInBeginSection": 660,
                    "offsetInEndSection": 885,
                    "text": "Thereafter, it was shown that periostin can be a surrogate biomarker of type 2 immune responses, the basis of the notion that a detection system of serum periostin is potentially a companion diagnostic for type 2 antagonists.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26344077",
                    "offsetInBeginSection": 1096,
                    "offsetInEndSection": 1296,
                    "text": "Thus, serum periostin has two characteristics as a biomarker for bronchial asthma: it is both a surrogate biomarker of type 2 immune responses and a biomarker reflecting tissue remodeling or fibrosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32489361",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "text": "The serum periostin level is a promising biomarker of type 2- high inflammation pattern of bronchial asthma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27054127",
                    "offsetInBeginSection": 141,
                    "offsetInEndSection": 228,
                    "text": "Serum periostin is a biomarker which aid in understanding Th2 high eosinophilic asthma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27178891",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "text": "Periostin may be a useful biomarker of T-helper type 2 eosinophilic airway inflammation and has been linked to remodeling in asthma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28219384",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "text": "Periostin is a biomarker indicating the presence of type 2 inflammation and submucosal fibrosis; serum periostin levels have been associated with asthma severity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27725167",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 206,
                    "text": "The multifunctional cytokine IL-13 is thought to play a central role in Type 2 inflammation in asthma. Serum periostin has been explored as a candidate biomarker for evaluating IL-13 activity in the airway.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is Periostin a novel biomarker of TH2-driven asthma?",
            "type": "yesno",
            "id": "662cf8db187cba990d000003",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/10416987",
                "http://www.ncbi.nlm.nih.gov/pubmed/8548755",
                "http://www.ncbi.nlm.nih.gov/pubmed/18381405",
                "http://www.ncbi.nlm.nih.gov/pubmed/12005388",
                "http://www.ncbi.nlm.nih.gov/pubmed/11563632",
                "http://www.ncbi.nlm.nih.gov/pubmed/9690672",
                "http://www.ncbi.nlm.nih.gov/pubmed/7887443",
                "http://www.ncbi.nlm.nih.gov/pubmed/9499454",
                "http://www.ncbi.nlm.nih.gov/pubmed/12215292",
                "http://www.ncbi.nlm.nih.gov/pubmed/11355148"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10416987",
                    "offsetInBeginSection": 153,
                    "offsetInEndSection": 420,
                    "text": "Nine cell lines (26.4%) harbored mutations or deletions in all four tumor suppressor genes and 22 cell lines (64%) had alterations in at least three. Mutations/deletions were found at the following frequencies: TP53 (76.5%), p14ARF (64.7%), p16 (64.7%), PTEN (73.5%).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10416987",
                    "offsetInBeginSection": 421,
                    "offsetInEndSection": 674,
                    "text": "Thus, there was a high incidence of alterations in the cellular pathways involving the p53 transcription factor (94.1%), the retinoblastoma protein (64.7%) and the PTEN phosphatase (73.5%) and 91% of cell lines carried mutations in two or more pathways.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8548755",
                    "offsetInBeginSection": 1532,
                    "offsetInEndSection": 1807,
                    "text": "These data indicate that the vast majority of GBMs probably have inactivation of the p16-cdk4/cyclin D1-pRb pathway. The findings also provide corroborative evidence that CDKN2/p16 and RB are the critical glioma tumor suppressor genes on chromosomes 9p and 13q, respectively.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8548755",
                    "offsetInBeginSection": 1235,
                    "offsetInEndSection": 1413,
                    "text": "Thirty-six of 42 GBMs (86%) had alterations of either CDKN2/p16 (n = 22), RB (n = 10), or both (n = 4); these two genetic changes, however, were relatively exclusive (P = 0.003).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18381405",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 374,
                    "text": "Genomic alterations leading to aberrant activation of cyclin/cyclin-dependent kinase (cdk) complexes drive the pathogenesis of many common human tumor types. In the case of glioblastoma multiforme (GBM), these alterations are most commonly due to homozygous deletion of p16(INK4a) and less commonly due to genomic amplifications of individual genes encoding cyclins or cdks.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12005388",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 156,
                    "text": "One of the most frequent genetic abnormalities found in patients with glioblastoma multiforme (GBM) is homozygous deletion of the p16 tumor suppressor gene.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11563632",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "text": "Thirty-four to fifty-six percent of malignant gliomas harbor homozygous co-deletions of the INK4a(p16-p14ARF) and INK4b(p15) tumor suppressor genes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11563632",
                    "offsetInBeginSection": 840,
                    "offsetInEndSection": 987,
                    "text": "Loss of p15 protein expression was almost always accompanied by loss of p16 expression. p1 6/p15-negative tumors commonly lacked p14ARF expression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9690672",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 303,
                    "text": "Loss of heterozygosity (LOH) on chromosome 10 is the most frequent genetic alteration associated with the evolution of malignant astrocytic tumors and it may involve several loci. The tumor suppressor gene PTEN (MMAC1) on chromosome 10q23 is mutated in approximately 30% of glioblastomas (WHO Grade IV).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9690672",
                    "offsetInBeginSection": 545,
                    "offsetInEndSection": 821,
                    "text": "Nine of 28 (32%) primary glioblastomas contained a PTEN mutation and an additional case showed a homozygous PTEN deletion. This indicates that after overexpression/amplification of the EGF receptor, loss of PTEN function is the most common alteration in primary glioblastomas.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What tumor suppressor genes are commonly affected by glioblastoma mutations or deletions?",
            "type": "list",
            "id": "663020de187cba990d00002c",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20028915",
                "http://www.ncbi.nlm.nih.gov/pubmed/16525235",
                "http://www.ncbi.nlm.nih.gov/pubmed/36779459",
                "http://www.ncbi.nlm.nih.gov/pubmed/28246899"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20028915",
                    "offsetInBeginSection": 647,
                    "offsetInEndSection": 900,
                    "text": "The most sensitive scanogram findings were absence of rectal gas (19 of 21 cases, 90%) and an inverted-U-shaped distended sigmoid (18 of 21 cases, 86%) followed by the coffee bean sign and disproportionate sigmoid enlargement (both 16 of 21 cases, 76%).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16525235",
                    "offsetInBeginSection": 980,
                    "offsetInEndSection": 1191,
                    "text": "The classical coffee-bean sign was identified in nine out of 26 initial plain abdominal radiographs done at the emergency department and a further 11 were diagnosed after review by the surgical team in the ward.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36779459",
                    "offsetInBeginSection": 396,
                    "offsetInEndSection": 441,
                    "text": "Coffee bean sign was seen in abdominal x-ray.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28246899",
                    "offsetInBeginSection": 1101,
                    "offsetInEndSection": 1203,
                    "text": "The specific finding of a coffee-bean sign was retrospectively observed only by reader 2 in two cases.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28246899",
                    "offsetInBeginSection": 929,
                    "offsetInEndSection": 1020,
                    "text": "The most common presentation was abdominal distension (14/19 [74%]) and pain (11/19 [58%]).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16525235",
                    "offsetInBeginSection": 1387,
                    "offsetInEndSection": 1479,
                    "text": "As our aged population continues to grow, sigmoid volvulus may be more commonly encountered.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28246899",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 77,
                    "text": "Colonic volvulus is rare in children and associated with colonic dysmotility.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Coffee Bean Sign is characteristic to which disease?",
            "type": "factoid",
            "id": "65d144b81930410b13000041",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18024641",
                "http://www.ncbi.nlm.nih.gov/pubmed/31619404",
                "http://www.ncbi.nlm.nih.gov/pubmed/18052871",
                "http://www.ncbi.nlm.nih.gov/pubmed/21885920",
                "http://www.ncbi.nlm.nih.gov/pubmed/32072172",
                "http://www.ncbi.nlm.nih.gov/pubmed/28724958",
                "http://www.ncbi.nlm.nih.gov/pubmed/8627013",
                "http://www.ncbi.nlm.nih.gov/pubmed/28298901",
                "http://www.ncbi.nlm.nih.gov/pubmed/24731550",
                "http://www.ncbi.nlm.nih.gov/pubmed/25364378"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18024641",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 374,
                    "text": "Burkitt lymphoma (BL), a tumor occurring in endemic, sporadic and AIDS-associated forms, is the classic example of a human malignancy whose pathogenesis involves a specific cellular genetic change, namely, a chromosomal translocation deregulating expression of the c-myc oncogene, complemented in many cases by the action of an oncogenic virus, the Epstein-Barr virus (EBV).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31619404",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 216,
                    "text": "The discovery of Epstein-Barr virus (EBV) in Burkitt lymphoma tumors represented the first link between a virus and cancer in humans, but the underlying role of this virus in endemic Burkitt lymphoma remains unclear.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18052871",
                    "offsetInBeginSection": 501,
                    "offsetInEndSection": 662,
                    "text": "BL affects mainly children, and boys are more susceptible than girls. Evidence for a causal relationship between EBV and BL in the endemic form is fairly strong.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18052871",
                    "offsetInBeginSection": 781,
                    "offsetInEndSection": 894,
                    "text": "EBV may play a role in the pathogenesis of BL by deregulation of the oncogene c-MYC by chromosomal translocation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21885920",
                    "offsetInBeginSection": 458,
                    "offsetInEndSection": 699,
                    "text": "One suggests that P. falciparum malaria induces polyclonal B-cell expansion and lytic EBV reactivation, leading to the expansion of latently infected B cells and the likelihood of a c-myc translocation, a hallmark of Burkitt lymphoma tumors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21885920",
                    "offsetInBeginSection": 700,
                    "offsetInEndSection": 904,
                    "text": "The other advocates that EBV-specific T-cell immunity is impaired during P. falciparum malaria co-infection, either as a cause or consequence of enhanced EBV replication, leading to loss of viral control.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32072172",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "text": "Endemic Burkitt lymphoma (eBL) is associated with Epstein-Barr virus (EBV) and Plasmodium falciparum malaria coinfections.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21885920",
                    "offsetInBeginSection": 1045,
                    "offsetInEndSection": 1294,
                    "text": "EBV is necessary but not sufficient to cause eBL. A more dynamic model encompasses incremental contributions from both chronic and acute P. falciparum malaria leading to alterations in EBV persistence and EBV-specific immunity that culminate in eBL.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28724958",
                    "offsetInBeginSection": 284,
                    "offsetInEndSection": 572,
                    "text": "Recent studies have highlighted a genetic difference between endemic (EBV+) and sporadic (EBV-) BL, with the endemic variant showing a lower somatic mutation load, which suggests the involvement of an alternative virally-driven process of transformation in the pathogenesis of endemic BL.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28724958",
                    "offsetInBeginSection": 1149,
                    "offsetInEndSection": 1271,
                    "text": "In summary this study provides evidence that EBV may contribute to the pathogenesis of BL through an epigenetic mechanism.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Burkitt lymphoma and Epstein-Barr virus.",
            "type": "summary",
            "id": "66168a89fdcbea915f000054",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/32471101",
                "http://www.ncbi.nlm.nih.gov/pubmed/17949481",
                "http://www.ncbi.nlm.nih.gov/pubmed/9510330",
                "http://www.ncbi.nlm.nih.gov/pubmed/26172425",
                "http://www.ncbi.nlm.nih.gov/pubmed/25652405",
                "http://www.ncbi.nlm.nih.gov/pubmed/36646204",
                "http://www.ncbi.nlm.nih.gov/pubmed/36409584",
                "http://www.ncbi.nlm.nih.gov/pubmed/15265870",
                "http://www.ncbi.nlm.nih.gov/pubmed/10917598",
                "http://www.ncbi.nlm.nih.gov/pubmed/31512554"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32471101",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 206,
                    "text": "tRNA nucleotidyl transferase 1 (TRNT1) is an essential enzyme catalyzing the addition of terminal cytosine-cytosine-adenosine (CCA) trinucleotides to all mature tRNAs, which is necessary for aminoacylation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17949481",
                    "offsetInBeginSection": 384,
                    "offsetInEndSection": 493,
                    "text": "tRNA nucleotidyltransferase that synthesizes the 3'-terminal sequence C-C-A to all tRNAs (CCA-adding enzyme).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9510330",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "text": "The CCA-adding enzyme [ATP(CTP):tRNA nucleotidyltransferase] catalyzes the addition and regeneration of the 3'-terminal CCA sequence of tRNAs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26172425",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 114,
                    "text": "tRNA nucleotidyltransferase adds the invariant CCA-terminus to the tRNA 3'-end, a central step in tRNA maturation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25652405",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 254,
                    "text": "Addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs) is essential for translation and is catalyzed by the enzyme TRNT1 (tRNA nucleotidyl transferase), which functions in both the cytoplasm and mitochondria.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36646204",
                    "offsetInBeginSection": 100,
                    "offsetInEndSection": 256,
                    "text": "The CCA enzyme, also known as tRNA nucleotidyltransferase, catalyzes the addition or repair of CCA at the 3'-terminus of tRNAs to facilitate aminoacylation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36409584",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 105,
                    "text": "In tRNA maturation, CCA-addition by tRNA nucleotidyltransferase is a unique and highly accurate reaction.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26172425",
                    "offsetInBeginSection": 115,
                    "offsetInEndSection": 245,
                    "text": "This CCA-adding enzyme is a specialized RNA polymerase that synthesizes the CCA sequence at high fidelity in all kingdoms of life.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15265870",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 115,
                    "text": "The CCA-adding enzyme ATP(CTP):tRNA nucleotidyltransferase builds and repairs the 3'-terminal CCA sequence of tRNA.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10917598",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "text": "The tRNA 3' end contains the conserved CCA sequence at the 74-76 positions. The CCA sequence is synthesized and maintained by the CCA-adding enzymes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What process does tRNA nucleotidyl transferase 1 (TRNT1)  catalyze?",
            "type": "factoid",
            "id": "662cfc88187cba990d000008",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/38084924",
                "http://www.ncbi.nlm.nih.gov/pubmed/27932455"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38084924",
                    "offsetInBeginSection": 827,
                    "offsetInEndSection": 1038,
                    "text": "Furthermore, contrary to intra-TAD interactions, the formation of inter-TAD enhancer-promoter interactions is not solely driven by genomic distance, with distal interactions sometimes favored over proximal ones.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27932455",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 179,
                    "text": "Enhancers are intergenic DNA elements that regulate the transcription of target genes in response to signaling pathways by interacting with promoters over large genomic distances.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38084924",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 219,
                    "text": "Topologically Associating Domains (TADs) have been suggested to facilitate and constrain enhancer-promoter interactions. However, the role of TAD boundaries in effectively restricting these interactions remains unclear.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38084924",
                    "offsetInBeginSection": 220,
                    "offsetInEndSection": 453,
                    "text": "Here, we show that a significant proportion of enhancer-promoter interactions are established across TAD boundaries in Drosophila embryos, but that developmental genes are strikingly enriched in intra- but not inter-TAD interactions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Can enhancer-promoter interactions form independently of genomic distance?",
            "type": "yesno",
            "id": "662edc6f187cba990d00000c",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37256972",
                "http://www.ncbi.nlm.nih.gov/pubmed/37433216"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37256972",
                    "offsetInBeginSection": 350,
                    "offsetInEndSection": 520,
                    "text": "Genomic sequencing independently identified three heterozygous variants in a specific region of the gene that encodes signal transducer and activator of transcription 4 (",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37256972",
                    "offsetInBeginSection": 521,
                    "offsetInEndSection": 610,
                    "text": "Genome sequencing revealed three novel heterozygous missense gain-of-function variants in",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37256972",
                    "offsetInBeginSection": 612,
                    "offsetInEndSection": 640,
                    "text": "Gain-of-function variants in",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Mutation of which gene was implicated in Disabling pansclerotic morphea?",
            "type": "factoid",
            "id": "65cfdf1c1930410b13000028",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21773731",
                "http://www.ncbi.nlm.nih.gov/pubmed/35621863",
                "http://www.ncbi.nlm.nih.gov/pubmed/1345107",
                "http://www.ncbi.nlm.nih.gov/pubmed/8241213",
                "http://www.ncbi.nlm.nih.gov/pubmed/25132969",
                "http://www.ncbi.nlm.nih.gov/pubmed/31161081",
                "http://www.ncbi.nlm.nih.gov/pubmed/8312353",
                "http://www.ncbi.nlm.nih.gov/pubmed/8843520",
                "http://www.ncbi.nlm.nih.gov/pubmed/36929301",
                "http://www.ncbi.nlm.nih.gov/pubmed/2659182"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21773731",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 272,
                    "text": "The major diagnoses carried by children undergoing cardiac transplantation worldwide are congenital heart defects, cardiomyopathies, and retransplantation. The leading diagnosis in infancy is congenital heart disease, whereas cardiomyopathy predominates in older children.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35621863",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 430,
                    "text": "Significant surgical and medical advances over the past several decades have resulted in a growing number of infants and children surviving with hypoplastic left heart syndrome (HLHS) and other congenital heart defects associated with a single systemic right ventricle (RV). However, cardiac dysfunction and ultimately heart failure (HF) remain the most common cause of death and indication for transplantation in this population.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1345107",
                    "offsetInBeginSection": 240,
                    "offsetInEndSection": 577,
                    "text": "While dilated cardiomyopathy and isolated myocardial failure represent the main indications for cardiac transplantation, replacement of the lungs or heart and lungs is necessitated in cystic fibrosis, primary and secondary pulmonary hypertension as well as some types of complex congenital heart defects involving the pulmonary arteries.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8241213",
                    "offsetInBeginSection": 474,
                    "offsetInEndSection": 874,
                    "text": "Indications included hypoplastic left heart syndrome (seven patients), cardiomyopathy or myocarditis (seven patients), and postoperative congenital heart disease (10 patients) for heart transplantation; Eisenmenger's syndrome (three patients) for heart-lung transplantation; and primary pulmonary hypertension (two patients), broncho pulmonary dysplasia, and cystic fibrosis for lung transplantation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25132969",
                    "offsetInBeginSection": 245,
                    "offsetInEndSection": 381,
                    "text": "The most common indications for transplantation in children overall are cystic fibrosis (CF) and idiopathic pulmonary hypertension (PH).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25132969",
                    "offsetInBeginSection": 382,
                    "offsetInEndSection": 548,
                    "text": "The surfactant protein deficiencies, other interstitial lung diseases (ILDs), and congenital heart disease are important indications among young children and infants.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31161081",
                    "offsetInBeginSection": 71,
                    "offsetInEndSection": 153,
                    "text": "HF is most frequently related to cardiomyopathy or congenital heart disease (CHD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8312353",
                    "offsetInBeginSection": 313,
                    "offsetInEndSection": 528,
                    "text": "These indications consist of end-stage pulmonary disease, such as cystic fibrosis, or end-stage pulmonary vascular disease that is either primary or associated with correctable or corrected congenital heart disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8843520",
                    "offsetInBeginSection": 267,
                    "offsetInEndSection": 542,
                    "text": "Of all children under the age of 18 years undergoing lung transplantation, cystic fibrosis accounts for approximately 35%, pulmonary vascular disease, with or without associated congenital heart disease, accounts for 25-30%, and interstitial lung diseases comprise about 10%.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36929301",
                    "offsetInBeginSection": 256,
                    "offsetInEndSection": 410,
                    "text": "The main causes of HF are congenital heart defects (CHD), cardiomyopathies, arrhythmias, myocarditis, or heart failure secondary to oncological treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are the causes for heart and lung transplantation in children?",
            "type": "list",
            "id": "6614f810fdcbea915f000043",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30252132",
                "http://www.ncbi.nlm.nih.gov/pubmed/31519572",
                "http://www.ncbi.nlm.nih.gov/pubmed/19663767",
                "http://www.ncbi.nlm.nih.gov/pubmed/17664471",
                "http://www.ncbi.nlm.nih.gov/pubmed/29075780",
                "http://www.ncbi.nlm.nih.gov/pubmed/32533590",
                "http://www.ncbi.nlm.nih.gov/pubmed/24916700",
                "http://www.ncbi.nlm.nih.gov/pubmed/23885463",
                "http://www.ncbi.nlm.nih.gov/pubmed/19276250",
                "http://www.ncbi.nlm.nih.gov/pubmed/25993166"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30252132",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 181,
                    "text": "Expression of the epidermal growth factor ligands amphiregulin (AREG) and epiregulin (EREG) is positively correlated with a response to EGFR-targeted therapies in colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31519572",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "text": "Amphiregulin (AREG) and epiregulin (EREG) mRNA expression levels are predictors of response to anti-EGFR antibody therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19663767",
                    "offsetInBeginSection": 882,
                    "offsetInEndSection": 1085,
                    "text": "New data seem to support the role of BRAF mutational status. In addition, high mRNA levels of the EGFR-ligands Epiregulin and Amphiregulin have been associated with increased responsiveness to cetuximab.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17664471",
                    "offsetInBeginSection": 696,
                    "offsetInEndSection": 921,
                    "text": "Gene expression profiles showed that patients with tumors that express high levels of the EGFR ligands epiregulin and amphiregulin are more likely to have disease control with cetuximab (EREG, P = .000015; AREG, P = .000025).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17664471",
                    "offsetInBeginSection": 1083,
                    "offsetInEndSection": 1422,
                    "text": "Furthermore, patients with tumors that have high expression of EREG or AREG also have significantly longer progression-free survival (PFS) than patients with low expression (EREG: P = .0002, hazard ratio [HR] = 0.47, and median PFS, 103.5 v 57 days, respectively; AREG: P < .0001, HR = 0.44, and median PFS, 115.5 v 57 days, respectively).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17664471",
                    "offsetInBeginSection": 1423,
                    "offsetInEndSection": 1610,
                    "text": "Patients with tumors that have high gene expression levels of epiregulin and amphiregulin and patients with wild-type K-ras are more likely to have disease control on cetuximab treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29075780",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 279,
                    "text": "Epidermal growth factor receptor (EGFR) (HER1) signaling depends on ligand binding and dimerization with itself or other HER receptors. We previously showed in a randomized trial that high EGFR ligand expression is predictive of panitumumab benefit in advanced colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29075780",
                    "offsetInBeginSection": 2368,
                    "offsetInEndSection": 2730,
                    "text": "Combining HER3 and ligand data, patients with HER3-high, AREG/EREG-high tumors gained markedly from panitumumab (PFS HR, 0.24; 95% CI, 0.11-0.51; P < .005 and OS HR, 0.36; 95% CI, 0.18-0.73; P = .004). Conversely, patients with HER3-low, AREG/EREG-low tumors did not benefit (PFS HR, 1.14; 95% CI, 0.73-1.79; P = .57 and OS HR, 1.44; 95% CI, 0.92-2.26; P = .11).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32533590",
                    "offsetInBeginSection": 693,
                    "offsetInEndSection": 911,
                    "text": "Gene ontology data showed the upregulation of genes related to EGFR signaling, and we identified that FGFR4 overexpression secretes EGFR ligands such as amphiregulin (AREG) with consequent activation of EGFR and ErbB3.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24916700",
                    "offsetInBeginSection": 1251,
                    "offsetInEndSection": 1351,
                    "text": "Increased secretion of ligands by resistant cells can sustain EGFR/ERK signaling in sensitive cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What role does epiregulin and amphiregulin play in the use of EGFR inhibitors for colorectal cancer?",
            "type": "summary",
            "id": "662fc351187cba990d000014",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36440509",
                "http://www.ncbi.nlm.nih.gov/pubmed/24265581",
                "http://www.ncbi.nlm.nih.gov/pubmed/35367224",
                "http://www.ncbi.nlm.nih.gov/pubmed/19172427",
                "http://www.ncbi.nlm.nih.gov/pubmed/26562314",
                "http://www.ncbi.nlm.nih.gov/pubmed/18056690",
                "http://www.ncbi.nlm.nih.gov/pubmed/16834926",
                "http://www.ncbi.nlm.nih.gov/pubmed/12754707",
                "http://www.ncbi.nlm.nih.gov/pubmed/31708335",
                "http://www.ncbi.nlm.nih.gov/pubmed/28393671"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36440509",
                    "offsetInBeginSection": 655,
                    "offsetInEndSection": 765,
                    "text": "The prevalence of IDD in BMD was 8.0% (95% confidence interval 5.0-11.0), and in DMD it was 22.0% (18.0-27.0).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36440509",
                    "offsetInBeginSection": 1136,
                    "offsetInEndSection": 1284,
                    "text": "The global prevalence of intellectual developmental disorder (IDD) was 8% in Becker muscular dystrophy and 22% in Duchenne muscular dystrophy (DMD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24265581",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 236,
                    "text": "The presence of variable degrees of non progressive cognitive impairment is recognized as a clinical feature of patients with Duchenne and Becker muscular dystrophies (DMD and BMD), but its pathogenesis still remains a matter of debate.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24265581",
                    "offsetInBeginSection": 1430,
                    "offsetInEndSection": 1771,
                    "text": "According to our statistical results, there was not a significant difference in terms of general intelligence between the allelic forms of the disease, a higher frequency of mental retardation was observed in DMD patients. The patients with BMD had better results on tests, measuring long-term verbal learning memory and executive functions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35367224",
                    "offsetInBeginSection": 449,
                    "offsetInEndSection": 575,
                    "text": "BMD population is characterized by high rates of cognitive impairment, with specific involvement of different cognitive areas.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35367224",
                    "offsetInBeginSection": 624,
                    "offsetInEndSection": 737,
                    "text": "Neurodevelopmental and emotional/behavioral disorders have great importance in BMD, due to their high prevalence.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35367224",
                    "offsetInBeginSection": 886,
                    "offsetInEndSection": 1088,
                    "text": "The results suggest that cognitive and neuropsychiatric comorbid symptoms may affect a significant proportion of BMD patients therefore it is important to mental health and neuropsychological screening.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19172427",
                    "offsetInBeginSection": 177,
                    "offsetInEndSection": 355,
                    "text": "Many patients with Duchenne and Becker muscular dystrophies (D/BMD) have cognitive impairment, learning disability, and an increased incidence of some neuropsychiatric disorders.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35367224",
                    "offsetInBeginSection": 327,
                    "offsetInEndSection": 448,
                    "text": "Studies examining neuropsychological and neurobehavioral functioning in BMD are few and have several methods limitations.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35367224",
                    "offsetInBeginSection": 738,
                    "offsetInEndSection": 885,
                    "text": "Lack of Dp140 or Dp71 can cause intellectual disability, these isoforms are probably responsible for the other brain-related comorbidities as well.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the prevalence of intellectual developmental disorders in Becker Muscular Dystrophy?",
            "type": "factoid",
            "id": "66300d3e187cba990d00001b",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36316327",
                "http://www.ncbi.nlm.nih.gov/pubmed/22026270",
                "http://www.ncbi.nlm.nih.gov/pubmed/34920079",
                "http://www.ncbi.nlm.nih.gov/pubmed/35154132",
                "http://www.ncbi.nlm.nih.gov/pubmed/20604930",
                "http://www.ncbi.nlm.nih.gov/pubmed/19035881",
                "http://www.ncbi.nlm.nih.gov/pubmed/18063918",
                "http://www.ncbi.nlm.nih.gov/pubmed/38036877",
                "http://www.ncbi.nlm.nih.gov/pubmed/7657597",
                "http://www.ncbi.nlm.nih.gov/pubmed/24333430"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36316327",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 206,
                    "text": "Oxysterols are oxygenated derivatives of cholesterol that contain an additional hydroxy, epoxide, or ketone group in the sterol nucleus and/or a hydroxyl group in the side chain of the cholesterol molecule.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22026270",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "text": "Products of oxidizing cholesterol-called oxysterols, are having different physicochemical properties and various from not-modified sterols, biological activity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34920079",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 112,
                    "text": "Oxysterols are a family of over 25 cholesterol metabolites naturally produced by enzymatic or radical oxidation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35154132",
                    "offsetInBeginSection": 249,
                    "offsetInEndSection": 368,
                    "text": "Oxysterols are oxidized forms of cholesterol that regulate cellular cholesterol and alter immune responses to bacteria.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20604930",
                    "offsetInBeginSection": 521,
                    "offsetInEndSection": 671,
                    "text": "Cytochrome P450-enzymes, physiological factors in maintaining cholesterol homeostasis, generate oxysterols for the elimination of surplus cholesterol.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19035881",
                    "offsetInBeginSection": 443,
                    "offsetInEndSection": 816,
                    "text": "Oxysterols are formed in amounts proportional to cholesterol content in the cell and therefore LXR operate as cholesterol sensors which protect from cholesterol overload by inhibiting intestinal cholesterol absorption, stimulating cholesterol efflux from cells to high-density lipoproteins (HDL), its transport to the liver, conversion to bile acids, and biliary excretion.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18063918",
                    "offsetInBeginSection": 437,
                    "offsetInEndSection": 611,
                    "text": "Oxysterols are formed in amounts proportional to cholesterol content in the cell and therefore the LXRs operate as cholesterol sensors which protect from cholesterol overload",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38036877",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 280,
                    "text": "Cholesterol is a key molecule for synaptic transmission, and both central and peripheral synapses are cholesterol rich. During intense neuronal activity, a substantial portion of synaptic cholesterol can be oxidized by either enzymatic or non-enzymatic pathways to form oxysterols",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7657597",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 158,
                    "text": "Cholesterol oxidation products (oxysterols) have been detected in many different tissues, often at concentrations 10(3) to 10(4) times lower than cholesterol.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24333430",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 189,
                    "text": "Liver X receptors LXR (NR1H3) and LXR (NR1H2) are transcription factors belonging to the nuclear receptor superfamily, activated by specific oxysterols, oxidized derivatives of cholesterol.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Oxysterol is produced by the oxidation of what waxy, fat-like substance made in the liver?",
            "type": "factoid",
            "id": "662a4b08b9f8b89d7e00000b",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16822843",
                "http://www.ncbi.nlm.nih.gov/pubmed/36878665",
                "http://www.ncbi.nlm.nih.gov/pubmed/34638290",
                "http://www.ncbi.nlm.nih.gov/pubmed/16822844",
                "http://www.ncbi.nlm.nih.gov/pubmed/19723652",
                "http://www.ncbi.nlm.nih.gov/pubmed/31408415",
                "http://www.ncbi.nlm.nih.gov/pubmed/21464030",
                "http://www.ncbi.nlm.nih.gov/pubmed/37494076",
                "http://www.ncbi.nlm.nih.gov/pubmed/21810512",
                "http://www.ncbi.nlm.nih.gov/pubmed/30964753"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16822843",
                    "offsetInBeginSection": 1435,
                    "offsetInEndSection": 1710,
                    "text": "Beyond surgical resection and postoperative adjuvant chemotherapy for stage III colon cancer, for patients who survive and are recurrence free approximately 6 months after adjuvant chemotherapy, physical activity appears to reduce the risk of cancer recurrence and mortality.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36878665",
                    "offsetInBeginSection": 1593,
                    "offsetInEndSection": 1862,
                    "text": "In this observational study of patients with stage III colon cancer, postoperative physical activity is associated with improved disease-free survival by lowering the recurrence rate within the first year of treatment, which translates into an overall survival benefit.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36878665",
                    "offsetInBeginSection": 1022,
                    "offsetInEndSection": 1244,
                    "text": "The risk of recurrence in physically active patients never exceeded that of physically inactive patients during follow-up, suggesting that physical activity prevents-as opposed to delays-cancer recurrence in some patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16822843",
                    "offsetInBeginSection": 593,
                    "offsetInEndSection": 931,
                    "text": "Compared with patients engaged in less than three metabolic equivalent task (MET) -hours per week of physical activity, the adjusted hazard ratio for disease-free survival was 0.51 (95% CI, 0.26 to 0.97) for 18 to 26.9 MET-hours per week and 0.55 (95% CI, 0.33 to 0.91) for 27 or more MET-hours per week. The adjusted P for trend was .01.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16822843",
                    "offsetInBeginSection": 932,
                    "offsetInEndSection": 1085,
                    "text": "Postdiagnosis activity was associated with similar improvements in recurrence-free survival (P for trend = .03) and overall survival (P for trend = .01).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34638290",
                    "offsetInBeginSection": 538,
                    "offsetInEndSection": 996,
                    "text": "In the surgically treated group, a high level of activity (the weighted sum of the frequencies for walking, moderate, and vigorous activity greater than or equal to 3 times/week) was inversely associated with all-cause mortality (colon cancer: HR, 0.79; 95% CI, 0.72 to 0.88; rectal cancer: HR, 0.75; 95% CI, 0.66 to 0.86) and colorectal cancer-specific mortality (colon cancer: HR, 0.85; 95% CI, 0.76 to 0.97; rectal cancer: HR, 0.77; 95% CI, 0.66 to 0.90).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16822844",
                    "offsetInBeginSection": 550,
                    "offsetInEndSection": 729,
                    "text": "Increasing levels of exercise after diagnosis of nonmetastatic colorectal cancer reduced cancer-specific mortality (P for trend = .008) and overall mortality (P for trend = .003).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16822844",
                    "offsetInBeginSection": 1548,
                    "offsetInEndSection": 1708,
                    "text": "Recreational physical activity after the diagnosis of stages I to III colorectal cancer may reduce the risk of colorectal cancer-specific and overall mortality.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19723652",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "text": "Physical activity in colon cancer survivors has been associated with lower cancer recurrences and improved survival.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31408415",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "text": "Regular physical activity is associated with reduced risk of recurrence and mortality in patients with nonmetastatic colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Does physical exercise reduce the risk of recurrence from colorectal cancer?",
            "type": "yesno",
            "id": "662fc122187cba990d000012",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36963652",
                "http://www.ncbi.nlm.nih.gov/pubmed/28357131",
                "http://www.ncbi.nlm.nih.gov/pubmed/6888414",
                "http://www.ncbi.nlm.nih.gov/pubmed/30692784",
                "http://www.ncbi.nlm.nih.gov/pubmed/2650976",
                "http://www.ncbi.nlm.nih.gov/pubmed/17053635",
                "http://www.ncbi.nlm.nih.gov/pubmed/33346889",
                "http://www.ncbi.nlm.nih.gov/pubmed/20437929",
                "http://www.ncbi.nlm.nih.gov/pubmed/37990809"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36963652",
                    "offsetInBeginSection": 352,
                    "offsetInEndSection": 592,
                    "text": "While there is no current cure for DMD, several treatment options focus on improving the quality of life and slowing progression of symptoms associated with the disease. The current treatment for DMD is glucocorticoids and physical therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28357131",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 87,
                    "text": "Standard treatment of Duchenne muscular dystrophy (DMD) includes regular physiotherapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6888414",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 251,
                    "text": "Physical methods of treatment for neuromuscular diseases constitute the mainstay of current management. The overall goals of management are the maintenance of independent ambulation and the optimal functional state consistent with the disease process.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30692784",
                    "offsetInBeginSection": 282,
                    "offsetInEndSection": 394,
                    "text": "Physiotherapy (PT) is advised for these children as a regular treatment for maintaining their functional status.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6888414",
                    "offsetInBeginSection": 252,
                    "offsetInEndSection": 454,
                    "text": "Maintenance of muscle strength requires regular daily physical activity. An active exercise program can give limited increases of strength in muscular dystrophy dependent on the severity of the disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6888414",
                    "offsetInBeginSection": 707,
                    "offsetInEndSection": 821,
                    "text": "contracture development can be retarded by passive stretching and splinting initiated early in the disease course.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2650976",
                    "offsetInBeginSection": 175,
                    "offsetInEndSection": 367,
                    "text": "DMD must be diagnosed early, not only to enable genetic counseling concerning future pregnancy and screening of female siblings, but also to stage physical therapy to delay muscle contracture.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17053635",
                    "offsetInBeginSection": 272,
                    "offsetInEndSection": 541,
                    "text": "The transition from childhood to adulthood for individuals with Duchenne muscular dystrophy requires a physical therapy care plan that focuses on the use of assistive technology to maintain independence in mobility and to minimize or to facilitate caregiver assistance.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33346889",
                    "offsetInBeginSection": 1044,
                    "offsetInEndSection": 1288,
                    "text": "In the nonambulant group the emphasis was placed on chest physiotherapy, stretching of upper extremities, positioning and wheelchair ergonomics. The program for the ambulant group focused on lower extremities stretching and full body exercises.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2650976",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "text": "Treatment in muscular dystrophy should be prospective and aimed at maintaining maximal function so that the patient can be as independent as possible for as long as possible.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is KineDMD?",
            "type": "summary",
            "id": "663023f3187cba990d000030",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7481384",
                "http://www.ncbi.nlm.nih.gov/pubmed/18558790"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7481384",
                    "offsetInBeginSection": 536,
                    "offsetInEndSection": 783,
                    "text": "The report of exacerbation of myasthenia gravis with other antibiotic belonging to the group of fluoroquinolones (ciprofloxacin, norfloxacin and ofloxacin) prompt us to recommend caution with the use of all fluoroquinolones in myasthenic patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7481384",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 311,
                    "text": "Pefloxacine 800 mg single dose was given as routine treatment after a cystomanometric examination to a 45-year-old woman with a 30-month history of generalized myasthenia gravis. One hour after, the patient developed exacerbation of myasthenia gravis with bilateral ptosis and an increased generalized weakness.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18558790",
                    "offsetInBeginSection": 1755,
                    "offsetInEndSection": 1823,
                    "text": "Telithromycin is contraindicated in patients with myasthenia gravis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Can fluoroquinolones be used for patient with myasthenia gravis?",
            "type": "yesno",
            "id": "65d12a181930410b1300002f",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/10653004",
                "http://www.ncbi.nlm.nih.gov/pubmed/28960585",
                "http://www.ncbi.nlm.nih.gov/pubmed/11596960",
                "http://www.ncbi.nlm.nih.gov/pubmed/9885980",
                "http://www.ncbi.nlm.nih.gov/pubmed/9690672",
                "http://www.ncbi.nlm.nih.gov/pubmed/10604735",
                "http://www.ncbi.nlm.nih.gov/pubmed/9499454",
                "http://www.ncbi.nlm.nih.gov/pubmed/7621407",
                "http://www.ncbi.nlm.nih.gov/pubmed/7687872",
                "http://www.ncbi.nlm.nih.gov/pubmed/1975510"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10653004",
                    "offsetInBeginSection": 439,
                    "offsetInEndSection": 550,
                    "text": "Loss of heterozygosity (LOH) on chromosome 10 (LOH#10) is the most frequent genetic alteration in glioblastomas",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28960585",
                    "offsetInBeginSection": 86,
                    "offsetInEndSection": 253,
                    "text": "Loss of heterozygosity (LOH) at markers of the long arm of chromosome 10 is the most common genetic alteration in glioblastoma, being detectable in up to 80% of cases.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11596960",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 114,
                    "text": "The most frequent genetic abnormality in human malignant gliomas is loss of heterozygosity (LOH) on chromosome 10.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9885980",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 124,
                    "text": "Extensive genomic deletions involving chromosome 10 are the most common genetic alteration in glioblastoma multiforme (GBM).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9690672",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 179,
                    "text": "Loss of heterozygosity (LOH) on chromosome 10 is the most frequent genetic alteration associated with the evolution of malignant astrocytic tumors and it may involve several loci.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10604735",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "Loss of heterozygosity (LOH) for chromosome 10 is the most frequent genetic abnormality observed in high-grade gliomas.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9499454",
                    "offsetInBeginSection": 75,
                    "offsetInEndSection": 258,
                    "text": "Allelic deletions encompassing all or part of chromosome 10q occur frequently in GBMs, indicating that loss of one or more tumor suppressor genes on 10q plays a role in GBM formation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7621407",
                    "offsetInBeginSection": 81,
                    "offsetInEndSection": 320,
                    "text": "The fact that deleted copies of chromosome 10 are observed frequently in primary GBM tumors supports the hypothesis that one or more tumor suppressor genes located on chromosome 10 occupy crucial growth control checkpoints for glial cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7687872",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 230,
                    "text": "Cytogenetic and restriction fragment length polymorphism (RFLP) studies have shown that loss of one entire copy of chromosome 10 is a common genetic event in glioblastoma multiforme, the most malignant glial brain tumor in humans.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1975510",
                    "offsetInBeginSection": 1070,
                    "offsetInEndSection": 1286,
                    "text": "A high-resolution restriction fragment length polymorphism study of chromosome 10 loci in these patients showed that loss of broad regions of chromosome 10 was a common event, particularly in glioblastoma multiforme.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Which chromosome is most commonly affected by loss of heterozygosity in glioblastoma?",
            "type": "factoid",
            "id": "6630154c187cba990d000021",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23074441",
                "http://www.ncbi.nlm.nih.gov/pubmed/23331163",
                "http://www.ncbi.nlm.nih.gov/pubmed/23420959",
                "http://www.ncbi.nlm.nih.gov/pubmed/16782621",
                "http://www.ncbi.nlm.nih.gov/pubmed/15751317",
                "http://www.ncbi.nlm.nih.gov/pubmed/17637083",
                "http://www.ncbi.nlm.nih.gov/pubmed/28282321",
                "http://www.ncbi.nlm.nih.gov/pubmed/10532275",
                "http://www.ncbi.nlm.nih.gov/pubmed/11200414",
                "http://www.ncbi.nlm.nih.gov/pubmed/18043115"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23074441",
                    "offsetInBeginSection": 6646,
                    "offsetInEndSection": 6805,
                    "text": "However, small bowel transplant is still associated with significant mortality and morbidity. The outcomes are inferior to those of total parenteral nutrition.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23074441",
                    "offsetInBeginSection": 6806,
                    "offsetInEndSection": 6918,
                    "text": "Evidence suggests that this procedure should only be used when total parenteral nutrition is no longer feasible.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23331163",
                    "offsetInBeginSection": 1308,
                    "offsetInEndSection": 1386,
                    "text": "Long-term survival remains higher on HPN than with intestinal transplantation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23074441",
                    "offsetInBeginSection": 2000,
                    "offsetInEndSection": 2058,
                    "text": "The experience in small bowel transplant is still limited.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23420959",
                    "offsetInBeginSection": 989,
                    "offsetInEndSection": 1196,
                    "text": "Even, if the results in terms of patient survival have improved over the past 20 years, the 5-year survival rate still does not exceed 50%. Thus, each case should be discussed in a dedicated tertiary center.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23074441",
                    "offsetInBeginSection": 6379,
                    "offsetInEndSection": 6573,
                    "text": "There is evidence that small bowel transplant can prolong the life of some patients with irreversible intestinal failure who can no longer continue to be managed by parenteral nutrition therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16782621",
                    "offsetInBeginSection": 988,
                    "offsetInEndSection": 1285,
                    "text": "Although most of the long-term survivors are TPN-independent and have a good quality of life, the risk of the procedure and long-term adverse effects of immunosuppressive medication limits small bowel, or liver/small bowel transplantation only to patients with severe complications of TPN therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15751317",
                    "offsetInBeginSection": 1036,
                    "offsetInEndSection": 1332,
                    "text": "Although most of the long-term survivors are TPN-independent and have a good quality of life, the risk of the procedure and long-term adverse effects ofimmunosuppressive medication limits small bowel, or liver/small bowel transplantation only to patients with severe complications of TPN therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17637083",
                    "offsetInBeginSection": 1239,
                    "offsetInEndSection": 1401,
                    "text": "Currently, small intestinal transplantation is reserved for patients with irreversible small intestinal failure who have a poor prognosis on parenteral nutrition.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28282321",
                    "offsetInBeginSection": 197,
                    "offsetInEndSection": 502,
                    "text": "Over recent years, ITx has become a more common operation with approximately 2500 procedures carried out worldwide by 2014. It is reserved for patients with intestinal failure and who have developed complications of home parenteral nutrition or who have a high risk of dying from their underlying disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is bowel transplantation commonly performed in patients with severe gastrointestinal disease?",
            "type": "yesno",
            "id": "65f84c78c4010b4d78000049",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/33053208",
                "http://www.ncbi.nlm.nih.gov/pubmed/24410805",
                "http://www.ncbi.nlm.nih.gov/pubmed/32998960",
                "http://www.ncbi.nlm.nih.gov/pubmed/28778566",
                "http://www.ncbi.nlm.nih.gov/pubmed/23058249",
                "http://www.ncbi.nlm.nih.gov/pubmed/32404931",
                "http://www.ncbi.nlm.nih.gov/pubmed/25135958"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33053208",
                    "offsetInBeginSection": 587,
                    "offsetInEndSection": 713,
                    "text": "FHL1 is highly expressed and positively correlated with EGFR levels in human GBM, particularly those of the classical subtype.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24410805",
                    "offsetInBeginSection": 905,
                    "offsetInEndSection": 1187,
                    "text": "The classical subtype, with high EGFR and low p53 expression, was most common in GBMs (39%), followed by the proneural (29%) and mesenchymal (with high CD44 and MERTK expression) (29%) subtypes, a frequency that is in line with previously published data based on molecular genetics.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32998960",
                    "offsetInBeginSection": 740,
                    "offsetInEndSection": 1050,
                    "text": "IHC revealed that the TCGA classical subtype was identified by high expression of EGFR and low expression of PTEN, while the mesenchymal subtype was identified by low expression of SOX2 and high expression of two antibodies, SHC1 and TCIRG1, selected on the basis of RNA differential transcriptomic expression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28778566",
                    "offsetInBeginSection": 233,
                    "offsetInEndSection": 474,
                    "text": "We found that miR-524-3p and miR-524-5p were suppressed in the classical molecular subtype of glioblastoma (GBM) from Chinese Glioma Genome Atlas (CGGA) data, and the suppression was associated with EGFR overexpression and EGFRvIII mutation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28778566",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 152,
                    "text": "The epidermal growth factor receptor (EGFR) frequently undergoes high-level genomic amplification and variant III (vIII) deletion in adult glioblastoma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23058249",
                    "offsetInBeginSection": 971,
                    "offsetInEndSection": 1182,
                    "text": "Our results indicate that granular cell glioblastomas, despite having its peculiar granular cell changes, share common molecular genetic features with conventional glioblastoma, especially the classical subtype.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32404931",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 197,
                    "text": "Glioblastomas (GBM) can be classified into three major transcriptional subgroups (proneural, mesenchymal, classical), underlying different molecular alterations, prognosis, and response to therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33053208",
                    "offsetInBeginSection": 359,
                    "offsetInEndSection": 586,
                    "text": "FHL1 interacts with the transcription factor SP1 to upregulate epidermal growth factor receptor (EGFR) expression and activate the downstream signaling cascades, including Src, Akt, Erk1/2, and Stat3, leading to GBM malignancy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23058249",
                    "offsetInBeginSection": 588,
                    "offsetInEndSection": 881,
                    "text": "Array-based comparative genomic hybridization and focused molecular genetic analyses demonstrated gain of chromosome 7; losses of chromosome 1p, 8p, 9p, 10, 13q, and 22q; amplification of epidermal growth factor receptor; and homozygous deletion of CDKN2A as well as MGMT promoter methylation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25135958",
                    "offsetInBeginSection": 1179,
                    "offsetInEndSection": 1264,
                    "text": "Expression of the ZM fusion was mutually exclusive with EGFR overexpression in sGBMs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Which genetic alteration is most commonly associated with the classical subtype of glioblastoma?",
            "type": "factoid",
            "id": "663016bb187cba990d000023",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29387208",
                "http://www.ncbi.nlm.nih.gov/pubmed/31421281",
                "http://www.ncbi.nlm.nih.gov/pubmed/25746834",
                "http://www.ncbi.nlm.nih.gov/pubmed/30057200",
                "http://www.ncbi.nlm.nih.gov/pubmed/37190069",
                "http://www.ncbi.nlm.nih.gov/pubmed/34571139",
                "http://www.ncbi.nlm.nih.gov/pubmed/26057830",
                "http://www.ncbi.nlm.nih.gov/pubmed/35453621",
                "http://www.ncbi.nlm.nih.gov/pubmed/34417752",
                "http://www.ncbi.nlm.nih.gov/pubmed/26721494"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29387208",
                    "offsetInBeginSection": 176,
                    "offsetInEndSection": 332,
                    "text": "circRNAs are formed with covalently closed continuous loops and are mainly generated by back-splicing processes or lariat introns from exons and/or introns.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31421281",
                    "offsetInBeginSection": 180,
                    "offsetInEndSection": 399,
                    "text": "Whereas in linear splicing a 5' splice site is connected to a downstream 3' splice site, in back-splicing the 5' splice site is connected to an upstream 3' splice site. Both mechanisms use the spliceosome for catalysis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31421281",
                    "offsetInBeginSection": 400,
                    "offsetInEndSection": 714,
                    "text": "For back-splicing to occur, the back-splice sites must frequently be brought into close proximity, which is achieved through the formation of secondary structures in the pre-mRNA. In general, these pre-mRNA structures are formed by RNA base pairing between complementary sequences flanking the back-splicing sites.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25746834",
                    "offsetInBeginSection": 547,
                    "offsetInEndSection": 722,
                    "text": "Recent studies have uncovered that back-splicing requires canonical spliceosomal machinery and can be facilitated by both complementary sequences and specific protein factors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30057200",
                    "offsetInBeginSection": 248,
                    "offsetInEndSection": 405,
                    "text": "Recent studies have shown that their biogenesis requires spliceosomal machinery and can be modulated by both cis complementary sequences and protein factors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37190069",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 327,
                    "text": "Circular RNAs (circRNAs) are a recently discovered class of RNAs derived from protein-coding genes that have important biological and pathological roles. They are formed through backsplicing during co-transcriptional alternative splicing; however, the unified mechanism that accounts for backsplicing decisions remains unclear.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37190069",
                    "offsetInBeginSection": 328,
                    "offsetInEndSection": 567,
                    "text": "Factors that regulate the transcriptional timing and spatial organization of pre-mRNA, including RNAPII kinetics, the availability of splicing factors, and features of gene architecture, have been shown to influence backsplicing decisions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34571139",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 247,
                    "text": "Circular RNA (circRNA) is a group of highly stable RNA molecules with suggested roles in development and disease. They derive from linear pre-mRNAs when a 5'-splice site splices back to an upstream 3'-splice site in a process termed back-splicing.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26057830",
                    "offsetInBeginSection": 526,
                    "offsetInEndSection": 731,
                    "text": "Through systematic splice site mutagenesis and the identification of splicing intermediates, we show that circular RNA in Schizosaccharomyces pombe is generated through an exon-containing lariat precursor.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35453621",
                    "offsetInBeginSection": 205,
                    "offsetInEndSection": 454,
                    "text": "circRNAs are thought to be generated by back-splicing of pre-mRNA transcripts, which can be facilitated by reverse complementary sequences in the flanking introns and trans-acting factors, such as splicing regulatory factors and RNA-binding factors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Circular RNAs (circRNAs) are a distinct family of RNAs, how are they derived?",
            "type": "summary",
            "id": "662cfadc187cba990d000006",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37927998",
                "http://www.ncbi.nlm.nih.gov/pubmed/26599625",
                "http://www.ncbi.nlm.nih.gov/pubmed/33132785",
                "http://www.ncbi.nlm.nih.gov/pubmed/22040245",
                "http://www.ncbi.nlm.nih.gov/pubmed/27708501",
                "http://www.ncbi.nlm.nih.gov/pubmed/28132601",
                "http://www.ncbi.nlm.nih.gov/pubmed/19042905",
                "http://www.ncbi.nlm.nih.gov/pubmed/37404273",
                "http://www.ncbi.nlm.nih.gov/pubmed/11991568",
                "http://www.ncbi.nlm.nih.gov/pubmed/33240348"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37927998",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 380,
                    "text": "Research has found that transgender-related enacted stigma-including discrimination, harassment, violence, cyberbullying, community rejection, and conversion efforts-is associated with negative mental health among transgender people. Transgender people also experience physical health disparities that could be due to chronic gender minority stress caused by stigma and prejudice.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26599625",
                    "offsetInBeginSection": 229,
                    "offsetInEndSection": 463,
                    "text": "This review demonstrates that transgender stigma limits opportunities and access to resources in a number of critical domains (e.g., employment, healthcare), persistently affecting the physical and mental health of transgender people.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26599625",
                    "offsetInBeginSection": 464,
                    "offsetInEndSection": 640,
                    "text": "The applied social ecological model employed here elucidates that transgender stigma operates at multiple levels (i.e., individual, interpersonal, structural) to impact health.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33132785",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "text": "Transgender individuals face heightened risks for discrimination, harassment, and violence that impact their psychosocial well-being and physical health.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22040245",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 262,
                    "text": "Lesbian, gay, bisexual, and transgender (LGBT) persons, while widely diverse in many ways, share health disparities related to the stigma and discrimination they experience, including disproportionate rates of psychiatric disorders, substance abuse, and suicide.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26599625",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 125,
                    "text": "Transgender people in the United States experience widespread prejudice, discrimination, violence, and other forms of stigma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27708501",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 157,
                    "text": "Research suggests that transgender people face high levels of discrimination in society, which may contribute to their disproportionate risk for poor health.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27708501",
                    "offsetInBeginSection": 693,
                    "offsetInEndSection": 889,
                    "text": "The results suggest that gender nonconforming trans people face more discrimination and, in turn, are more likely to engage in health-harming behaviors than trans people who are gender conforming.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27708501",
                    "offsetInBeginSection": 890,
                    "offsetInEndSection": 1019,
                    "text": "Our findings highlight the important role of gender nonconformity in the social experiences and well-being of transgender people.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28132601",
                    "offsetInBeginSection": 382,
                    "offsetInEndSection": 737,
                    "text": "Findings show that respondents face pervasive stigma and violence due to multiple marginalised social identities (transgender status, sex work, gender non-conformity), which reinforce and intersect with social inequities (economic and housing insecurity, employment discrimination, poverty), fuelling HIV vulnerability at the micro, meso and macro levels.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Transgender identity and mortality.",
            "type": "summary",
            "id": "66169f9bfdcbea915f000057",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25973534",
                "http://www.ncbi.nlm.nih.gov/pubmed/27672042",
                "http://www.ncbi.nlm.nih.gov/pubmed/25367198",
                "http://www.ncbi.nlm.nih.gov/pubmed/27914130",
                "http://www.ncbi.nlm.nih.gov/pubmed/33934428",
                "http://www.ncbi.nlm.nih.gov/pubmed/16024606",
                "http://www.ncbi.nlm.nih.gov/pubmed/23549875",
                "http://www.ncbi.nlm.nih.gov/pubmed/35461290",
                "http://www.ncbi.nlm.nih.gov/pubmed/20635392",
                "http://www.ncbi.nlm.nih.gov/pubmed/26172302"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25973534",
                    "offsetInBeginSection": 708,
                    "offsetInEndSection": 939,
                    "text": "Compared with BRAF wild type, BRAF(V600E) was a risk for poor survival (overall survival; 5 years: 62.3% vs 51.6%, P=0.014; HR 1.43, CI 1.07-1.90, P=0.009), especially in rectal cancer (for DSS, HR: 10.60, CI: 3.04-36.92, P<0.001).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27672042",
                    "offsetInBeginSection": 1057,
                    "offsetInEndSection": 1217,
                    "text": "Consistent with other published series, patients with BRAF V600E mutation exhibited a significantly shorter overall survival (hazard ratio = 1.500, P = 0.0432).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25367198",
                    "offsetInBeginSection": 932,
                    "offsetInEndSection": 1128,
                    "text": "BRAF V600E was associated with advanced TNM (P < 0.001), more distant metastases (P = 0.025), and worse overall survival (OS, P < 0.001; multivariate HR = 4.2, P = 0.004) in colon cancer patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914130",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 161,
                    "text": "In patients with colorectal cancer (CRC), the BRAF V600E mutation has been reported to be associated with several clinicopathological features and poor survival.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33934428",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 184,
                    "text": "The BRAF V600E mutation occurs in approximately 10% of patients with metastatic colorectal cancer (CRC) and constitutes a distinct subtype of the disease with extremely poor prognosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16024606",
                    "offsetInBeginSection": 690,
                    "offsetInEndSection": 1105,
                    "text": "The poor survival was observed in a univariate analysis of 5-year survival (16.7% versus 60.0%; P < 0.01); in an analysis adjusted for age, stage, and tumor site [hazard rate ratio (HRR), 2.97; 95% CI, 2.05-4.32]; in stage-specific, age-adjusted analyses for AJCC stages 2 to 4 (HRR, 4.88, 3.60, and 2.04, respectively); and in Kaplan-Meier survival estimates for AJCC stages 2 to 4 (P < 0.01 for all three stages).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16024606",
                    "offsetInBeginSection": 1269,
                    "offsetInEndSection": 1508,
                    "text": "We conclude that the BRAF V600E mutation in microsatellite-stable colon cancer is associated with a significantly poorer survival in stages 2 to 4 colon cancer but has no effect on the excellent prognosis of microsatellite-unstable tumors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23549875",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 93,
                    "text": "BRAF(V600E) mutations are associated with poor clinical prognosis in colorectal cancer (CRC).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35461290",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "text": "BRAF V600E-mutant colorectal cancers (CRCs) are associated with shorter survival than BRAF wild-type tumors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20635392",
                    "offsetInBeginSection": 1066,
                    "offsetInEndSection": 1266,
                    "text": "BRAF(V600E) was associated with inferior overall survival in metastatic CRC (HR = 2.02; 95% CI 1.26-3.26), particularly evident in patients treated with chemotherapy, and is independent of MSI status.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Are BRAF V600E mutation associated to worse prognosis in colorectal cancer patients?",
            "type": "yesno",
            "id": "66099eb9fdcbea915f000026",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [],
            "snippets": [],
            "body": "What is the mechanism of action of Mezigdomide?",
            "type": "summary",
            "id": "65cfac201930410b13000013",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15548414",
                "http://www.ncbi.nlm.nih.gov/pubmed/36401046"
            ],
            "snippets": [],
            "body": "What is PUL-2 in Duchenne Muscular Dystrophy?",
            "type": "factoid",
            "id": "66302487187cba990d000031",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/10826427",
                "http://www.ncbi.nlm.nih.gov/pubmed/18820881",
                "http://www.ncbi.nlm.nih.gov/pubmed/10613484",
                "http://www.ncbi.nlm.nih.gov/pubmed/21866447",
                "http://www.ncbi.nlm.nih.gov/pubmed/2626780",
                "http://www.ncbi.nlm.nih.gov/pubmed/9408305",
                "http://www.ncbi.nlm.nih.gov/pubmed/25830038",
                "http://www.ncbi.nlm.nih.gov/pubmed/34012646",
                "http://www.ncbi.nlm.nih.gov/pubmed/24265711",
                "http://www.ncbi.nlm.nih.gov/pubmed/24649353"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10826427",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 215,
                    "text": "One-year, two-year, three-year, and four-year survival rates and median survival time for patients with inoperable liver metastases from colorectal cancer is 32, 10, and 3 percent and 7.4 to 11 months, respectively.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10826427",
                    "offsetInBeginSection": 216,
                    "offsetInEndSection": 321,
                    "text": "Systemic chemotherapy produces a modest improvement to 48, 21, and 3 percent and 12 months, respectively.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10826427",
                    "offsetInBeginSection": 322,
                    "offsetInEndSection": 434,
                    "text": "Regional chemotherapy produces a further improvement to 64, 25, and 5 percent and 15 to 17 months, respectively.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18820881",
                    "offsetInBeginSection": 551,
                    "offsetInEndSection": 918,
                    "text": "However, since metastasis may be initiated before diagnosis of the primary tumour, growth of the primary tumour and the metastases may be two autonomous processes. Thus survival following metastasis is almost unrelated to prognostic factors from the primary tumour, and median survival time after diagnosis of metastases is therefore almost comparable with 17 months.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10613484",
                    "offsetInBeginSection": 858,
                    "offsetInEndSection": 898,
                    "text": "Median survival time was only 16 months.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21866447",
                    "offsetInBeginSection": 1175,
                    "offsetInEndSection": 1234,
                    "text": "The median survival time was 6 months in the entire cohort.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2626780",
                    "offsetInBeginSection": 566,
                    "offsetInEndSection": 609,
                    "text": "Median survival time was short, 7.5 months.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9408305",
                    "offsetInBeginSection": 481,
                    "offsetInEndSection": 832,
                    "text": "The mean survival time was 8.5 (1-27) months for all patients, 11 months for patients with solitary hepatic tumour (n = 13) and 7.5 months for those with multiple tumours (n = 34). Patients who had liver and other distant metastases simultaneously (n = 9) survived a shorter time than those with hepatic secondaries only (4 and 9 months respectively).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25830038",
                    "offsetInBeginSection": 673,
                    "offsetInEndSection": 792,
                    "text": "Combined with regimens such as FOLFOX or FOLFIRI, median survival rates have been increased to an average of 23 months.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34012646",
                    "offsetInBeginSection": 1139,
                    "offsetInEndSection": 1311,
                    "text": "The 1Y-PFS was 28.5% [median survival time (MST): 7.4 months], 1Y-OS was 76.6% (MST not reached), 3Y-PFS was 5.5% (MST: 7.4 months), and 3Y-OS was 26.4% (MST: 25.2 months).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the average median survival for advanced colorectal cancer patients?",
            "type": "factoid",
            "id": "66099907fdcbea915f000015",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30087076",
                "http://www.ncbi.nlm.nih.gov/pubmed/26080283",
                "http://www.ncbi.nlm.nih.gov/pubmed/34315986",
                "http://www.ncbi.nlm.nih.gov/pubmed/28363508",
                "http://www.ncbi.nlm.nih.gov/pubmed/26744954",
                "http://www.ncbi.nlm.nih.gov/pubmed/24796100",
                "http://www.ncbi.nlm.nih.gov/pubmed/31505259",
                "http://www.ncbi.nlm.nih.gov/pubmed/37793911",
                "http://www.ncbi.nlm.nih.gov/pubmed/15533611",
                "http://www.ncbi.nlm.nih.gov/pubmed/16910266"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30087076",
                    "offsetInBeginSection": 865,
                    "offsetInEndSection": 1019,
                    "text": "Statin use was associated with a significantly lower incidence of dementia (adjusted hazard ratio, .81; 95% confidence interval, .73-.89) than nonuse was.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30087076",
                    "offsetInBeginSection": 1346,
                    "offsetInEndSection": 1464,
                    "text": "In this nationwide cohort study, statin use was associated with decreased risk of dementia among patients with stroke.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26080283",
                    "offsetInBeginSection": 1219,
                    "offsetInEndSection": 1339,
                    "text": "In this large-scale nationwide cohort study, statin use was associated with a lower risk of non-vascular dementia in AF.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26080283",
                    "offsetInBeginSection": 854,
                    "offsetInEndSection": 1021,
                    "text": "Statin use exhibited a protective effect on the occurrence of non-vascular dementia, with an adjusted hazard ratio (HR) of 0.832 (95% confidence interval=0.801-0.864).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30087076",
                    "offsetInBeginSection": 1020,
                    "offsetInEndSection": 1115,
                    "text": "In particular, lipophilic and high-potency statins were associated with lower risk of dementia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30087076",
                    "offsetInBeginSection": 1116,
                    "offsetInEndSection": 1212,
                    "text": "Statin exposure duration was inversely related to the risk of dementia (P < .001 for the trend).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34315986",
                    "offsetInBeginSection": 1022,
                    "offsetInEndSection": 1200,
                    "text": "Our findings indicate that less persistent statin use is associated with increased risk of AD, whereas persistent and adherent statin use is associated with decreased risk of AD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34315986",
                    "offsetInBeginSection": 826,
                    "offsetInEndSection": 1021,
                    "text": "However, days of prescription  540 and cumulative defined daily dose  540 of statin were associated with decreased risk of AD [aHR (95% CI) = 0.87 (0.80-0.95) and 0.79 (0.68-0.92), respectively].",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28363508",
                    "offsetInBeginSection": 650,
                    "offsetInEndSection": 915,
                    "text": "Several factors including statins, light-to-moderate alcohol consumption, compliance with a Mediterranean diet, higher educational attainment, physically and cognitively stimulating activities, and APOE 2 appeared to be associated with a decreased risk of AD onset.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26744954",
                    "offsetInBeginSection": 1369,
                    "offsetInEndSection": 1565,
                    "text": "The use of statins (OR: 0.94; 0.90-0.99), proton-pump inhibitors (PPI) (0.93; 0.90-0.97), and antihypertensive drugs (0.96, 0.94-0.99) were associated with a decreased risk of developing dementia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Has statin use been associated with a higher risk of dementia?",
            "type": "yesno",
            "id": "6616a122fdcbea915f000058",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21576368",
                "http://www.ncbi.nlm.nih.gov/pubmed/30552228",
                "http://www.ncbi.nlm.nih.gov/pubmed/19143637",
                "http://www.ncbi.nlm.nih.gov/pubmed/23184942",
                "http://www.ncbi.nlm.nih.gov/pubmed/19690328",
                "http://www.ncbi.nlm.nih.gov/pubmed/19166929",
                "http://www.ncbi.nlm.nih.gov/pubmed/23928304",
                "http://www.ncbi.nlm.nih.gov/pubmed/21757713",
                "http://www.ncbi.nlm.nih.gov/pubmed/20660299",
                "http://www.ncbi.nlm.nih.gov/pubmed/37508495"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576368",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 236,
                    "text": "The mammalian target of rapamycin complex 1 (mTORC1) functions as an environmental sensor to promote critical cellular processes such as protein synthesis, cell growth, and cell proliferation in response to growth factors and nutrients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30552228",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "text": "The mechanistic (or mammalian) target of rapamycin complex 1 (mTORC1) controls cell growth, proliferation, and metabolism in response to diverse stimuli.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19143637",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 165,
                    "text": "Signalling through mTORC1 (mammalian target of rapamycin complex 1) is important in controlling many cell functions, including protein synthesis, which it activates.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19143637",
                    "offsetInBeginSection": 311,
                    "offsetInEndSection": 554,
                    "text": "mTORC1 signalling regulates several components of the protein synthetic machinery, including initiation and elongation factors, protein kinases which phosphorylate the ribosome and/or translation factors, and the translation of specific mRNAs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184942",
                    "offsetInBeginSection": 169,
                    "offsetInEndSection": 298,
                    "text": "mTORC1, which is directly inhibited by rapamycin, promotes cell growth by stimulating protein synthesis and inhibiting autophagy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184942",
                    "offsetInBeginSection": 299,
                    "offsetInEndSection": 448,
                    "text": "A wide range of extra and intracellular signals, including growth factors, nutrients, energy levels, and various stress conditions, regulates mTORC1.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19690328",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 217,
                    "text": "High nutrient availability stimulates the mammalian target of rapamycin complex 1 (mTORC1) to coordinately activate anabolic processes, such as protein synthesis, while inhibiting the cellular catabolism of autophagy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19690328",
                    "offsetInBeginSection": 414,
                    "offsetInEndSection": 676,
                    "text": "The complementary inhibitory mechanism in which mTORC1 phosphorylates the autophagy regulatory complex containing unc-51-like kinase 1 (ULK1), the mammalian Atg13 protein, and focal adhesion kinase interacting protein of 200 kD (FIP200) has also been elucidated.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19166929",
                    "offsetInBeginSection": 417,
                    "offsetInEndSection": 553,
                    "text": "mTORC1 signalling is classically known for its role in regulating cell growth and proliferation through modulation of protein synthesis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23928304",
                    "offsetInBeginSection": 187,
                    "offsetInEndSection": 620,
                    "text": "Mechanistic target of rapamycin (mTOR) signaling is the essential nutrient-sensing pathway that controls anabolic processes in cells. The central component of this pathway is mTOR, a highly conserved and essential protein kinase that exists in two distinct functional complexes. The nutrient-sensitive mTOR complex 1 (mTORC1) controls cell growth and cell size by phosphorylation of the regulators of protein synthesis S6K1 and 4EBP1",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the function of the mTORC1 kinase?",
            "type": "summary",
            "id": "662cfa24187cba990d000005",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26510177",
                "http://www.ncbi.nlm.nih.gov/pubmed/32348735",
                "http://www.ncbi.nlm.nih.gov/pubmed/29958539",
                "http://www.ncbi.nlm.nih.gov/pubmed/14729589",
                "http://www.ncbi.nlm.nih.gov/pubmed/21304276",
                "http://www.ncbi.nlm.nih.gov/pubmed/10888886",
                "http://www.ncbi.nlm.nih.gov/pubmed/11121095",
                "http://www.ncbi.nlm.nih.gov/pubmed/10471500",
                "http://www.ncbi.nlm.nih.gov/pubmed/16861263",
                "http://www.ncbi.nlm.nih.gov/pubmed/10615135"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26510177",
                    "offsetInBeginSection": 681,
                    "offsetInEndSection": 892,
                    "text": "Underscoring the complex relationships between CpG methylation and gene expression, here hypermethylation was never associated with gene silencing, nor was hypomethylation always associated with gene activation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32348735",
                    "offsetInBeginSection": 305,
                    "offsetInEndSection": 578,
                    "text": "Classically, dense promoter DNA methylation is associated with transcriptional repression. However, growing evidence suggests that this association may not always hold true, and promoter hypermethylation now also appears to be associated with high transcriptional activity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29958539",
                    "offsetInBeginSection": 110,
                    "offsetInEndSection": 428,
                    "text": "In the standard model, methylation in gene promoters has received the most attention since it is generally associated with transcriptional silencing. Nevertheless, recent studies in human tissues reveal that methylation of the region downstream of the transcription start site is highly informative of gene expression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14729589",
                    "offsetInBeginSection": 159,
                    "offsetInEndSection": 384,
                    "text": "Whereas changes in DNA methylation play a key role in a number of human diseases, in particular cancer, in normal DNA CpG islands are nearly always methylation free, regardless of the expression status of the associated gene.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14729589",
                    "offsetInBeginSection": 385,
                    "offsetInEndSection": 509,
                    "text": "Only limited evidence supports a role for DNA methylation in controlling tissue-specific expression in adult somatic tissue.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14729589",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 158,
                    "text": "Over 50% of human genes are associated with CpG islands and DNA methylation within such CpG islands has been clearly correlated with inhibition of expression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21304276",
                    "offsetInBeginSection": 1219,
                    "offsetInEndSection": 1353,
                    "text": "Expectedly, DNA methylation in promoter regions overlapping with CpG islands was associated with gene silencing in both PBLs and LCLs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10888886",
                    "offsetInBeginSection": 396,
                    "offsetInEndSection": 586,
                    "text": "Whether DNA methylation is always causal for the assembly of repressive chromatin or whether features of transcriptionally silent chromatin might target methyltransferase remains unresolved.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11121095",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "text": "CpG methylation, the most common epigenetic modification of vertebrate genomes, is primarily associated with transcriptional repression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10471500",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 138,
                    "text": "Methylation of DNA at the dinucleotide CpG is essential for mammalian development and is correlated with stable transcriptional silencing.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is DNA methylation always associated with gene silencing?",
            "type": "yesno",
            "id": "6630254b187cba990d000032",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/34723071",
                "http://www.ncbi.nlm.nih.gov/pubmed/34958044",
                "http://www.ncbi.nlm.nih.gov/pubmed/31272741",
                "http://www.ncbi.nlm.nih.gov/pubmed/36172196",
                "http://www.ncbi.nlm.nih.gov/pubmed/32113230",
                "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
                "http://www.ncbi.nlm.nih.gov/pubmed/37980539",
                "http://www.ncbi.nlm.nih.gov/pubmed/33844190",
                "http://www.ncbi.nlm.nih.gov/pubmed/34359358",
                "http://www.ncbi.nlm.nih.gov/pubmed/28860778"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34723071",
                    "offsetInBeginSection": 587,
                    "offsetInEndSection": 934,
                    "text": "Stride velocity 95th centile (SV95C) is the first wearable acquired digital endpoint to receive qualification from the European Medicines Agency (EMA) to quantify the ambulation ability of ambulant DMD patients aged 5 years in drug therapeutic studies; it is also currently under review for the US Food and Drug Administration (FDA) qualification.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34958044",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 245,
                    "text": "In 2019, stride velocity 95th centile (SV95C) became the first wearable-derived digital clinical outcome assessment (COA) qualified by the European Medicines Agency (EMA) for use as a secondary endpoint in trials for Duchenne muscular dystrophy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34958044",
                    "offsetInBeginSection": 496,
                    "offsetInEndSection": 681,
                    "text": "SV95C is an objective, real-world digital ambulation measure of peak performance, representing the speed of the fastest strides taken by the wearer over a recording period of 180 hours.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34958044",
                    "offsetInBeginSection": 682,
                    "offsetInEndSection": 915,
                    "text": "SV95C is correlated with traditional clinic-based assessments of motor function and has greater sensitivity to clinical change over 6 months than other wearable-derived stride variables, for example, median stride length or velocity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31272741",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 621,
                    "text": "Development of novel therapies for Duchenne muscular dystrophy (DMD) are driving the need for more efficient ways of detecting changes in disease- progression in DMD [1]. However, medicines' approval must be based on outcome measures that are acceptable from a regulatory perspective. In this article, European regulators provide an update on the recent regulatory consideration of a new endpoint (Stride Velocity 95th Centile (SV95C)) that could be used in therapeutic DMD trials. This new endpoint aims to quantify a patient's ambulation directly, reliably and continuously in a home environment with a wearable device.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36172196",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 299,
                    "text": "Digital health technologies are transforming the way health outcomes are captured and measured. Digital biomarkers may provide more objective measurements than traditional approaches as they encompass continuous and longitudinal data collection and use of automated analysis for data interpretation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34723071",
                    "offsetInBeginSection": 333,
                    "offsetInEndSection": 517,
                    "text": "Digital tools, such as wearable devices and other remote sensors, provide the opportunity for continuous, objective, and sensitive measurements of functional ability during daily life.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32113230",
                    "offsetInBeginSection": 1359,
                    "offsetInEndSection": 1634,
                    "text": "As a functional biomarker extracted in the phase space of the gait data, the proposed coupling degree index RCC could sensitively distinguish between DMD and TD children at the same age and provide alternative insights and potentially valuable tools for the screening of DMD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
                    "offsetInBeginSection": 912,
                    "offsetInEndSection": 1367,
                    "text": "Finally, using Bayesian optimization, we constructed a behavioral biomarker, termed the KineDMD ethomic biomarker, which is derived from daily-life behavioral data and whose value progresses with age in an S-shaped sigmoid curve form. The biomarker developed in this study, derived from digital readouts of daily-life movement behavior, can predict disease progression in patients with muscular dystrophy and can potentially track the response to therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37980539",
                    "offsetInBeginSection": 243,
                    "offsetInEndSection": 438,
                    "text": "Electrical impedance myography (EIM) is an emerging tool that provides noninvasive monitoring of muscle conditions and has been suggested as a treatment response biomarker in diverse indications.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Are there any digital biomarkers for Duchenne Muscular Dystrophy?",
            "type": "yesno",
            "id": "66302174187cba990d00002e",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/32616433",
                "http://www.ncbi.nlm.nih.gov/pubmed/25616671",
                "http://www.ncbi.nlm.nih.gov/pubmed/25137165",
                "http://www.ncbi.nlm.nih.gov/pubmed/29804191",
                "http://www.ncbi.nlm.nih.gov/pubmed/27551256",
                "http://www.ncbi.nlm.nih.gov/pubmed/24445500",
                "http://www.ncbi.nlm.nih.gov/pubmed/25325116",
                "http://www.ncbi.nlm.nih.gov/pubmed/19717258",
                "http://www.ncbi.nlm.nih.gov/pubmed/29073892",
                "http://www.ncbi.nlm.nih.gov/pubmed/31579770"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32616433",
                    "offsetInBeginSection": 2191,
                    "offsetInEndSection": 2315,
                    "text": "Adding AFL or RAM to FOLFIRI in the second line of mCRC treatment was not cost-effective in the Japanese health care system.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25616671",
                    "offsetInBeginSection": 2150,
                    "offsetInEndSection": 2500,
                    "text": "The base-case incremental cost-effectiveness ratio (ICER) for the overall population was reported by the manufacturer to be 36,294 per quality-adjusted life-year (QALY). After correcting the model programming and updating the model to include the ERG's preferred parameter estimates, the ICER from the ERG's alternative base case was 54,368 per QALY.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25616671",
                    "offsetInBeginSection": 2622,
                    "offsetInEndSection": 2753,
                    "text": "Additional scenarios related to the extrapolation of OS undertaken by the ERG resulted in ICERs between 62,894 and 92,089 per QALY.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25616671",
                    "offsetInBeginSection": 2754,
                    "offsetInEndSection": 3193,
                    "text": "After consideration of the manufacturer's submission and the ERG's critique, and submissions from other stakeholders, the NICE Appraisal Committee concluded that aflibercept in combination with irinotecan and fluorouracil-based therapy could not be considered a cost effective use of National Health Service resources for treating metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32616433",
                    "offsetInBeginSection": 1648,
                    "offsetInEndSection": 1991,
                    "text": "Compared with FOLFIRI alone, combination AFL or RAM with FOLFIRI had incremental effects of 0.173 QALYs (0.253 LYs) and 0.137 QALYs (0.197 LYs), incremental costs of 3,423,481 (US $31,010) and 5,766,106 (US $52,229), and incremental cost-effectiveness ratios of 19, 836, 504 (US $179,678) and 41, 947, 989 (US $379,964) per QALY, respectively.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25137165",
                    "offsetInBeginSection": 1183,
                    "offsetInEndSection": 1308,
                    "text": "In the cost-effectiveness analysis Euros 38,931/LYG was obtained with aflibercept in combination with FOLFIRI versus FOLFIRI.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25137165",
                    "offsetInBeginSection": 1463,
                    "offsetInEndSection": 1603,
                    "text": "Aflibercept in combination with FOLFIRI is an efficient strategy for second-line mCRC treatment from the National Health System perspective.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29804191",
                    "offsetInBeginSection": 947,
                    "offsetInEndSection": 1146,
                    "text": "Combining pharmacological costs of drugs with the measure of efficacy represented by the PFS, aflibercept in combination with FOLFIRI is a cost-effective second-line treatment for patients with mCRC.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29804191",
                    "offsetInBeginSection": 747,
                    "offsetInEndSection": 946,
                    "text": "Dividing the costs of therapy by the measure of efficacy represented by PFS, we found out that the lowest cost per month of PFS gained (4581 ) was associated with the use of FOLFIRI plus aflibercept.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32616433",
                    "offsetInBeginSection": 2529,
                    "offsetInEndSection": 2583,
                    "text": "Of the 2 agents, AFL was more cost-effective than RAM.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is FOLFIRI plus Aflibercept a cost-effective treatment in patients with advanced colorectal caner?",
            "type": "yesno",
            "id": "66099ba9fdcbea915f000022",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/33944562",
                "http://www.ncbi.nlm.nih.gov/pubmed/34413118",
                "http://www.ncbi.nlm.nih.gov/pubmed/37249450",
                "http://www.ncbi.nlm.nih.gov/pubmed/36631720",
                "http://www.ncbi.nlm.nih.gov/pubmed/36108418",
                "http://www.ncbi.nlm.nih.gov/pubmed/34133152",
                "http://www.ncbi.nlm.nih.gov/pubmed/32960514",
                "http://www.ncbi.nlm.nih.gov/pubmed/37694740",
                "http://www.ncbi.nlm.nih.gov/pubmed/33875484",
                "http://www.ncbi.nlm.nih.gov/pubmed/33875485"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33944562",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "text": "Here, we describe the molecular engineering of insulin icodec to achieve a plasma half-life of 196 h in humans, suitable for once-weekly subcutaneously administration.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34413118",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "text": "Insulin icodec is a novel, long-acting insulin analog designed to cover basal insulin requirements with once-weekly subcutaneous administration.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34413118",
                    "offsetInBeginSection": 1591,
                    "offsetInEndSection": 1926,
                    "text": "The clinical pharmacology trial in people with type 2 diabetes showed that insulin icodec was well tolerated and has pharmacokinetic/pharmacodynamic properties that are suited for once-weekly dosing, with a mean half-life of 196 hours and close to even distribution of glucose-lowering effect over the entire dosing interval of 1 week.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37249450",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "text": "Insulin Icodec is a novel basal insulin analogue designed for once-weekly administration, therefore might propitiate reduction in the frequency of injections and facilitate treatment adherence.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36631720",
                    "offsetInBeginSection": 847,
                    "offsetInEndSection": 1018,
                    "text": "Icodec can be administered subcutaneously in the thigh, abdomen or upper arm with no clinically relevant difference in exposure and with a similar glucose-lowering effect.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36631720",
                    "offsetInBeginSection": 251,
                    "offsetInEndSection": 448,
                    "text": "In a randomised, open-label, crossover trial, 25 individuals with type 2 diabetes received single subcutaneous icodec injections (5.6 U/kg) in the thigh, abdomen or upper arm (9-13 weeks' washout).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36108418",
                    "offsetInBeginSection": 612,
                    "offsetInEndSection": 750,
                    "text": "Phase 1 study showed insulin icodec having a half-life of 196 h (>1 week) while a steady state is achieved after 3 to 4 weekly injections.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34133152",
                    "offsetInBeginSection": 157,
                    "offsetInEndSection": 365,
                    "text": "Insulin icodec, a novel ultralong-acting lipidated analog validates the concept of a once-weekly basal injection that is less burdensome, yet equally safe and efficacious as conventional once-daily treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34133152",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 156,
                    "text": "Basal glucose control is commonly maintained by a single, once-daily administration of insulin through subcutaneous injection or a continuous pump-infusion.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32960514",
                    "offsetInBeginSection": 165,
                    "offsetInEndSection": 301,
                    "text": "Insulin icodec is a basal insulin analogue designed for once-weekly administration that is in development for the treatment of diabetes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "How should Insulin icodec be administered?",
            "type": "summary",
            "id": "65cfd2681930410b1300001e",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/10494258",
                "http://www.ncbi.nlm.nih.gov/pubmed/16217119",
                "http://www.ncbi.nlm.nih.gov/pubmed/33756528",
                "http://www.ncbi.nlm.nih.gov/pubmed/20042915"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10494258",
                    "offsetInBeginSection": 93,
                    "offsetInEndSection": 333,
                    "text": "This article discusses the initial management of adolescents who have been sexually assaulted, including obtaining the history and performing a careful physical examination, forensic evidence collection, and medical and psychologic therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16217119",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 216,
                    "text": "In sexual assault nurse examiner (SANE) programs, specially trained forensic nurses provide 24-hour-a-day, first-response medical care and crisis intervention to rape survivors in either hospitals or clinic settings.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33756528",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "text": "Sexual assault nurse examiners (SANEs) are specially trained to meet the postassault medical forensic needs of sexual assault patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20042915",
                    "offsetInBeginSection": 992,
                    "offsetInEndSection": 1167,
                    "text": "Most received a pregnancy test (98.3%), a pelvic bimanual or speculum examination (81.9%), and prophylactic or immediate treatment of a sexually transmitted infection (88.8%).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33756528",
                    "offsetInBeginSection": 572,
                    "offsetInEndSection": 908,
                    "text": "Compared to cases treated by non-SANE medical providers, cases treated by SANEs were significantly more likely to have emergency contraception administered, less likely to have a toxicology kit collected, less likely to have a police report filed at the time of examination, and more likely to have a mandatory child abuse report filed.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16217119",
                    "offsetInBeginSection": 217,
                    "offsetInEndSection": 840,
                    "text": "This article reviews the empirical literature regarding the effectiveness of SANE programs in five domains:(a) promoting the psychological recovery of survivors, (b) providing comprehensive and consistent post-rape medical care (e.g., emergency contraception, sexually transmitted disease [STD] prophylaxis), (c) documenting the forensic evidence of the crime completely and accurately, (d) improving the prosecution of sexual assault cases by providing better forensics and expert testimony, and (e) creating community change by bringing multiple service providers together to provide comprehensive care to rape survivors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33756528",
                    "offsetInBeginSection": 1079,
                    "offsetInEndSection": 1134,
                    "text": "SANEs provide a tailored, comprehensive first response.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the immediate treatment after a sexual assault?",
            "type": "list",
            "id": "66150639fdcbea915f000047",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22560791",
                "http://www.ncbi.nlm.nih.gov/pubmed/36565132",
                "http://www.ncbi.nlm.nih.gov/pubmed/33741226",
                "http://www.ncbi.nlm.nih.gov/pubmed/36315559",
                "http://www.ncbi.nlm.nih.gov/pubmed/25660133",
                "http://www.ncbi.nlm.nih.gov/pubmed/30443431",
                "http://www.ncbi.nlm.nih.gov/pubmed/26836830",
                "http://www.ncbi.nlm.nih.gov/pubmed/37861890"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560791",
                    "offsetInBeginSection": 1171,
                    "offsetInEndSection": 1435,
                    "text": "Our results suggest that ADHD is a frequent feature in DMD. The risk of ADHD appears to be higher in patients carrying mutations predicted to affect dystrophin isoforms expressed in the brain and are known to be associated with higher risk of cognitive impairment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560791",
                    "offsetInBeginSection": 853,
                    "offsetInEndSection": 1170,
                    "text": "ADHD occurred more frequently in association with mutations predicted to affect Dp140 expression (exon 45-55) and in those with mutations predicted to affect all dystrophin product, including Dp71 (ie, those that have promoter region and specific first exon between exons 62 and 63 but were also relatively frequent).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36565132",
                    "offsetInBeginSection": 1043,
                    "offsetInEndSection": 1172,
                    "text": "In DMD, Dp140+/Dp71+ vs. Dp140- /Dp71- had a PR of 0.40 (0.28, 0.57), and Dp71+ vs. Dp71- had a PR of 0.47 (0.36, 0.63) for ADHD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36565132",
                    "offsetInBeginSection": 1401,
                    "offsetInEndSection": 1535,
                    "text": "In BMD, Dp140 and Dp71 could be associated with developmental disorders, while ADHD might be associated with the Dp71 genotype in DMD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33741226",
                    "offsetInBeginSection": 107,
                    "offsetInEndSection": 351,
                    "text": "Neuropsychiatric phenotype associated to DMD gene mutations include now low IQ scores, epilepsy, autism, and attention deficit disorder. These have been observed with higher frequency in mutations that disrupt the short isoforms Dp71 and Dp140.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36315559",
                    "offsetInBeginSection": 306,
                    "offsetInEndSection": 471,
                    "text": "The changes of expression of dystrophin isoforms in the brain due to DMD gene mutations are thought to be related to the cognitive and neurobehavior profiles of DMD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25660133",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 241,
                    "text": "Duchenne muscular dystrophy is a progressive neuromuscular condition that has a high rate of cognitive and learning disabilities as well as neurobehavioral disorders, some of which have been associated with disruption of dystrophin isoforms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25660133",
                    "offsetInBeginSection": 573,
                    "offsetInEndSection": 775,
                    "text": "Mutations affecting Dp260 isoform and 5'untranslated region of Dp140 were observed in 60% with learning disability, 50% intellectual disability, 77% with autism spectrum disorders, and 94% with anxiety.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30443431",
                    "offsetInBeginSection": 1290,
                    "offsetInEndSection": 1408,
                    "text": "Neurodevelopmental needs were more commonly reported by care-givers in those with DMD mutations downstream of exon 51.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36315559",
                    "offsetInBeginSection": 472,
                    "offsetInEndSection": 642,
                    "text": "This cross-sectional study aimed to characterize cognitive and neurodevelopmental profiles of patients with DMD and to explore underlying genotype-phenotype associations.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is there an association between specific genotypes and the risk of ADHD for Duchenne Muscular Dystrophy?",
            "type": "yesno",
            "id": "663020d7187cba990d00002b",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37437144",
                "http://www.ncbi.nlm.nih.gov/pubmed/31369091",
                "http://www.ncbi.nlm.nih.gov/pubmed/37477404"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37437144",
                    "offsetInBeginSection": 1408,
                    "offsetInEndSection": 1609,
                    "text": "In this small, single-group study involving patients with papillary craniopharyngiomas, 15 of 16 patients had a partial response or better to the BRAF-MEK inhibitor combination vemurafenib-cobimetinib.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37437144",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 595,
                    "text": "Craniopharyngiomas, primary brain tumors of the pituitary-hypothalamic axis, can cause clinically significant sequelae. Treatment with the use of surgery, radiation, or both is often associated with substantial morbidity related to vision loss, neuroendocrine dysfunction, and memory loss. Genotyping has shown that more than 90% of papillary craniopharyngiomas carry  Eligible patients who had papillary craniopharyngiomas that tested positive for  Of the 16 patients in the study, 15 (94%; 95% confidence interval [CI], 70 to 100) had a durable objective partial response or better to therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31369091",
                    "offsetInBeginSection": 931,
                    "offsetInEndSection": 1286,
                    "text": "In most PCPs there is primary activation of the Ras/Raf/MEK/ERK pathway secondary to BRAF-V600E mutations. BRAF inhibitors, such as dabrafenib or vemurafenib, either alone or in combination with the MEK inhibitors trametinib and cobimetinib, have been administered to patients with PCPs producing clinically useful and, in some cases, sustained responses.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37477404",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 99,
                    "text": "Vemurafenib plus cobimetinib is effective in patients with BRAF-mutant papillary craniopharyngioma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is vemurafenibâ€“cobimetinib promising for craniopharyngioma?",
            "type": "yesno",
            "id": "65cfd8551930410b13000023",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/31857085",
                "http://www.ncbi.nlm.nih.gov/pubmed/19366918",
                "http://www.ncbi.nlm.nih.gov/pubmed/36173175",
                "http://www.ncbi.nlm.nih.gov/pubmed/19188353",
                "http://www.ncbi.nlm.nih.gov/pubmed/26173688",
                "http://www.ncbi.nlm.nih.gov/pubmed/21233422",
                "http://www.ncbi.nlm.nih.gov/pubmed/37644520",
                "http://www.ncbi.nlm.nih.gov/pubmed/12476774"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31857085",
                    "offsetInBeginSection": 793,
                    "offsetInEndSection": 1023,
                    "text": "BFT damages the colonic epithelial barrier by inducing cleavage of the zonula adherens protein E-cadherin and initiating a cell signaling response characterized by inflammation and c-Myc-dependent pro-oncogenic hyperproliferation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19366918",
                    "offsetInBeginSection": 615,
                    "offsetInEndSection": 1049,
                    "text": "Although the mechanism of action of BFT is incompletely understood, available data suggest that BFT binds to a specific intestinal epithelial cell receptor, stimulating intestinal cell signal transduction pathways that result in cell morphology changes, cleavage of E-cadherin, reduced colonic barrier function, and increased epithelial cell proliferation and cytokine expression (such as the proinflammatory chemokine interleukin-8).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36173175",
                    "offsetInBeginSection": 325,
                    "offsetInEndSection": 548,
                    "text": "ETBF's only recognized specific virulence factor is a zinc-dependent metallopeptidase (MP) called B. fragilis toxin (BFT) or fragilysin, which damages the intestinal mucosa and triggers disease-related signaling mechanisms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19188353",
                    "offsetInBeginSection": 132,
                    "offsetInEndSection": 304,
                    "text": "The only known ETBF virulence factor is the Bacteroides fragilis toxin (BFT), which induces E-cadherin cleavage, interleukin-8 secretion, and epithelial cell proliferation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36173175",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 259,
                    "text": "Bacteroides fragilis is an abundant commensal component of the healthy human colon. However, under dysbiotic conditions, enterotoxigenic B. fragilis (ETBF) may arise and elicit diarrhea, anaerobic bacteremia, inflammatory bowel disease, and colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26173688",
                    "offsetInBeginSection": 198,
                    "offsetInEndSection": 391,
                    "text": "Through its primary virulence factor, B. fragilis toxin (BFT), ETBF causes asymptomatic, chronic colitis in C57BL/6 mice and increased colon tumorigenesis in multiple intestinal neoplasia mice.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21233422",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 434,
                    "text": "Enterotoxigenic Bacteroides fragilis is the most frequent disease-causing anaerobe in the intestinal tract of humans and livestock and its specific virulence factor is fragilysin, also known as B. fragilis toxin. This is a 21-kDa zinc-dependent metallopeptidase existing in three closely related isoforms that hydrolyze E-cadherin and contribute to secretory diarrhea, and possibly to inflammatory bowel disease and colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37644520",
                    "offsetInBeginSection": 160,
                    "offsetInEndSection": 274,
                    "text": "Bacteroides fragilis can lead to tumorigenesis by changing signaling pathways, including the WNT/-catenin pathway.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12476774",
                    "offsetInBeginSection": 432,
                    "offsetInEndSection": 590,
                    "text": "Recent studies suggest that BFT is related to inflammatory bowel disease and colon cancer by triggering nuclear activation with potential oncogene expression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31857085",
                    "offsetInBeginSection": 1185,
                    "offsetInEndSection": 1362,
                    "text": "The recent observation of ETBF-bearing biofilms in colon biopsies from humans with colon cancer susceptibility loci strongly suggests that ETBF is a driver of colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the molecular mechanism by which Bacteroides Fragilis is associated to colorectal cancer development?",
            "type": "summary",
            "id": "66214db9b9f8b89d7e000004",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/32249354",
                "http://www.ncbi.nlm.nih.gov/pubmed/23460121",
                "http://www.ncbi.nlm.nih.gov/pubmed/12043991",
                "http://www.ncbi.nlm.nih.gov/pubmed/27114807",
                "http://www.ncbi.nlm.nih.gov/pubmed/23115605",
                "http://www.ncbi.nlm.nih.gov/pubmed/19753173",
                "http://www.ncbi.nlm.nih.gov/pubmed/25279075",
                "http://www.ncbi.nlm.nih.gov/pubmed/24686904",
                "http://www.ncbi.nlm.nih.gov/pubmed/29887631",
                "http://www.ncbi.nlm.nih.gov/pubmed/17689775"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32249354",
                    "offsetInBeginSection": 702,
                    "offsetInEndSection": 887,
                    "text": "So far described conservative treatment includes non-weight bearing or protected weight bearing with a knee brace, nonsteroidal anti-inflammatory drugs, analgesics, and bisphosphonates.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23460121",
                    "offsetInBeginSection": 797,
                    "offsetInEndSection": 914,
                    "text": "BME syndrome is generally treated conservatively. Infusion of prostacycline or bisphosphonates is a promising option.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23460121",
                    "offsetInBeginSection": 713,
                    "offsetInEndSection": 796,
                    "text": "Conservative or surgical treatment is considered, depending on the etiology of BME.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23460121",
                    "offsetInBeginSection": 915,
                    "offsetInEndSection": 1001,
                    "text": "Ischemic BME and early stages of ON can be successfully treated by core decompression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12043991",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 215,
                    "text": "Treatment options of bone marrow edema syndrome, which is associated with vascular disturbances, are protracted nonoperative treatment or core decompression which still demands several weeks until complete recovery.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12043991",
                    "offsetInBeginSection": 216,
                    "offsetInEndSection": 478,
                    "text": "We obtained excellent results by the use of the vasoactive drug iloprost, a stable prostacyclin analogue, leading to a complete relief of symptoms in cases of bone marrow edema which had initially suggested early avascular necrosis of the second metatarsal head.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27114807",
                    "offsetInBeginSection": 1277,
                    "offsetInEndSection": 1481,
                    "text": "The medical treatment of bone marrow edema or avascular osteonecrosis by Iloprost provides an safe and effective alternative strategy in the management of AVN presenting in the early stages (ARCO 1 or 2).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27114807",
                    "offsetInBeginSection": 1482,
                    "offsetInEndSection": 1566,
                    "text": "For more advanced stages (ARCO 3 or 4), surgical intervention should be prioritized.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23115605",
                    "offsetInBeginSection": 1021,
                    "offsetInEndSection": 1098,
                    "text": "Conservative management of AVN includes rest and reduction of weight bearing.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23115605",
                    "offsetInBeginSection": 1335,
                    "offsetInEndSection": 1435,
                    "text": "Surgical therapy of AVN includes core decompression, osteotomy, bone grafting and joint replacement.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Please list some treatment options for bone marrow edema syndrome,",
            "type": "list",
            "id": "662cf96f187cba990d000004",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24904289",
                "http://www.ncbi.nlm.nih.gov/pubmed/35544684",
                "http://www.ncbi.nlm.nih.gov/pubmed/33177991",
                "http://www.ncbi.nlm.nih.gov/pubmed/31147872",
                "http://www.ncbi.nlm.nih.gov/pubmed/33799798",
                "http://www.ncbi.nlm.nih.gov/pubmed/37754516",
                "http://www.ncbi.nlm.nih.gov/pubmed/32448615",
                "http://www.ncbi.nlm.nih.gov/pubmed/36338705",
                "http://www.ncbi.nlm.nih.gov/pubmed/29081734",
                "http://www.ncbi.nlm.nih.gov/pubmed/32566921"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24904289",
                    "offsetInBeginSection": 745,
                    "offsetInEndSection": 937,
                    "text": "In particular, a subpopulation of chemo- and radio-therapy resistant tumorigenic cancer stem-like cells (CSCs) is believed to be the main responsible for tumor cell dissemination to the brain.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24904289",
                    "offsetInBeginSection": 1109,
                    "offsetInEndSection": 1461,
                    "text": "The microenvironment contribution in GBM development is increasingly emphasized. An interplay exists between CSCs, differentiated GBM cells, and the microenvironment, mainly through secreted chemokines (e.g., CXCL12) causing recruitment of fibroblasts, endothelial, mesenchymal and inflammatory cells to the tumor, via specific receptors such as CXCR4.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35544684",
                    "offsetInBeginSection": 274,
                    "offsetInEndSection": 454,
                    "text": "Accumulating evidence suggests that cancer stem cells in GBM, termed glioma stem cells (GSCs), play a crucial role in tumor propagation, treatment resistance, and tumor recurrence.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35544684",
                    "offsetInBeginSection": 455,
                    "offsetInEndSection": 643,
                    "text": "GSCs, possessing the capacity for self-renewal and multilineage differentiation, are responsible for tumor growth and heterogeneity, leading to primary obstacles to current cancer therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35544684",
                    "offsetInBeginSection": 644,
                    "offsetInEndSection": 887,
                    "text": "In this respect, increasing efforts have been devoted to the development of anti-GSC strategies based on targeting GSC surface markers, blockage of essential signaling pathways of GSCs, and manipulating the tumor microenvironment (GSC niches).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33177991",
                    "offsetInBeginSection": 122,
                    "offsetInEndSection": 396,
                    "text": "A major difficulty in eradicating GBM is the presence of microscopic residual infiltrating disease remaining after multimodality treatment. Glioma cancer stem cells (CSCs) have been pinpointed as the treatment-resistant tumor component that seeds ultimate tumor progression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33177991",
                    "offsetInBeginSection": 397,
                    "offsetInEndSection": 630,
                    "text": "Despite the key role of CSCs, the ideal preclinical model to study the genetic and epigenetic landmarks driving their malignant behavior while simulating an accurate interaction with the tumor microenvironment (TME) is still missing.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31147872",
                    "offsetInBeginSection": 584,
                    "offsetInEndSection": 749,
                    "text": "In recent years, many investigations have highlighted the role of GBM stem cells (GSCs) and their microenvironment in the initiation and maintenance of tumor tissue.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31147872",
                    "offsetInBeginSection": 1364,
                    "offsetInEndSection": 1524,
                    "text": "Pericytes are multipotent perivascular cells that play a vital role within the GBM microenvironment by assisting in tumor initiation, survival, and progression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31147872",
                    "offsetInBeginSection": 1525,
                    "offsetInEndSection": 1858,
                    "text": "Due to their role in regulating the blood-brain barrier permeability, promoting angiogenesis, tumor growth, clearing extracellular matrix for infiltrating GBM cells and in helping GBM cells evade immune surveillance, pericytes could be ideal therapeutic targets for stymieing or exploiting their role within the GBM microenvironment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the potential role of the tumor microenvironment and factors like stem cells in contributing to the recurrence of glioblastoma?",
            "type": "summary",
            "id": "6630562c187cba990d000036",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24672433",
                "http://www.ncbi.nlm.nih.gov/pubmed/10923985",
                "http://www.ncbi.nlm.nih.gov/pubmed/20107133",
                "http://www.ncbi.nlm.nih.gov/pubmed/6389041",
                "http://www.ncbi.nlm.nih.gov/pubmed/2333150",
                "http://www.ncbi.nlm.nih.gov/pubmed/30077619",
                "http://www.ncbi.nlm.nih.gov/pubmed/2153714",
                "http://www.ncbi.nlm.nih.gov/pubmed/9336230",
                "http://www.ncbi.nlm.nih.gov/pubmed/17499111",
                "http://www.ncbi.nlm.nih.gov/pubmed/33002233"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24672433",
                    "offsetInBeginSection": 549,
                    "offsetInEndSection": 845,
                    "text": "The BG are a highly organized network of subcortical nuclei composed of the striatum (caudate and putamen), subthalamic nucleus (STN), internal and external globus pallidus (or entopeduncular nucleus in rodents, GPi/EP and GPe) and substantia nigra (pars compacta, SNc, and pars reticulata, SNr).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10923985",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 137,
                    "text": "The basal ganglia are a group of subcortical nuclei involved in a variety of processes including motor, cognitive and mnemonic functions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20107133",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 272,
                    "text": "The basal ganglia are a subcortical assembly of nuclei involved in many aspects of behavior. Three of the nuclei have high firing rates and inhibitory influences: the substantia nigra pars reticulata (SNr), globus pallidus interna (GPi), and globus pallidus externa (GPe).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6389041",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 300,
                    "text": "Studies of single-cell discharge in the basal ganglia of behaving primates have revealed: characteristic patterns of spontaneous discharge in the striatum, external (GPe) and internal (GPi) globus pallidus, pars reticulata and pars compacta of the substantia nigra, and the subthalamic nucleus (STN);",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10923985",
                    "offsetInBeginSection": 1214,
                    "offsetInEndSection": 1695,
                    "text": "Recent studies have demonstrated that the organisation of these pathways is more complex than previously suggested. Thus the cortical input to the basal ganglia, in addition to innervating the spiny projection neurons, also innervates GABA interneurons, which in turn provide a feed-forward inhibition of the spiny output neurons. Individual neurons of the globus pallidus innervate basal ganglia output nuclei as well as the subthalamic nucleus and substantia nigra pars compacta.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2333150",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 214,
                    "text": "Similarities in cellular morphology, afferentation, efferentation, and neurotransmitter content between the internal and external parts of the pallidum and the substantia nigra pars reticulata have long been noted.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30077619",
                    "offsetInBeginSection": 947,
                    "offsetInEndSection": 1142,
                    "text": "In the basal ganglia, they were found in the caudate putamen, core part of accumbens nucleus, lateral globus pallidus, subthalamic nucleus, and substantia nigra pars compacta and pars reticulata.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2153714",
                    "offsetInBeginSection": 708,
                    "offsetInEndSection": 904,
                    "text": "In the basal ganglia, high levels of binding of 125I-351A are found in the caudate nucleus, putamen, nucleus accumbens, both divisions of the globus pallidus, and substantia nigra pars reticulata.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9336230",
                    "offsetInBeginSection": 782,
                    "offsetInEndSection": 995,
                    "text": "In the basal ganglia and related nuclei, cadherin-8 is expressed by parts of the striatum, globus pallidus, substantia nigra, entopeduncular nucleus, subthalamic nucleus, zona incerta, and pedunculopontine nuclei.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17499111",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "The external segment of the pallidum (GP(e)) is a relatively large nucleus located caudomedial to the neostriatum (Str).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Where in the body would the globus pallidus be found?",
            "type": "factoid",
            "id": "662cfbf5187cba990d000007",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37861890",
                "http://www.ncbi.nlm.nih.gov/pubmed/35849899",
                "http://www.ncbi.nlm.nih.gov/pubmed/28027854"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37861890",
                    "offsetInBeginSection": 272,
                    "offsetInEndSection": 538,
                    "text": "Although the association of intellectual disability with the dystrophinopathies Duchenne (DMD) and Becker muscular dystrophy (BMD) has been long established, their association with ASD is more recent, and the dystrophin genotype-ASD phenotype correlation is unclear.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35849899",
                    "offsetInBeginSection": 1218,
                    "offsetInEndSection": 1345,
                    "text": "The results show that boys with DMD who have intellectual disability commonly have DMD variants in exon 45 or downstream to it.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37861890",
                    "offsetInBeginSection": 1272,
                    "offsetInEndSection": 1543,
                    "text": "Whole exome sequencing in these ASD-DMD/BMD individuals together with the literature suggest, although based on preliminary data, a complex and heterogeneous genetic architecture underlying ASD in dystrophinopathies, that include rare variants of large and medium effect.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28027854",
                    "offsetInBeginSection": 1107,
                    "offsetInEndSection": 1283,
                    "text": "Finally, a c.707T>G variant (p.Phe236Cys) in the DMD gene was identified in a patient retrospectively recognized to be affected by Becker muscular dystrophy (BMD, OMIM 300376).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is there an association between specific genotypes and the risk of neurodevelopmental disorders for Becker Muscular Dystrophy?",
            "type": "yesno",
            "id": "66301fcb187cba990d000029",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [],
            "snippets": [],
            "body": "What medication are included in the Juvisync pill?",
            "type": "list",
            "id": "65d375b31930410b1300004b",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37156255",
                "http://www.ncbi.nlm.nih.gov/pubmed/12848952",
                "http://www.ncbi.nlm.nih.gov/pubmed/34795665",
                "http://www.ncbi.nlm.nih.gov/pubmed/9281381",
                "http://www.ncbi.nlm.nih.gov/pubmed/19411081",
                "http://www.ncbi.nlm.nih.gov/pubmed/20080387",
                "http://www.ncbi.nlm.nih.gov/pubmed/19944780",
                "http://www.ncbi.nlm.nih.gov/pubmed/37476013",
                "http://www.ncbi.nlm.nih.gov/pubmed/29251660",
                "http://www.ncbi.nlm.nih.gov/pubmed/16513876"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37156255",
                    "offsetInBeginSection": 3407,
                    "offsetInEndSection": 3565,
                    "text": "Autoimmune diseases affect approximately one in ten individuals, and their burden continues to increase over time at varying rates across individual diseases.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12848952",
                    "offsetInBeginSection": 335,
                    "offsetInEndSection": 508,
                    "text": "Prevalence rates range from less than 5 per 100,000 (e.g. chronic active hepatitis, uveitis) to more than 500 per 100,000 (Grave disease, rheumatoid arthritis, thyroiditis).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34795665",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 59,
                    "text": "The global prevalence of autoimmune diseases is increasing.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9281381",
                    "offsetInBeginSection": 2838,
                    "offsetInEndSection": 2999,
                    "text": "Overall we estimate that 8,511,845 persons in the United States or approximately 1 in 31 Americans are currently afflicted with one of these autoimmune diseases.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19411081",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 78,
                    "text": "The majority of autoimmune disorders are characterized by female predominance.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12848952",
                    "offsetInBeginSection": 509,
                    "offsetInEndSection": 628,
                    "text": "At least 85% of thyroiditis, systemic sclerosis, systemic lupus erythematosus, and Sjogren disease patients are female.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12848952",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "Autoimmune diseases are among the leading causes of death among young and middle-aged women in the United States.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20080387",
                    "offsetInBeginSection": 287,
                    "offsetInEndSection": 427,
                    "text": "In North America and Northern Europe, the incidence of RA is estimated at 20-50 cases per 100,000 population and the prevalence at 0.5-1.1%.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19944780",
                    "offsetInBeginSection": 287,
                    "offsetInEndSection": 434,
                    "text": "In North America and Northern Europe, the incidence of RA is estimated at 20 to 50 cases per 100,000 population and the prevalence at 0.5% to 1.1%.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37476013",
                    "offsetInBeginSection": 192,
                    "offsetInEndSection": 509,
                    "text": "In Korea, several epidemiologic studies reporting prevalence and incidence rates of RA have been conducted using large databases such as claims databases, national surveys, prospective cohort databases or electronic health records; according to these data sources, the estimated prevalence ranged from 0.27% to 1.85%.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the approximate prevalence of autoimmune diseases?",
            "type": "factoid",
            "id": "66151045fdcbea915f000048",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27538328",
                "http://www.ncbi.nlm.nih.gov/pubmed/18805301",
                "http://www.ncbi.nlm.nih.gov/pubmed/35554594",
                "http://www.ncbi.nlm.nih.gov/pubmed/14631747",
                "http://www.ncbi.nlm.nih.gov/pubmed/17162989",
                "http://www.ncbi.nlm.nih.gov/pubmed/32492554",
                "http://www.ncbi.nlm.nih.gov/pubmed/21102987"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27538328",
                    "offsetInBeginSection": 422,
                    "offsetInEndSection": 645,
                    "text": "Narcolepsy with cataplexy remains a clinical diagnosis but nighttime and daytime polysomnography (multiple sleep latency tests) are useful to document mean sleep latency below 8 min and at least two sleep-onset REM periods.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18805301",
                    "offsetInBeginSection": 484,
                    "offsetInEndSection": 709,
                    "text": "Narcolepsy with cataplexy remains a clinical diagnosis but nighttime and daytime polysomnography (multiple sleep latency tests) are useful to document a mean sleep latency below 8 min and at least two sleep-onset REM periods.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35554594",
                    "offsetInBeginSection": 625,
                    "offsetInEndSection": 956,
                    "text": "Compared to those with normal hypocretin-1 levels (>200 pg/mL), a higher percentage of individuals with intermediate hypocretin-1 levels had typical cataplexy (75% or 12/16 vs 9% or 8/88, p < .05), and/or met the diagnostic polysomnographic (PSG) and Multiple Sleep Latency Test (MSLT) criteria for narcolepsy (50 vs 6%, p < .001).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14631747",
                    "offsetInBeginSection": 49,
                    "offsetInEndSection": 286,
                    "text": "The diagnostic criteria were met by the clinical symptoms including excessive daytime sleepiness and cataplexy, and by the results of overnight polysomnography (PSG), multiple sleep latency test (MSLT), and human leukocyte antigen (HLA).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35554594",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 155,
                    "text": "The diagnosis of narcolepsy type 1 (NT1) is based upon the presence of cataplexy and/or a cerebrospinal fluid (CSF) hypocretin-1/orexin-A level  110 pg/mL.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27538328",
                    "offsetInBeginSection": 776,
                    "offsetInEndSection": 992,
                    "text": "In contrast, a low hypocretin-1/orexin-A levels (values below 110 pg/mL) in the cerebrospinal fluid was highly specific for narcolepsy with cataplexy and was included in the recent diagnostic criteria for narcolepsy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18805301",
                    "offsetInBeginSection": 840,
                    "offsetInEndSection": 985,
                    "text": "In contrast, a low hypocretin levels (values below 110 pg/ml) in the cerebrospinal fluid (CSF) was highly specific for narcolepsy with cataplexy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17162989",
                    "offsetInBeginSection": 404,
                    "offsetInEndSection": 677,
                    "text": "The gold standard for diagnosis was ICSD-2 criteria. Patients and controls completed the Stanford Sleep Inventory, and agreed to HLA typing. Polysomnography (87%), Multiple Sleep Latency Test (MSLT) (96%), and CSF hypocretin-1 measurements (53%) were conducted in patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32492554",
                    "offsetInBeginSection": 580,
                    "offsetInEndSection": 773,
                    "text": "All patients were examined using an extensive clinical interview followed by two weeks of actigraphy and sleep diary recordings, polysomnography (PSG) and multiple sleep latency testing (MSLT).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21102987",
                    "offsetInBeginSection": 156,
                    "offsetInEndSection": 361,
                    "text": "HLA-DQB1*0602 typing (all tested, and 100% positive), polysomnography or Multiple Sleep Latency Test (76%), and cerebrospinal fluid hypocretin-1 measurements (26%, all with low levels) were also conducted.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the gold standard for a diagnosis of narcolepsy?",
            "type": "factoid",
            "id": "66156200fdcbea915f00004d",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19996293",
                "http://www.ncbi.nlm.nih.gov/pubmed/23877318",
                "http://www.ncbi.nlm.nih.gov/pubmed/21289278",
                "http://www.ncbi.nlm.nih.gov/pubmed/24460285",
                "http://www.ncbi.nlm.nih.gov/pubmed/36367045",
                "http://www.ncbi.nlm.nih.gov/pubmed/28748342",
                "http://www.ncbi.nlm.nih.gov/pubmed/34020723",
                "http://www.ncbi.nlm.nih.gov/pubmed/19765000",
                "http://www.ncbi.nlm.nih.gov/pubmed/21163902",
                "http://www.ncbi.nlm.nih.gov/pubmed/34503108"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19996293",
                    "offsetInBeginSection": 339,
                    "offsetInEndSection": 507,
                    "text": "IDH1 and IDH2 mutations define a specific subtype of gliomas and may have significant utility for the diagnosis, prognosis, and treatment of patients with these tumors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23877318",
                    "offsetInBeginSection": 133,
                    "offsetInEndSection": 302,
                    "text": "IDH1 and IDH2 are mutated in 50%-80% of astrocytomas, oligodendrogliomas, oligoastrocytomas, and secondary glioblastomas but are seldom mutated in primary glioblastomas.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23877318",
                    "offsetInBeginSection": 414,
                    "offsetInEndSection": 582,
                    "text": "IDH1 and IDH2 mutations may serve as prognostic factors because patients with an IDH-mutated glioma survive significantly longer than those with an IDH-wild-type tumor.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23877318",
                    "offsetInBeginSection": 684,
                    "offsetInEndSection": 858,
                    "text": "The production of 2-hydroxyglutarate and enhanced NADP+ levels in tumor cells with mutant IDH1/2 suggest mechanisms through which these mutations contribute to tumorigenesis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23877318",
                    "offsetInBeginSection": 859,
                    "offsetInEndSection": 1066,
                    "text": "Elucidating the pathogenesis of IDH mutations will improve understanding of the molecular mechanisms of gliomagenesis and may lead to development of a new molecular classification system and novel therapies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21289278",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "text": "Point mutations of the NADP(+)-dependent isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) occur early in the pathogenesis of gliomas.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24460285",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 187,
                    "text": "Recent genome wide sequencing has identified mutations in IDH1/IDH2 predominantly in grade II-III gliomas and secondary glioblastomas which are associated with favorable clinical outcome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24460285",
                    "offsetInBeginSection": 188,
                    "offsetInEndSection": 320,
                    "text": "These mutations have become molecular markers of significant diagnostic and prognostic relevance in the assessment of human gliomas.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24460285",
                    "offsetInBeginSection": 1235,
                    "offsetInEndSection": 1403,
                    "text": "Since IDH mutations are associated with good prognosis, their use in routine clinical practice will enable better risk stratification and management of glioma patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36367045",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 223,
                    "text": "Somatic point mutations in the metabolic enzyme isocitrate dehydrogenase (IDH) are a defining feature of the majority of WHO grade 2-3 diffuse glioma and the most powerful positive prognostic factor for survival in gliomas.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the role of Isocitrate dehydrogenase (IDH) mutations in glioma?",
            "type": "summary",
            "id": "662ee24a187cba990d00000d",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22513196",
                "http://www.ncbi.nlm.nih.gov/pubmed/15956652",
                "http://www.ncbi.nlm.nih.gov/pubmed/17144568",
                "http://www.ncbi.nlm.nih.gov/pubmed/17474869",
                "http://www.ncbi.nlm.nih.gov/pubmed/17823383",
                "http://www.ncbi.nlm.nih.gov/pubmed/19169007",
                "http://www.ncbi.nlm.nih.gov/pubmed/12671534",
                "http://www.ncbi.nlm.nih.gov/pubmed/10443950",
                "http://www.ncbi.nlm.nih.gov/pubmed/19234733",
                "http://www.ncbi.nlm.nih.gov/pubmed/21888535"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22513196",
                    "offsetInBeginSection": 1692,
                    "offsetInEndSection": 1806,
                    "text": "Our findings from this meta-analysis suggest that fish consumption is inversely associated with colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22513196",
                    "offsetInBeginSection": 1003,
                    "offsetInEndSection": 1129,
                    "text": "Our analysis found that fish consumption decreased the risk of colorectal cancer by 12% (summary OR, 0.88; 95% CI, 0.80-0.95).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15956652",
                    "offsetInBeginSection": 2213,
                    "offsetInEndSection": 2383,
                    "text": "Our data confirm that colorectal cancer risk is positively associated with high consumption of red and processed meat and support an inverse association with fish intake.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17144568",
                    "offsetInBeginSection": 1574,
                    "offsetInEndSection": 1747,
                    "text": "However, increasing intake of fish/n-3 polyunsaturated fatty acids for preventing colon cancer is suggested from review of experimental and epidemiological research overall.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17474869",
                    "offsetInBeginSection": 1156,
                    "offsetInEndSection": 1221,
                    "text": "Fish intake is negatively associated with colorectal cancer risk.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17823383",
                    "offsetInBeginSection": 1187,
                    "offsetInEndSection": 1275,
                    "text": "In cohort studies, fish consumption was shown to slightly reduce colorectal cancer risk.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19169007",
                    "offsetInBeginSection": 1688,
                    "offsetInEndSection": 1822,
                    "text": "The study results indicate that increased fish intake may have a preventive effect on CRC and modulate the effect of meat consumption.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12671534",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 187,
                    "text": "Several clinical studies have suggested that supplementation with fish oils can suppress the proliferation of colorectal mucosa and therefore inhibit the development of colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10443950",
                    "offsetInBeginSection": 853,
                    "offsetInEndSection": 976,
                    "text": "Clinical studies on markers of colorectal cancer indicate that fish n-3 polyunsaturated fatty acids may reduce cancer risk.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19234733",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 273,
                    "text": "Epidemiological studies suggest that high fish intake is associated with a decreased risk of colorectal cancer which has been linked to the high content of the n-3 polyunsaturated fatty acids (PUFAs) eicosapentaenoic acids (EPA) and docosahexaenoic acid (DHA) in some fish.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is fish intake a protective factor against colorectal cancer?",
            "type": "yesno",
            "id": "66214cc6b9f8b89d7e000003",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22713677",
                "http://www.ncbi.nlm.nih.gov/pubmed/37229681",
                "http://www.ncbi.nlm.nih.gov/pubmed/22199396",
                "http://www.ncbi.nlm.nih.gov/pubmed/29107462",
                "http://www.ncbi.nlm.nih.gov/pubmed/33614387",
                "http://www.ncbi.nlm.nih.gov/pubmed/25199652",
                "http://www.ncbi.nlm.nih.gov/pubmed/36889360",
                "http://www.ncbi.nlm.nih.gov/pubmed/27428889",
                "http://www.ncbi.nlm.nih.gov/pubmed/22740325",
                "http://www.ncbi.nlm.nih.gov/pubmed/33130170"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22713677",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 253,
                    "text": "The 'exposome' represents the accumulation of all environmental exposures across a lifetime. Top-down strategies are required to assess something this comprehensive, and could transform our understanding of how environmental factors affect human health.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37229681",
                    "offsetInBeginSection": 201,
                    "offsetInEndSection": 337,
                    "text": "The role of the exposome is to understand how the totality of an individual's exposures throughout the lifetime can impact human health.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37229681",
                    "offsetInBeginSection": 747,
                    "offsetInEndSection": 1159,
                    "text": "The general external exposome includes measurable population-level exposures such as air pollution or meteorological factors. The specific external exposome includes information on individual exposures, such as lifestyle factors, typically obtained from questionnaires. Meanwhile, the internal exposome encompasses multiple biological responses to external factors, detected through molecular and omics analyses.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22199396",
                    "offsetInBeginSection": 1066,
                    "offsetInEndSection": 1249,
                    "text": "The concept of the 'exposome'-representing the totality of exposures from gestation onwards-has recently been introduced as a complement to the genome in studies of disease aetiology.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37229681",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 200,
                    "text": "The exposome concept arises from the need to integrate different disciplines of public health and environmental sciences, mainly including environmental epidemiology, exposure science, and toxicology.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37229681",
                    "offsetInBeginSection": 609,
                    "offsetInEndSection": 746,
                    "text": "Generally, the exposome is explained through three domains: general external exposome, specific external exposome, and internal exposome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29107462",
                    "offsetInBeginSection": 162,
                    "offsetInEndSection": 365,
                    "text": "Exposome science examines the total accumulated environmental exposures (both detrimental and beneficial) as a means to understand the response of the 'total organism to the total environment' over time.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33614387",
                    "offsetInBeginSection": 460,
                    "offsetInEndSection": 558,
                    "text": "To capture the totality of environmental exposures the concept of the exposome has been developed.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25199652",
                    "offsetInBeginSection": 263,
                    "offsetInEndSection": 446,
                    "text": "The idea that interactions between environment and genetics influence health outcomes is a central concept of the exposome, a measure of environmental exposures throughout a lifetime.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36889360",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 199,
                    "text": "Since the initial development of the exposome concept, much effort has been devoted to the characterisation of the exposome through analytical, epidemiological, and toxicological/mechanistic studies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the exposome?",
            "type": "summary",
            "id": "6616b259fdcbea915f00005a",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35052459",
                "http://www.ncbi.nlm.nih.gov/pubmed/31679626",
                "http://www.ncbi.nlm.nih.gov/pubmed/18288927",
                "http://www.ncbi.nlm.nih.gov/pubmed/17488095",
                "http://www.ncbi.nlm.nih.gov/pubmed/20229235",
                "http://www.ncbi.nlm.nih.gov/pubmed/19536106",
                "http://www.ncbi.nlm.nih.gov/pubmed/19801552",
                "http://www.ncbi.nlm.nih.gov/pubmed/15064719",
                "http://www.ncbi.nlm.nih.gov/pubmed/15923619",
                "http://www.ncbi.nlm.nih.gov/pubmed/28723729"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35052459",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 95,
                    "text": "LRP6 is a member of the low-density lipoprotein receptor superfamily of cell-surface receptors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31679626",
                    "offsetInBeginSection": 137,
                    "offsetInEndSection": 304,
                    "text": "Lipoprotein receptor-related protein 6 (LRP6) is a member of the low-density lipoprotein receptor (LDLR) family composed of structurally related cell surface receptors",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18288927",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 348,
                    "text": "The LDL receptor gene family constitutes a class of structurally closely related cell surface receptors fulfilling diverse functions in different organs, tissues, and cell types. The LDL receptor is the prototype of this family, which also includes the VLDLR, ApoER2/LRP8, LRP1 and LRP1B, as well as Megalin/GP330, SorLA/LR11, LRP5, LRP6 and MEGF7.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17488095",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "Proteins of the low-density lipoprotein receptor family (LRPs) are complex, multimodular type I transmembrane receptors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20229235",
                    "offsetInBeginSection": 146,
                    "offsetInEndSection": 299,
                    "text": "Wnts transduce signals via transmembrane receptors of the Frizzled (Fzd/Fz) family and the low density lipoprotein receptor-related protein 5/6 (Lrp5/6).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19536106",
                    "offsetInBeginSection": 180,
                    "offsetInEndSection": 457,
                    "text": "Binding of Wnt to the Frizzled family of receptors and to low density lipoprotein receptor-related protein 5 (LRP5) or LRP6 co-receptors stimulates the intracellular Wnt-beta-catenin signalling pathway, which regulates beta-cateninstability and context-dependent transcription.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19801552",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 233,
                    "text": "Wnt ligands conduct their functions in canonical Wnt signaling by binding to two receptors, the single transmembrane low density lipoprotein receptor-related proteins 5 and 6 (LRP5/6) and seven transmembrane (7TM) Frizzled receptors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15064719",
                    "offsetInBeginSection": 196,
                    "offsetInEndSection": 419,
                    "text": "The identification of both Frizzled and LRP5/6 (LRP: low-density lipoprotein receptor-related protein) proteins as components of cell-surface receptors for Wnt proteins has raised questions about their individual functions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15923619",
                    "offsetInBeginSection": 214,
                    "offsetInEndSection": 350,
                    "text": "Wnt signaling involves the binding of Wnt ligands to cell surface receptors of the frizzled family and coreceptors of the LRP5/6 family.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28723729",
                    "offsetInBeginSection": 82,
                    "offsetInEndSection": 334,
                    "text": "Complex signals regulating low-density lipoprotein receptor-related protein (LRP) and frizzled protein family members - the plasma membrane receptors for the cadre of Wnt polypeptide morphogens - contribute to the control of cardiovascular homeostasis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "LRP6 is a member of what  superfamily of cell-surface receptors?",
            "type": "factoid",
            "id": "662cfd21187cba990d000009",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20479398",
                "http://www.ncbi.nlm.nih.gov/pubmed/23970477",
                "http://www.ncbi.nlm.nih.gov/pubmed/21931021",
                "http://www.ncbi.nlm.nih.gov/pubmed/31328874",
                "http://www.ncbi.nlm.nih.gov/pubmed/24192697",
                "http://www.ncbi.nlm.nih.gov/pubmed/23438035",
                "http://www.ncbi.nlm.nih.gov/pubmed/27582545",
                "http://www.ncbi.nlm.nih.gov/pubmed/26727948",
                "http://www.ncbi.nlm.nih.gov/pubmed/28792659",
                "http://www.ncbi.nlm.nih.gov/pubmed/35788723"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20479398",
                    "offsetInBeginSection": 643,
                    "offsetInEndSection": 874,
                    "text": "PDGFRA was the predominant target of focal amplification in childhood HGG, including diffuse intrinsic pontine gliomas, and gene expression analyses supported an important role for deregulated PDGFRalpha signaling in pediatric HGG.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23970477",
                    "offsetInBeginSection": 244,
                    "offsetInEndSection": 450,
                    "text": "Genome-wide analyses of copy number imbalances previously showed that platelet-derived growth factor receptor  (PDGFRA) is the most frequent target of focal amplification in pediatric HGGs, including DIPGs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21931021",
                    "offsetInBeginSection": 786,
                    "offsetInEndSection": 977,
                    "text": "Focal amplifications of genes within the receptor tyrosine kinase-Ras-phosphoinositide 3-kinase signaling pathway were found in 47% of DIPGs, the most common of which involved PDGFRA and MET.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31328874",
                    "offsetInBeginSection": 199,
                    "offsetInEndSection": 812,
                    "text": "Genomic studies show that DIPG is driven by somatic mutations to histone H3, either H3.1 or H3.3 variants (HIST1H3B/C and H3F3A), altering the epigenetic landscape of primitive oligodendrocyte or astrocyte precursor cells of the pontine region of the brainstem. Lysine-to-methionine point mutations at amino acid 27 (H3K27M) co-occur with alterations in signaling genes, including the receptor tyrosine kinases (PDGFR/KIT/VEGFR/MET/EGFR), activin A receptor (ACVR1), intracellular kinases (PI3K/AKT/mTOR), cyclin-dependent kinases (CDKs1/4/6), transcriptional regulators (MYCN), and tumor suppressors (PTEN/TP53).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24192697",
                    "offsetInBeginSection": 583,
                    "offsetInEndSection": 797,
                    "text": "Other recently discovered alterations include amplification of components of the receptor tyrosine kinase/Ras/phosphatidylinositol 3-kinase signaling pathway, particularly platelet-derived growth factor receptor A.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23438035",
                    "offsetInBeginSection": 252,
                    "offsetInEndSection": 345,
                    "text": "PDGFRA amplification is common in HGAs, although its prognostic significance remains unclear.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23438035",
                    "offsetInBeginSection": 693,
                    "offsetInEndSection": 773,
                    "text": "PDGFRA amplification was frequent in pediatric (29.3%) and adult (20.9%) tumors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23438035",
                    "offsetInBeginSection": 1030,
                    "offsetInEndSection": 1139,
                    "text": "In HGAs, PDGFRA amplification is common and can manifest as high-level and focal or low-level amplifications.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27582545",
                    "offsetInBeginSection": 132,
                    "offsetInEndSection": 260,
                    "text": "PDGFRA is frequently mutated/ amplified in pediatric HGG, but the significance of this finding has not been fully characterized.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26727948",
                    "offsetInBeginSection": 1398,
                    "offsetInEndSection": 1460,
                    "text": "PDGFRA amplification and mutation were spatially heterogeneous",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Which receptor tyrosine kinase is commonly mutated or amplified in pediatric glioma cases?",
            "type": "factoid",
            "id": "6630390b187cba990d000035",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36158418",
                    "offsetInBeginSection": 1218,
                    "offsetInEndSection": 1469,
                    "text": "At cut-off of 5 mg/dl for CRP and 2.5 ng/dl for PCT1 and PCT3, the sensitivity (36.0%, 25.8%, 100%), specificity (84.1%, 83.3%, 97.5%), positive predictive value (52.2%, 73.9%, 91.3%), and negative predictive values (73.4%, 38.0%, 100%) were observed.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36158418",
                    "offsetInBeginSection": 1481,
                    "offsetInEndSection": 1650,
                    "text": "PCT on Day three of suspected sepsis has higher sensitivity, specificity, and accuracy for prognostication of surgical neonatal sepsis at the cut-off value of 2.5 ng/ml.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36158418",
                    "offsetInBeginSection": 1651,
                    "offsetInEndSection": 1716,
                    "text": "The rising trend of PCT levels is indicative of a poor prognosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34850276",
                    "offsetInBeginSection": 606,
                    "offsetInEndSection": 997,
                    "text": "Deceased patients had a significantly lower postmenstrual age (30 [29-32] vs. 28 [27-30], p = 0.025) and weight (1072 [850-1320] vs. 820 [730-1065], p = 0.016) at the time of LONS diagnosis. Although PCT values were not different between both groups at the time of LONS diagnosis, it was more elevated during the first 24 h in deceased patients (12 [1.1-20.3] vs. 1.57 [0.6-4.1], p = 0.041).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34850276",
                    "offsetInBeginSection": 998,
                    "offsetInEndSection": 1169,
                    "text": "Accuracy of PCT for predicting 60-day mortality in preterm neonates with LONS ranged from 0.70 to 0.82 of area under the curve on receiver operating characteristic curves.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34850276",
                    "offsetInBeginSection": 1327,
                    "offsetInEndSection": 1491,
                    "text": "The estimated survival probability at day 60 was above 95% for patient with a PCT value at sepsis diagnosis under 8.92 g/L and less than 45% if higher (p < 0.0001).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34850276",
                    "offsetInBeginSection": 1492,
                    "offsetInEndSection": 1591,
                    "text": "A PCT value > 8.92 g/L obtained at LONS diagnosis suspicion seems to be a good prognosis biomarker.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31753088",
                    "offsetInBeginSection": 1135,
                    "offsetInEndSection": 1293,
                    "text": "The Cox regression model analysis showed that low ALB, high PCT and high RPR were independent risk factors for the prognosis of children with sepsis (P<0.05).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31753088",
                    "offsetInBeginSection": 1693,
                    "offsetInEndSection": 1885,
                    "text": "RPR on the first day of admission into the PICU is closely associated with the prognosis of children with sepsis and has an important value in predicting the prognosis of children with sepsis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28358790",
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 176,
                    "text": "To investigate the prognostic value of procalcitonin (PCT), high-sensitivity C-reactive protein (hs-CRP), and pancreatic stone protein (PSP) in children with sepsis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Can procalcitonin be used as a predictor for mortality in paediatric sepsis?",
            "type": "yesno",
            "id": "66300c23187cba990d00001a",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22494847",
                "http://www.ncbi.nlm.nih.gov/pubmed/17999367",
                "http://www.ncbi.nlm.nih.gov/pubmed/36270476",
                "http://www.ncbi.nlm.nih.gov/pubmed/23409010",
                "http://www.ncbi.nlm.nih.gov/pubmed/22784623",
                "http://www.ncbi.nlm.nih.gov/pubmed/23325432",
                "http://www.ncbi.nlm.nih.gov/pubmed/26987530",
                "http://www.ncbi.nlm.nih.gov/pubmed/32484849",
                "http://www.ncbi.nlm.nih.gov/pubmed/38086861",
                "http://www.ncbi.nlm.nih.gov/pubmed/33020990"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22494847",
                    "offsetInBeginSection": 300,
                    "offsetInEndSection": 525,
                    "text": "Because DNA methylation is critical in programming gene expression, a change in methylation from a normal to diseased state should be similarly reflected in a signature of DNA methylation that involves multiple gene pathways.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17999367",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "text": "DNA methylation is a heritable modification of genomic DNA central to development, imprinting, transcriptional regulation, chromatin structure, and overall genomic stability.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36270476",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 188,
                    "text": "DNA methylation profiles are in dynamic equilibrium via the initiation of methylation, maintenance of methylation and demethylation, which control gene expression and chromosome stability.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23409010",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 52,
                    "text": "Epigenetic signatures are highly cell type specific.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22784623",
                    "offsetInBeginSection": 774,
                    "offsetInEndSection": 959,
                    "text": "We have identified unique signatures of global DNA methylation for human heart, kidney and liver, and showed that DNA methylation data can be used to correctly classify various tissues.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17999367",
                    "offsetInBeginSection": 1269,
                    "offsetInEndSection": 1411,
                    "text": "Our data suggest that DNA methylation signatures distinguish brain regions and may help account for region-specific functional specialization.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23325432",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 219,
                    "text": "As studies of DNA methylation increase in scope, it has become evident that methylation has a complex relationship with gene expression, plays an important role in defining cell types, and is disrupted in many diseases.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36270476",
                    "offsetInBeginSection": 189,
                    "offsetInEndSection": 372,
                    "text": "Changes in DNA methylation patterns play important roles in carcinogenesis and primarily manifests as hypomethylation of the entire genome and the hypermethylation of individual loci.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26987530",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 106,
                    "text": "Epigenetic biomarkers, such as DNA methylation, can increase cancer risk through altering gene expression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32484849",
                    "offsetInBeginSection": 150,
                    "offsetInEndSection": 261,
                    "text": "DNA methylation is more stable than gene expression and could be used as a biomarker for early tumor diagnosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are episignatures?",
            "type": "factoid",
            "id": "66301e04187cba990d000027",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/33389864",
                "http://www.ncbi.nlm.nih.gov/pubmed/21602308",
                "http://www.ncbi.nlm.nih.gov/pubmed/34148614",
                "http://www.ncbi.nlm.nih.gov/pubmed/36711747",
                "http://www.ncbi.nlm.nih.gov/pubmed/26703651",
                "http://www.ncbi.nlm.nih.gov/pubmed/34193094",
                "http://www.ncbi.nlm.nih.gov/pubmed/31701261",
                "http://www.ncbi.nlm.nih.gov/pubmed/27278956",
                "http://www.ncbi.nlm.nih.gov/pubmed/34568072",
                "http://www.ncbi.nlm.nih.gov/pubmed/37760515"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33389864",
                    "offsetInBeginSection": 186,
                    "offsetInEndSection": 499,
                    "text": "Colorectal cancer (CRC) is one of the leading causes of cancer deaths in the United States and it disproportionately affects the non-Hispanic Black or African American (AA) population. When compared to the non-Hispanic White (nHW) population, incidence and death rates in AAs are 28% and 60% higher, respectively.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21602308",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "text": "Colorectal cancer (CRC) incidence and mortality rates are higher in African-Americans as compared with other racial/ethnic groups.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34148614",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 207,
                    "text": "The occurrence of colorectal cancer (CRC) shows a large disparity among recognized races and ethnicities in the U.S., with Black Americans demonstrating the highest incidence and mortality from this disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36711747",
                    "offsetInBeginSection": 132,
                    "offsetInEndSection": 225,
                    "text": "Black Americans having a higher risk of CRC incidence and mortality compared to other groups.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26703651",
                    "offsetInBeginSection": 145,
                    "offsetInEndSection": 253,
                    "text": "The mortality rate from CRC is highest among African Americans compared to any other racial or ethnic group.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34193094",
                    "offsetInBeginSection": 1012,
                    "offsetInEndSection": 1131,
                    "text": "In 2016, CRC incidence was higher among Blacks (42.5 per 100,000) than Whites (38.0), Latinos (31.7) and Asians (30.0).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31701261",
                    "offsetInBeginSection": 948,
                    "offsetInEndSection": 1040,
                    "text": "CRC incidence was significantly higher in African Americans compared to non-Hispanic whites.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27278956",
                    "offsetInBeginSection": 749,
                    "offsetInEndSection": 920,
                    "text": "CRC age-adjusted incidence is increasing among all three racial groups and was higher for African Americans compared to NHW and API across all years 2000-2012 (P < 0.001).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21602308",
                    "offsetInBeginSection": 833,
                    "offsetInEndSection": 1067,
                    "text": "After a mean follow-up of 10.8 years (SD 2.9), CRC incidence was the highest in African-Americans (annualized rate = 0.14%), followed by Whites and Native Americans (0.12% each), Asian/Pacific Islanders (0.10%), and Hispanics (0.08%).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34568072",
                    "offsetInBeginSection": 1753,
                    "offsetInEndSection": 1854,
                    "text": "Blacks and American Indians/Alaskan Natives have the highest rates of both early- and late-onset CRC.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the race with the highest incidence of colorectal cancer?",
            "type": "factoid",
            "id": "66214c5db9f8b89d7e000002",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16197623",
                "http://www.ncbi.nlm.nih.gov/pubmed/25442812",
                "http://www.ncbi.nlm.nih.gov/pubmed/37336705",
                "http://www.ncbi.nlm.nih.gov/pubmed/32919889",
                "http://www.ncbi.nlm.nih.gov/pubmed/30281700",
                "http://www.ncbi.nlm.nih.gov/pubmed/21208845",
                "http://www.ncbi.nlm.nih.gov/pubmed/29085005",
                "http://www.ncbi.nlm.nih.gov/pubmed/25169487",
                "http://www.ncbi.nlm.nih.gov/pubmed/27670894",
                "http://www.ncbi.nlm.nih.gov/pubmed/29936654"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16197623",
                    "offsetInBeginSection": 2074,
                    "offsetInEndSection": 2184,
                    "text": "However, the benefit of PTR and multiple-agent chemotherapy is questionable in patients with an ECOG PS of >1.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25442812",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 200,
                    "text": "Although chemotherapy is standard for patients with mCRC and ECOG PS of 0/1, the real benefit for patients with ECOG PS > 2 remains uncertain, because they are generally excluded from clinical trials.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25442812",
                    "offsetInBeginSection": 993,
                    "offsetInEndSection": 1127,
                    "text": "Among those with ECOG PS of 3/4, chemotherapy use led to a nonsignificant survival gain (median, 6.8 vs. 2.3 months for BSC; P = .13).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25442812",
                    "offsetInBeginSection": 1677,
                    "offsetInEndSection": 1891,
                    "text": "Our retrospective study suggests that chemotherapy might benefit selected mCRC patients with poor PS. With up-front dose reduction and close monitoring for toxicity, the risk of serious adverse events is minimized.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37336705",
                    "offsetInBeginSection": 1387,
                    "offsetInEndSection": 1668,
                    "text": "In the present study, palliative multiagent chemotherapy in poor performance status patients with non-molecularly selected colorectal cancer tended to impact tumor symptoms control; however, there is no benefit in OS and a considerable risk of toxicity and treatment-related death.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32919889",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 223,
                    "text": "The management of metastatic colorectal cancer patients with a poor performance status (PS) continues to be a clinical dilemma, with the potential activity and safety of treating this population remaining poorly understood.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32919889",
                    "offsetInBeginSection": 1146,
                    "offsetInEndSection": 1242,
                    "text": "Treatment with chemotherapy was associated with longer median overall survival across PS groups.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32919889",
                    "offsetInBeginSection": 1512,
                    "offsetInEndSection": 1682,
                    "text": "In routine clinical care, a substantial proportion of poor and very poor PS patients receive active treatment, which is often associated with meaningful clinical benefit.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30281700",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 405,
                    "text": "Patients with unresectable metastatic colorectal cancer live for a median of three years when treated with standard therapies. While the evidence guiding cancer-directed treatment of this disease comes from phase III trials that have mostly enrolled patients with good performance status, some patients present with poor clinical conditions. The best treatment for these patients remains to be determined.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30281700",
                    "offsetInBeginSection": 1081,
                    "offsetInEndSection": 1302,
                    "text": "Although some studies suggested benefits in terms of symptomatic response with standard chemotherapy, with good safety profiles when dose-reduced regimens were administered, a true survival gain could not be demonstrated.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is chemotherapy an effective treatment for patients with advance colorectal cancer and poor performance status (ECOG/PS >1)",
            "type": "yesno",
            "id": "66215690b9f8b89d7e00000a",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/31575509",
                "http://www.ncbi.nlm.nih.gov/pubmed/23259531",
                "http://www.ncbi.nlm.nih.gov/pubmed/21284856",
                "http://www.ncbi.nlm.nih.gov/pubmed/28710437",
                "http://www.ncbi.nlm.nih.gov/pubmed/32227398",
                "http://www.ncbi.nlm.nih.gov/pubmed/29719620",
                "http://www.ncbi.nlm.nih.gov/pubmed/32379362",
                "http://www.ncbi.nlm.nih.gov/pubmed/28610597",
                "http://www.ncbi.nlm.nih.gov/pubmed/32447983",
                "http://www.ncbi.nlm.nih.gov/pubmed/29860398"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31575509",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 310,
                    "text": "Connective tissue growth factor (CTGF) is a secreted glycoprotein that has a central role in the process of fibrosis. This study was designed to assess the safety, tolerability, and efficacy of pamrevlumab (FG-3019), a fully recombinant human monoclonal antibody against CTGF, in idiopathic pulmonary fibrosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23259531",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 308,
                    "text": "CTGF is a secreted matricellular protein with very complex biology. It has been shown to modulate many signaling pathways leading to cell adhesion and migration, angiogenesis, myofibroblast activation, and extracellular matrix deposition and remodeling, which together lead to tissue remodeling and fibrosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21284856",
                    "offsetInBeginSection": 1502,
                    "offsetInEndSection": 1928,
                    "text": "Thus, FG-3019 antibody treatment consistently reduced excessive collagen deposition and the pathologic severity of fibrosis in all models. Cooperative interactions between CTGF and TGF- signaling are required to elicit overt tissue fibrosis. This interdependence and the observed anti-fibrotic effects of FG-3019 indicate that anti-CTGF therapy may provide therapeutic benefit in different forms of fibroproliferative disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23259531",
                    "offsetInBeginSection": 1118,
                    "offsetInEndSection": 1236,
                    "text": "When considered together, these data indicate that inhibition of CTGF can prevent and reverse the process of fibrosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23259531",
                    "offsetInBeginSection": 523,
                    "offsetInEndSection": 827,
                    "text": "A monoclonal antibody to CTGF that is currently in clinical development (FG-3019) has demonstrated the ability to reverse vascular stiffening and improve cardiac function in a rat model of diabetic complications. FG-3019 has also exhibited activity in a murine radiation-induced pulmonary fibrosis model.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28710437",
                    "offsetInBeginSection": 504,
                    "offsetInEndSection": 640,
                    "text": "FG-3019, an anti-CTGF monoclonal antibody, was used to inhibit CTGF. CG-induced PF was significantly attenuated in FG-3019-treated mice.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28710437",
                    "offsetInBeginSection": 641,
                    "offsetInEndSection": 771,
                    "text": "CG challenges induced marked accumulations of proliferating fibroblasts and of myofibroblasts, which were both reduced by FG-3019.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32227398",
                    "offsetInBeginSection": 1011,
                    "offsetInEndSection": 1231,
                    "text": "Each of these fibrogenic changes was restored to control levels by the blocking of CCN2 signaling in HRHF-Rest/FG-3019 rats, as were HRHF task-induced increases in serum CCN2 and pro-collagen I intact N-terminal protein.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21284856",
                    "offsetInBeginSection": 253,
                    "offsetInEndSection": 1006,
                    "text": "In this study, the importance of CTGF in tissue fibrosis was directly examined in three murine models of fibrotic disease: a novel model of multiorgan fibrosis induced by repeated intraperitoneal injections of CTGF and TGF-2; the unilateral ureteral obstruction (UUO) renal fibrosis model; and an intratracheal bleomycin instillation model of pulmonary fibrosis. Intraperitoneal coadministration of CTGF and TGF-2 elicited a profound fibrotic response that was inhibited by the human anti-CTGF antibody FG-3019, as indicated by the ability of FG-3019 to ameliorate the histologic signs of fibrosis and reduce the otherwise increased hydroxyproline:proline (Hyp:Pro) ratios by 25% in kidney (P < 0.05), 30% in liver (P < 0.01) and 63% in lung (P < 0.05).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28710437",
                    "offsetInBeginSection": 142,
                    "offsetInEndSection": 298,
                    "text": "Connective tissue growth factor (CTGF) is known to regulate fibroblast activities. We therefore examined if CTGF inhibition has anti-fibrotic effects in PF.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "How does Pamrevlumab work?",
            "type": "summary",
            "id": "663027bb187cba990d000033",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36457635",
                "http://www.ncbi.nlm.nih.gov/pubmed/39813",
                "http://www.ncbi.nlm.nih.gov/pubmed/7984332",
                "http://www.ncbi.nlm.nih.gov/pubmed/15534571",
                "http://www.ncbi.nlm.nih.gov/pubmed/12041959",
                "http://www.ncbi.nlm.nih.gov/pubmed/16632785",
                "http://www.ncbi.nlm.nih.gov/pubmed/17056450",
                "http://www.ncbi.nlm.nih.gov/pubmed/7740994",
                "http://www.ncbi.nlm.nih.gov/pubmed/20603091",
                "http://www.ncbi.nlm.nih.gov/pubmed/34461075"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36457635",
                    "offsetInBeginSection": 181,
                    "offsetInEndSection": 439,
                    "text": "For patients who elect to continue IUD use, pain and irregular bleeding are the most commonly reported complications, but more serious and less common complications include expulsion, contraception failure, pelvic inflammatory disease (PID), and perforation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39813",
                    "offsetInBeginSection": 336,
                    "offsetInEndSection": 458,
                    "text": "The risks of IUDs include increased blood loss, uterine perforation, pelvic infection and pregnancy-related complications.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7984332",
                    "offsetInBeginSection": 151,
                    "offsetInEndSection": 304,
                    "text": "The major health risks associated with IUD use are perforation of the uterus, pregnancy (both intrauterine and ectopic), and pelvic inflammatory disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15534571",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "text": "The intrauterine device (IUD) is still related to pelvic inflammatory disease (PID), pregnancy, expulsion, perforation and menstrual problems, particularly in nulliparous women.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12041959",
                    "offsetInBeginSection": 267,
                    "offsetInEndSection": 403,
                    "text": "The main concerns of the use of IUDs are risk of pelvic inflammatory diseases and increased menstrual blood loss and irregular bleeding.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16632785",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 229,
                    "text": "An intrauterine device (IUD) is a highly effective and prevalent form of birth control with a low failure rate. It is not without complications, including irregular bleeding and pelvic pain, perforation, expulsion, and pregnancy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36457635",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "text": "Intrauterine devices (IUDs) are a form of long-acting reversible contraception (LARC). As with all medical therapies, their use carries several risks and potential adverse effects.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17056450",
                    "offsetInBeginSection": 751,
                    "offsetInEndSection": 868,
                    "text": "The possible side effects of IUD use are: pelvic pain, irregular meshes, infections, bleeding and uterine perforation",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7984332",
                    "offsetInBeginSection": 305,
                    "offsetInEndSection": 528,
                    "text": "Perforation of the uterus by an IUD is a serious complication and this is possible both during the insertion and later. Perforation of the uterus is rare, but potentially fatal. The incidence is of 0.12-0.68/1000 insertion.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17056450",
                    "offsetInBeginSection": 487,
                    "offsetInEndSection": 750,
                    "text": "IUD utilization is associated with an increasing risk of pelvic infection (0.5%) in the 8 years from initial use, and the common risk of pelvic inflammatory infection (PID) is about one to two cases per year; this risk, for copper IUD users, is 0.2-0.5% per year.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "List of major risks of intrauterine device.",
            "type": "list",
            "id": "661686e4fdcbea915f000052",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26025658",
                "http://www.ncbi.nlm.nih.gov/pubmed/24987334",
                "http://www.ncbi.nlm.nih.gov/pubmed/35229995",
                "http://www.ncbi.nlm.nih.gov/pubmed/36552331",
                "http://www.ncbi.nlm.nih.gov/pubmed/26171115",
                "http://www.ncbi.nlm.nih.gov/pubmed/33476985",
                "http://www.ncbi.nlm.nih.gov/pubmed/30536948",
                "http://www.ncbi.nlm.nih.gov/pubmed/32784025",
                "http://www.ncbi.nlm.nih.gov/pubmed/25468143",
                "http://www.ncbi.nlm.nih.gov/pubmed/35017413"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26025658",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 247,
                    "text": "Alzheimer's disease is a neurodegenerative disorder characterized by extracellular amyloid plaque deposits, mainly composed of amyloid-beta peptide and intracellular neurofibrillary tangles consisting of aggregated hyperphosphorylated tau protein.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24987334",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 370,
                    "text": "Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by cognitive decline, brain atrophy due to neuronal and synapse loss, and formation of two pathological lesions: extracellular amyloid plaques, composed largely of amyloid-beta peptide (A), and neurofibrillary tangles formed by intracellular aggregates of hyperphosphorylated tau protein.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35229995",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 247,
                    "text": "Alzheimer's disease (AD) is a neurodegenerative disorder. The pathology of AD is characterized by extracellular amyloid beta (A) plaques, neurofibrillary tangles composed of hyperphosphorylated tau, neuronal death, synapse loss, and brain atrophy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36552331",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 197,
                    "text": "Alzheimer's disease (AD), which is characterized by extracellular accumulation of amyloid-beta peptide and intracellular aggregation of hyperphosphorylated tau, is the most common form of dementia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26171115",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 196,
                    "text": "Alzheimer's disease (AD) is the most common form of dementia. The pathological hallmarks of AD are amyloid plaques [aggregates of amyloid-beta (A)] and neurofibrillary tangles (aggregates of tau).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33476985",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 204,
                    "text": "Alzheimer's disease (AD) is the most common form of dementia. The pathological hallmarks of AD are amyloid plaques [aggregates of amyloid beta (A)] and neurofibrillary tangles (aggregates of tau protein).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30536948",
                    "offsetInBeginSection": 110,
                    "offsetInEndSection": 311,
                    "text": "AD is defined neuropathologically by the presence of extracellular plaques of aggregated amyloid  protein and intracellular neurofibrillary tangles (NFTs) of aggregated hyperphosphorylated tau protein.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36552331",
                    "offsetInBeginSection": 198,
                    "offsetInEndSection": 338,
                    "text": "Memory loss, cognitive decline and disorientation are the ultimate consequences of neuronal death, synapse loss and neuroinflammation in AD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32784025",
                    "offsetInBeginSection": 116,
                    "offsetInEndSection": 323,
                    "text": "AD is an age-related neurodegenerative disease with two major hallmarks which includes extracellular amyloid plaques made of amyloid- (A) and intracellular neurofibrillary tangles of hyperphosphorylated tau.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25468143",
                    "offsetInBeginSection": 292,
                    "offsetInEndSection": 492,
                    "text": "Histopathologic features of spAD include (i) extra-cellular cerebral amyloid plaques and intracellular neurofibrillary tangles that embody hyperphosphorylated tau; and (ii) neuronal and synaptic loss.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is Alzheimer's disease?",
            "type": "summary",
            "id": "663014c8187cba990d000020",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35103791",
                "http://www.ncbi.nlm.nih.gov/pubmed/26615375",
                "http://www.ncbi.nlm.nih.gov/pubmed/37923987",
                "http://www.ncbi.nlm.nih.gov/pubmed/31683174",
                "http://www.ncbi.nlm.nih.gov/pubmed/31673654",
                "http://www.ncbi.nlm.nih.gov/pubmed/36072238",
                "http://www.ncbi.nlm.nih.gov/pubmed/31234886",
                "http://www.ncbi.nlm.nih.gov/pubmed/34100244",
                "http://www.ncbi.nlm.nih.gov/pubmed/27984651",
                "http://www.ncbi.nlm.nih.gov/pubmed/30904869"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35103791",
                    "offsetInBeginSection": 1950,
                    "offsetInEndSection": 2115,
                    "text": "These findings suggest that SCRT-TNT followed by TME incurs lower cost and improved QALYs compared with conventional LCCRT followed by TME and adjuvant chemotherapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35103791",
                    "offsetInBeginSection": 2116,
                    "offsetInEndSection": 2265,
                    "text": "These data offer further rationale to support SCRT-TNT as a novel cost-saving treatment paradigm in the management of locally advanced rectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26615375",
                    "offsetInBeginSection": 1068,
                    "offsetInEndSection": 1442,
                    "text": "Short course schedule can be performed carefully in patients with staged rectal cancer without concerning about serious complications. This shorter treatment schedule is cost-effective and would be more convenient for patients due to fewer trips to the hospital and the main treatment, i.e. operating the patient, will be done with the shortest time the following diagnosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37923987",
                    "offsetInBeginSection": 1857,
                    "offsetInEndSection": 2043,
                    "text": "SCRT followed by FOLFOX chemotherapy is expected to improve disease-free survival compared with CRT, with potential advantages in tumor response, quality of life, and cost-effectiveness.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31683174",
                    "offsetInBeginSection": 688,
                    "offsetInEndSection": 935,
                    "text": "SCPRT is highly cost-effective with high compliance rates, hence is gaining traction in Europe and East Asia, partly because of inherent flexibility in timing and the ability to add neoadjuvant systemic chemotherapy as there is a delay to surgery.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31673654",
                    "offsetInBeginSection": 1075,
                    "offsetInEndSection": 1444,
                    "text": "This works adds to the growing evidence that short-course RT is not only equivalent to long-course RT, but also may provide additional benefits, such as allowing for a transition to full dose systemic therapy in the neoadjuvant setting, selective organ preservation in complete responders, and providing a more convenient and cost-effective way of delivering pelvic RT.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36072238",
                    "offsetInBeginSection": 1387,
                    "offsetInEndSection": 1614,
                    "text": "Despite using IMRT/VMAT, SCRT-TNT is a less expensive approach for patients with RC when compared to LCRT. The costs to patients using SCRT-TNT are much lower, but it is also a better option because it saves hospital resources.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31234886",
                    "offsetInBeginSection": 1825,
                    "offsetInEndSection": 2022,
                    "text": "Compared with LCCRT, SCRT plus chemotherapy is a more cost-effective strategy for locally advanced resectable RC in the DFS state as well as in the all states when the cost of PD state below $1920.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34100244",
                    "offsetInBeginSection": 1000,
                    "offsetInEndSection": 1150,
                    "text": "Short-course radiotherapy has proved comparable disease-control outcomes to long-course chemoradiation with a significantly improved cost-performance.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27984651",
                    "offsetInBeginSection": 1879,
                    "offsetInEndSection": 2126,
                    "text": "Further research is necessary to determine whether longer follow-up coupled with the benefits of lower cost, increased patient convenience, and lower acute toxicity will increase the adoption of SC-RT by radiation oncologists in the United States.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is short-course radiation therapy a cost-effective therapy in the neoadjuvant treatment of locally advanced rectal cancer?",
            "type": "yesno",
            "id": "662fbfc4187cba990d000010",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36572586",
                "http://www.ncbi.nlm.nih.gov/pubmed/34197911"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36572586",
                    "offsetInBeginSection": 744,
                    "offsetInEndSection": 1140,
                    "text": "To further investigate DMD pathophysiology, we assessed the genome-wide DNA methylation profiles of peripheral blood from 36 patients with DMD using the combination of Illumina Infinium Methylation EPIC bead chip array and EpiSign technology. We identified a unique episignature for DMD that whose specificity was confirmed in relation other neurodevelopmental disorders with known episignatures.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34197911",
                    "offsetInBeginSection": 941,
                    "offsetInEndSection": 1321,
                    "text": "We also observe a progressive mitochondrial biogenesis impairment associated with increased deacetylation of peroxisome proliferator-activated receptor-gamma coactivator 1  (PGC-1) promoter. Such histone deacetylation is inhibited by givinostat that positively modifies the epigenetic profile of PGC-1 promoter, sustaining mitochondrial biogenesis and oxidative fiber type switch.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Are there any episignatures for Duchenne Muscular Dystrophy?",
            "type": "yesno",
            "id": "66301f5a187cba990d000028",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [],
            "snippets": [],
            "body": "What are the clinical indication for Transarterial Chemoembolization (TACE) in liver metastasis for colorectal cancer?",
            "type": "factoid",
            "id": "662fbec6187cba990d00000f",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24619767",
                "http://www.ncbi.nlm.nih.gov/pubmed/27524897",
                "http://www.ncbi.nlm.nih.gov/pubmed/18667451",
                "http://www.ncbi.nlm.nih.gov/pubmed/37212070",
                "http://www.ncbi.nlm.nih.gov/pubmed/25731937",
                "http://www.ncbi.nlm.nih.gov/pubmed/22332132",
                "http://www.ncbi.nlm.nih.gov/pubmed/23632738",
                "http://www.ncbi.nlm.nih.gov/pubmed/28604599",
                "http://www.ncbi.nlm.nih.gov/pubmed/29042427",
                "http://www.ncbi.nlm.nih.gov/pubmed/37080889"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24619767",
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 286,
                    "text": "Duchenne muscular dystrophy (DMD), the most common and severe type of dystrophinopathy, is a progressive disease affecting primordially skeletal and cardiac muscle. A coordinated multidisciplinary approach is required to address its multisystemic manifestations and secondary problems.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27524897",
                    "offsetInBeginSection": 645,
                    "offsetInEndSection": 991,
                    "text": "Current standard of care includes the use of corticosteroids to prolong ambulation and to delay the onset of secondary complications. Early use of cardioprotective agents, noninvasive positive pressure ventilation, and other supportive strategies has improved the life expectancy and health-related quality of life for many young adults with DMD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24619767",
                    "offsetInBeginSection": 1887,
                    "offsetInEndSection": 2203,
                    "text": "DMD has evolved from a pediatric disease to an adult condition. This underscores the need to prepare adult neurologists for the optimal surveillance and management of patients with a severe chronic disease that have outgrown the pediatric care and that may develop new disease manifestations with improved longevity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27524897",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 283,
                    "text": "Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy in childhood. It is caused by mutations of the DMD gene, leading to progressive muscle weakness, loss of independent ambulation by early teens, and premature death due to cardiorespiratory complications.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18667451",
                    "offsetInBeginSection": 199,
                    "offsetInEndSection": 498,
                    "text": "Improvements in general care, glucocorticoid corticosteroid treatment, non-invasive ventilatory support, and cardiomyopathy and scoliosis management have significantly changed the course of DMD in treated individuals, so that survival into adulthood is now a realistic possibility for most patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24619767",
                    "offsetInBeginSection": 1127,
                    "offsetInEndSection": 1250,
                    "text": "Noninvasive ventilatory support associated with cough assisting techniques has significantly improved the longevity in DMD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24619767",
                    "offsetInBeginSection": 1251,
                    "offsetInEndSection": 1471,
                    "text": "Pharmacologic treatment for cardiac manifestations includes the standard treatments of dilated cardiomyopathy and arrhythmia such as the use of angiotensin converting enzyme (ACE) inhibitors, beta-blockers and diuretics.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24619767",
                    "offsetInBeginSection": 1585,
                    "offsetInEndSection": 1777,
                    "text": "DMD is associated with low bone mineral content, which is aggravated by the use of corticosteroids. The use of biphosphonates can be considered in the treatment of painful vertebral fractures.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37212070",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "text": "In Duchenne muscular dystrophy (DMD), dysphagia is a common but often overlooked symptom, which may affect quality of life (QoL).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25731937",
                    "offsetInBeginSection": 1075,
                    "offsetInEndSection": 1242,
                    "text": "Fatigue, pain, anxiety, and depression, potentially treatable symptoms, occur frequently in adults with DMD and significantly influence health-related quality of life.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are the most common issues that need to be addressed in adults with Duchenne Muscular Dystrophy?",
            "type": "list",
            "id": "66301c47187cba990d000025",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [],
            "snippets": [],
            "body": "What are the minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice?",
            "type": "list",
            "id": "6621506cb9f8b89d7e000007",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22314188",
                "http://www.ncbi.nlm.nih.gov/pubmed/25710585",
                "http://www.ncbi.nlm.nih.gov/pubmed/30592501",
                "http://www.ncbi.nlm.nih.gov/pubmed/16403224",
                "http://www.ncbi.nlm.nih.gov/pubmed/37240418",
                "http://www.ncbi.nlm.nih.gov/pubmed/31094930",
                "http://www.ncbi.nlm.nih.gov/pubmed/34367685",
                "http://www.ncbi.nlm.nih.gov/pubmed/30618001",
                "http://www.ncbi.nlm.nih.gov/pubmed/26681025",
                "http://www.ncbi.nlm.nih.gov/pubmed/25924923"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22314188",
                    "offsetInBeginSection": 1306,
                    "offsetInEndSection": 1500,
                    "text": "BRAF-mutated adenocarcinomas frequently contained areas with mucinous histology (P=0.0002) and signet ring histology (P=0.03), compared with KRAS-mutated and KRAS/BRAF wild-type adenocarcinomas.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22314188",
                    "offsetInBeginSection": 2612,
                    "offsetInEndSection": 2956,
                    "text": "Our results demonstrate that BRAF-mutated proximal colon adenocarcinomas with proficient DNA mismatch repair have a dismal prognosis with an aggressive clinical course and often display mucinous differentiation, focal signet ring histology, and other adverse histologic features such as lymphatic and perineural invasion and high tumor budding.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25710585",
                    "offsetInBeginSection": 1208,
                    "offsetInEndSection": 1426,
                    "text": "Moreover, morphologic features significantly associated with BRAF mutation were: serrated adenocarcinoma subtype, adenocarcinomas with a mucinous component, high histologic grade, pushing margins, stromal inflammation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30592501",
                    "offsetInBeginSection": 681,
                    "offsetInEndSection": 848,
                    "text": "Often BRAF mutated carcinomas demonstrate adverse histological features such as lymphovascular invasion, perineural invasion, tumour budding and lymph node metastases.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16403224",
                    "offsetInBeginSection": 504,
                    "offsetInEndSection": 680,
                    "text": "They were 5-10-fold more frequent in tumors with infiltrating lymphocytes, location in the proximal colon, poor histological grade and mucinous appearance (P < 0.002 for each).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16403224",
                    "offsetInBeginSection": 856,
                    "offsetInEndSection": 1072,
                    "text": "The characteristic morphological features of tumors with BRAF mutation (infiltrating lymphocytes, poor grade, mucinous) remained after stratification according to microsatellite instability and methylator phenotypes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37240418",
                    "offsetInBeginSection": 645,
                    "offsetInEndSection": 911,
                    "text": "The prevalence of BRAF V600E was 6.77%. Female sex, primary in the right colon, high-grade, mucinous, signet cell, partially neuroendocrine histology, perineural and vascular invasion, and surgical tissue sample were factors associated with increased mutation rates.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31094930",
                    "offsetInBeginSection": 821,
                    "offsetInEndSection": 1022,
                    "text": "Most cases (>90%) of TSA-CRCs and BRAF-mut/MSS CRCs exhibited a constellation of serrated morphology, including epithelial serrations, abundant eosinophilic cytoplasm, and discernible/vesicular nuclei.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31094930",
                    "offsetInBeginSection": 1023,
                    "offsetInEndSection": 1103,
                    "text": "A majority (65%) of them qualified for the diagnosis of serrated adenocarcinoma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34367685",
                    "offsetInBeginSection": 1157,
                    "offsetInEndSection": 1327,
                    "text": "Positive BRAF V600E expression was observed in 83.9% of patients. Only histopathological subtypes revealed a significant association with BRAF V600E positive expression (",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What histological features are described in colorectal tumors with BRAF mutation?",
            "type": "list",
            "id": "6621510eb9f8b89d7e000008",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37517630"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37517630",
                    "offsetInBeginSection": 287,
                    "offsetInEndSection": 540,
                    "text": "Several arboviral vaccines have been licensed for many years and can be used to prevent infection in travelers, namely Japanese encephalitis, yellow fever, and tick-borne encephalitis vaccines. Recommendations on use of these vaccines in pregnancy vary.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37517630",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 208,
                    "text": "Pregnant women traveling abroad can be exposed to a variety of arboviruses, primarily spread by mosquitoes or ticks. Some arboviral infections can be of particular concern for pregnant women or their fetuses.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37517630",
                    "offsetInBeginSection": 209,
                    "offsetInEndSection": 286,
                    "text": "Vaccination is one preventive measure that can reduce the risk for infection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37517630",
                    "offsetInBeginSection": 541,
                    "offsetInEndSection": 718,
                    "text": "Other arboviral vaccines have been licensed but are not indicated for use in pregnant travelers (e.g., dengue vaccines) or are in development (e.g., chikungunya, Zika vaccines).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is vaccination against all arboviruses indicated for pregnant women?",
            "type": "yesno",
            "id": "662e44e9187cba990d00000b",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25753522",
                "http://www.ncbi.nlm.nih.gov/pubmed/34290017",
                "http://www.ncbi.nlm.nih.gov/pubmed/32475690",
                "http://www.ncbi.nlm.nih.gov/pubmed/30523303",
                "http://www.ncbi.nlm.nih.gov/pubmed/31079206",
                "http://www.ncbi.nlm.nih.gov/pubmed/28455745",
                "http://www.ncbi.nlm.nih.gov/pubmed/24011172",
                "http://www.ncbi.nlm.nih.gov/pubmed/37372416",
                "http://www.ncbi.nlm.nih.gov/pubmed/34032358",
                "http://www.ncbi.nlm.nih.gov/pubmed/23095811"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25753522",
                    "offsetInBeginSection": 200,
                    "offsetInEndSection": 350,
                    "text": "In humans, there are two types of PKD, autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34290017",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 229,
                    "text": "Polycystic kidney disease (PKD) is a condition typified by multiple renal cysts and renal enlargement. Classification is usually determined by mode of inheritance-autosomal dominant PKD (ADPKD) or autosomal recessive PKD (ARPKD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32475690",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 225,
                    "text": "Polycystic kidney disease (PKD), comprising autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD), is characterized by incessant cyst formation in the kidney and liver.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30523303",
                    "offsetInBeginSection": 93,
                    "offsetInEndSection": 291,
                    "text": "Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD) are cilia-related disorders and the two main forms of monogenic cystic kidney diseases.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31079206",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 158,
                    "text": "Polycystic kidney disease (PKD) is one of the most common genetic renal diseases and may be inherited in an autosomal dominant or autosomal recessive pattern.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28455745",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 258,
                    "text": "Polycystic kidney disease (PKD) encompasses a group of genetic disorders that are common causes of renal failure. The two classic forms of PKD are autosomal recessive polycystic kidney disease (ARPKD) and autosomal dominant polycystic kidney disease (ADPKD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24011172",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 189,
                    "text": "Polycystic kidney diseases (PKD) are a group of monogenic disorders that are inherited dominantly (autosomal dominant PKD; ADPKD) or recessively, including, autosomal recessive PKD (ARPKD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37372416",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 244,
                    "text": "Polycystic Kidney Diseases (PKDs) consist of a genetically and phenotypically heterogeneous group of inherited disorders characterized by numerous renal cysts. PKDs include autosomal dominant ADPKD, autosomal recessive ARPKD and atypical forms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34032358",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 297,
                    "text": "Polycystic kidney disease (PKD) is known to occur in three main forms, namely autosomal dominant PKD (ADPKD), autosomal recessive PKD (ARPKD) and syndromic PKD (SPKD), based on the clinical manifestations and genetic causes, which are diagnosable from the embryo stage to the later stages of life.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23095811",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 323,
                    "text": "Polycystic kidney disease (PKD) is a hereditary disorder with abnormal cellular proliferation, fluid accumulation in numerous cysts, remodeling of extracellular matrix, inflammation, and fibrosis in the kidney and liver. The two major types of PKD show autosomal dominant (ADPKD) or autosomal recessive inheritance (ARPKD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are the types of Polycystic Kidney Disease?",
            "type": "list",
            "id": "661d5fe1eac11fad33000024",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24763611",
                "http://www.ncbi.nlm.nih.gov/pubmed/29137323",
                "http://www.ncbi.nlm.nih.gov/pubmed/28008149",
                "http://www.ncbi.nlm.nih.gov/pubmed/37620408"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24763611",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "text": "Regorafenib, a multikinase inhibitor targeting the Ras/Raf/MEK/ERK pathway, has recently been approved for the treatment of metastatic colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24763611",
                    "offsetInBeginSection": 819,
                    "offsetInEndSection": 1117,
                    "text": "We found that regorafenib treatment induces PUMA in colorectal cancer cells irrespective of p53 status through the NF-B pathway following ERK inhibition and glycogen synthase kinase 3 activation. Upregulation of PUMA is correlated with apoptosis induction in different colorectal cancer cell lines.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24763611",
                    "offsetInBeginSection": 1299,
                    "offsetInEndSection": 1426,
                    "text": "Furthermore, deficiency in PUMA abrogates the in vivo antitumor, antiangiogenic, and chemosensitization effects of regorafenib.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29137323",
                    "offsetInBeginSection": 566,
                    "offsetInEndSection": 687,
                    "text": "In addition, NVP-BKM120 also synergized with 5-Fluorouracil or regorafenib to induce marked apoptosis via PUMA induction.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28008149",
                    "offsetInBeginSection": 684,
                    "offsetInEndSection": 794,
                    "text": "Idelalisib also synergized with 5-FU or regorafenib to induce marked apoptosis via PUMA in colon cancer cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are the mechanisms of action of regorafenib on tumor cells?",
            "type": "list",
            "id": "662fc4b1187cba990d000016",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11177741",
                "http://www.ncbi.nlm.nih.gov/pubmed/21874414",
                "http://www.ncbi.nlm.nih.gov/pubmed/19436196",
                "http://www.ncbi.nlm.nih.gov/pubmed/24256029",
                "http://www.ncbi.nlm.nih.gov/pubmed/15197779",
                "http://www.ncbi.nlm.nih.gov/pubmed/26783196",
                "http://www.ncbi.nlm.nih.gov/pubmed/25522766",
                "http://www.ncbi.nlm.nih.gov/pubmed/16894565",
                "http://www.ncbi.nlm.nih.gov/pubmed/32326511",
                "http://www.ncbi.nlm.nih.gov/pubmed/25198900"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11177741",
                    "offsetInBeginSection": 554,
                    "offsetInEndSection": 700,
                    "text": "Preliminary data suggest that gene expression levels of topoisomerase I, p21, bcl-2, and ICE may be predictive of response to therapy with CPT-11.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21874414",
                    "offsetInBeginSection": 634,
                    "offsetInEndSection": 771,
                    "text": "This article reviews the possibility of assessing Topo I protein expression in tumors as a biological marker for CPT-11 treatment in CRC.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19436196",
                    "offsetInBeginSection": 820,
                    "offsetInEndSection": 985,
                    "text": "The biopsies of the untreated tumour tissue of responding patients showed a significant higher expression of Topo I compared with nonresponding patients (P = 0.015).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19436196",
                    "offsetInBeginSection": 1331,
                    "offsetInEndSection": 1574,
                    "text": "Our data suggest that Topo I expression in rectal tumour mucosa might serve as a predictor of response to the neoadjuvant irinotecan-based chemoradiation, and hence might be a factor contributing to the development of individualized treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24256029",
                    "offsetInBeginSection": 744,
                    "offsetInEndSection": 930,
                    "text": "In univariate logistic regression models, the TOP1 signal count per cell and the TOP1/CEN-20 ratio were associated with objective response, which was evaluated according to RECIST v.1.1.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24256029",
                    "offsetInBeginSection": 1079,
                    "offsetInEndSection": 1243,
                    "text": "A borderline significant association (Odds ratio (OR): 1.62; p = 0.07) between a stepwise increase in the TOP1 signal count and objective response was demonstrated.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24256029",
                    "offsetInBeginSection": 1453,
                    "offsetInEndSection": 1660,
                    "text": "Despite limitations of the study the positive associations between TOP1 and objective response suggest that further analysis in larger tumor material, preferably in a randomized setting, is highly warranted.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15197779",
                    "offsetInBeginSection": 751,
                    "offsetInEndSection": 1118,
                    "text": "Patients with different TS tumour expression showed a similar percentage of Objective Clinical Response, OR (40% vs. 28% of OR in low and high TS-expressing tumours, respectively, p=ns); also, patients with different Topo-I tumour expression did not show a different probability of OR (39% vs. 29% of OR in high and low Topo-I expressing tumours, respectively; p=ns).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15197779",
                    "offsetInBeginSection": 1530,
                    "offsetInEndSection": 1864,
                    "text": "We can conclude that high TS tumour expression seems not to preclude a clinical activity for 5-FU/CPT-11 polichemotherapy in advanced colorectal cancer patients; furthermore, clinical response and prognosis of colorectal cancer patients treated with 5-FU/CPT-11 regimen do not differ in tumours with different TS or Topo-I expression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783196",
                    "offsetInBeginSection": 166,
                    "offsetInEndSection": 314,
                    "text": "It is controversial whether the response to irinotecan could be predicted by the expression level of topoisomerase-I, a direct target of irinotecan.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is tumor expression of Topoisomerase I a biomarker of response to irinotecan in colorectal cancer patients therapy?",
            "type": "yesno",
            "id": "66214f52b9f8b89d7e000005",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27419080",
                "http://www.ncbi.nlm.nih.gov/pubmed/32131740",
                "http://www.ncbi.nlm.nih.gov/pubmed/25179041",
                "http://www.ncbi.nlm.nih.gov/pubmed/36265656",
                "http://www.ncbi.nlm.nih.gov/pubmed/35715206",
                "http://www.ncbi.nlm.nih.gov/pubmed/32626628",
                "http://www.ncbi.nlm.nih.gov/pubmed/32394724",
                "http://www.ncbi.nlm.nih.gov/pubmed/24661739",
                "http://www.ncbi.nlm.nih.gov/pubmed/32485124",
                "http://www.ncbi.nlm.nih.gov/pubmed/26721785"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27419080",
                    "offsetInBeginSection": 93,
                    "offsetInEndSection": 318,
                    "text": "Several intensive care unit studies have demonstrated an association between vitamin D deficiency [25-hydroxyvitamin D (25(OH)D) < 20 ng/mL] and increased hospital length of stay (LOS), readmission rate, sepsis and mortality.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32131740",
                    "offsetInBeginSection": 839,
                    "offsetInEndSection": 954,
                    "text": "Severe vitamin D deficiency may be independently associated with increased mortality in adult patients with sepsis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25179041",
                    "offsetInBeginSection": 870,
                    "offsetInEndSection": 1033,
                    "text": "All-cause 30-day mortality was significantly higher in patients deficient in vitamin D (37% vs 20%; P = .04) and remained higher at 90 days (51% vs 25%, P = .005).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25179041",
                    "offsetInBeginSection": 1034,
                    "offsetInEndSection": 1243,
                    "text": "In multivariate analysis, age (odds ratio, 1.04; 95% CI 1.01-1.07; P = .01) and vitamin D deficiency (odds ratio, 2.7; 95% CI, 1.39-18.8; P = .02) were independently associated with increased 30-day mortality.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25179041",
                    "offsetInBeginSection": 1244,
                    "offsetInEndSection": 1403,
                    "text": "Patients deficient in vitamin D within 30 days of hospital admission for severe sepsis or septic shock may be at increased risk for all-cause 30-day mortality.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36265656",
                    "offsetInBeginSection": 1464,
                    "offsetInEndSection": 1579,
                    "text": "Vitamin D deficiency was prevalent in patients with septic shock visiting the ED and was associated with mortality.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36265656",
                    "offsetInBeginSection": 1012,
                    "offsetInEndSection": 1125,
                    "text": "Mortality was higher in vitamin D deficient patients than in non-deficient patients (31.8% vs. 13.6%, P = 0.004).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36265656",
                    "offsetInBeginSection": 1126,
                    "offsetInEndSection": 1463,
                    "text": "In multivariate analysis, vitamin D deficiency (odds ratio [OR], 2.43; 95 % confidence interval [CI], 1.03-5.74), hyperlactatemia (OR, 3.65; 95 % CI, 1.95-6.83), Sequential Organ Failure Assessment scores (OR, 1.22; 95% CI, 1.09-1.36), and albumin levels (OR, 0.39; 95% CI, 0.21-0.73) were significantly associated with 30-day mortality.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35715206",
                    "offsetInBeginSection": 1142,
                    "offsetInEndSection": 1416,
                    "text": "In a logistic regression accounting for sepsis severity and age-adjusted comorbidities, severe vitamin D deficiency was associated with increased mortality (OR=2.69 (95% CI 1.03 to 7.00), p=0.043), and lower chances of hospital discharge (sub-HR=0.66 (95% CI 0.44 to 0.98)).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35715206",
                    "offsetInBeginSection": 1677,
                    "offsetInEndSection": 1813,
                    "text": "Severe vitamin D deficiency at ED admission is associated with higher mortality and longer hospital stay in patients with severe sepsis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is Vitamin D deficiency associated with sepsis mortality?",
            "type": "yesno",
            "id": "662f401b187cba990d00000e",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/10772412",
                "http://www.ncbi.nlm.nih.gov/pubmed/2483912",
                "http://www.ncbi.nlm.nih.gov/pubmed/24225001",
                "http://www.ncbi.nlm.nih.gov/pubmed/2991145",
                "http://www.ncbi.nlm.nih.gov/pubmed/28378448",
                "http://www.ncbi.nlm.nih.gov/pubmed/3716620",
                "http://www.ncbi.nlm.nih.gov/pubmed/28948490",
                "http://www.ncbi.nlm.nih.gov/pubmed/10407566",
                "http://www.ncbi.nlm.nih.gov/pubmed/27716537",
                "http://www.ncbi.nlm.nih.gov/pubmed/15164248"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10772412",
                    "offsetInBeginSection": 419,
                    "offsetInEndSection": 570,
                    "text": "The highest rates were observed in Western countries, especially in North America, Australasia and, to a lesser extent, in northern and western Europe.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2483912",
                    "offsetInBeginSection": 104,
                    "offsetInEndSection": 365,
                    "text": "Incidence and mortality rates of colorectal cancer vary widely in the world. High rates are characteristic of highly developed countries in North America, northern and western Europe. The lowest rates are found in Asia, Africa and most Latin American countries.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24225001",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 225,
                    "text": "More than 12 million patients are diagnosed with colorectal cancer every year, and more than 600,000 die from the disease. Incidence strongly varies globally and is closely linked to elements of a so-called western lifestyle.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2991145",
                    "offsetInBeginSection": 293,
                    "offsetInEndSection": 423,
                    "text": "Colorectal cancer is common in most countries of North America and Europe, is rare in Asia and is particularly uncommon in Africa.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2991145",
                    "offsetInBeginSection": 424,
                    "offsetInEndSection": 611,
                    "text": "Internationally, the variation in colon cancer is 60-fold, and within Europe there is a 4-fold difference in the incidence of colon cancer between areas with the highest and lowest rates.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28378448",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 106,
                    "text": "New Zealand has among the highest rates of colorectal cancer in the world and is an unscreened population.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3716620",
                    "offsetInBeginSection": 145,
                    "offsetInEndSection": 236,
                    "text": "Switzerland has a typical western pattern of relatively high incidence and mortality rates.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2991145",
                    "offsetInBeginSection": 707,
                    "offsetInEndSection": 857,
                    "text": "Within the United Kingdom, colon cancer is uniformly higher in the 5 Scottish Cancer Registry Regions than in their counterparts in England and Wales.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10772412",
                    "offsetInBeginSection": 991,
                    "offsetInEndSection": 1254,
                    "text": "Examination of time trends during the last decades reveals a sharp increase in incidence of colorectal cancer in Japan and in eastern and southern Europe. On the other hand, incidence rates show some stagnation in North America and western Europe in recent years.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28948490",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 255,
                    "text": "Colorectal cancer (CRC) is the third most common cancer worldwide. CRC has been thought to be less common in Asia compared to Western countries. However, the incidence rates of CRC in Asia are high and there is an increasing trend in the Asian population.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Which countries have a higher incidence of colorectal cancer?",
            "type": "list",
            "id": "66214b9cb9f8b89d7e000001",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24229674"
            ],
            "snippets": [],
            "body": "What are the primary and secondary endpoints of Pamrevlumab?",
            "type": "list",
            "id": "66302978187cba990d000034",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36063655",
                "http://www.ncbi.nlm.nih.gov/pubmed/25628445",
                "http://www.ncbi.nlm.nih.gov/pubmed/33801379",
                "http://www.ncbi.nlm.nih.gov/pubmed/24054705"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36063655",
                    "offsetInBeginSection": 834,
                    "offsetInEndSection": 1029,
                    "text": "At present, the majority of patients display resistance due to alterations in genes related to the EGFR signalling pathway that eventually circumvent EGFR inhibition and allow cancer progression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36063655",
                    "offsetInBeginSection": 584,
                    "offsetInEndSection": 833,
                    "text": "However, the majority of the patients show no benefit from these molecules due to primary mechanisms of resistance, already present before treatment or show disease progression upon the acquisition of drug resistance mechanisms during the treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25628445",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 185,
                    "text": "KRAS and EGFR ectodomain-acquired mutations in patients with metastatic colorectal cancer (mCRC) have been correlated with acquired resistance to anti-EGFR monoclonal antibodies (mAbs).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33801379",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 368,
                    "text": "Epidermal growth factor receptor (EGFR) is one of the anticancer drug targets for certain malignancies, including nonsmall cell lung cancer (NSCLC), colorectal cancer (CRC), and head and neck squamous cell carcinoma. However, the grave issue of drug resistance through diverse mechanisms persists, including secondary EGFR-mutation and its downstream RAS/RAF mutation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24054705",
                    "offsetInBeginSection": 1289,
                    "offsetInEndSection": 1365,
                    "text": "Both primary and secondary KRAS mutations in CRC abrogate mAb effectiveness.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25628445",
                    "offsetInBeginSection": 1410,
                    "offsetInEndSection": 1680,
                    "text": "Newly detected KRAS and/or EGFR mutations in plasma ctDNA from patients refractory to anti-EGFR treatment appear to derive from rare, pre-existing clones in the primary tumors. These rare clones were associated with shorter PFS in patients receiving anti-EGFR treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25628445",
                    "offsetInBeginSection": 1681,
                    "offsetInEndSection": 1956,
                    "text": "Multiple simultaneous mutations in KRAS and EGFR in the ctDNA and the decline in allele frequency after discontinuation of anti-EGFR therapy in a subset of patients suggest that several resistance mechanisms can co-exist and that relative clonal burdens may change over time.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24054705",
                    "offsetInBeginSection": 1366,
                    "offsetInEndSection": 1467,
                    "text": "Several targets, including MET, BRAF, and PI3K, may serve useful in combination with anti-EGFR drugs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24054705",
                    "offsetInBeginSection": 1645,
                    "offsetInEndSection": 1789,
                    "text": "However, resistance mechanisms suggest that combination therapies or multitargeted agents will be crucial in making significant future advances.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33801379",
                    "offsetInBeginSection": 369,
                    "offsetInEndSection": 649,
                    "text": "Since the discovery of the role of human epidermal growth factor receptor 2 (HER2) and HER3 in drug resistance, HER2- or HER3-targeting treatment strategies using monoclonal antibodies have been intensively examined and have demonstrated impressive responsiveness and limitations.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are the mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment?",
            "type": "list",
            "id": "66099ac8fdcbea915f00001f",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36513805"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36513805",
                    "offsetInBeginSection": 58,
                    "offsetInEndSection": 248,
                    "text": "We assessed the utility of a validated pediatric prognostic tool called PERSEVERE II that uses decision tree methodology to predict mortality at discharge in neonates who experienced sepsis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36513805",
                    "offsetInBeginSection": 1003,
                    "offsetInEndSection": 1106,
                    "text": "IL-8 and nPERSEVERE demonstrated good prognostic performance in a small cohort of neonates with sepsis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36513805",
                    "offsetInBeginSection": 456,
                    "offsetInEndSection": 585,
                    "text": "In a cohort of 59 neonates with a mortality rate of 15.3%, PERSEVERE II was 67% sensitive and 59% specific for mortality, p 0.27.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Can the neonatal Pediatric Sepsis Biomarker Risk Model (nPERSEVERE) accurately predict mortality in neonatal sepsis?",
            "type": "yesno",
            "id": "661d19d5eac11fad33000007",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/31784301",
                "http://www.ncbi.nlm.nih.gov/pubmed/18843026",
                "http://www.ncbi.nlm.nih.gov/pubmed/10511318",
                "http://www.ncbi.nlm.nih.gov/pubmed/12708719",
                "http://www.ncbi.nlm.nih.gov/pubmed/16236494",
                "http://www.ncbi.nlm.nih.gov/pubmed/17215380",
                "http://www.ncbi.nlm.nih.gov/pubmed/8827015",
                "http://www.ncbi.nlm.nih.gov/pubmed/25773805",
                "http://www.ncbi.nlm.nih.gov/pubmed/8922297",
                "http://www.ncbi.nlm.nih.gov/pubmed/19116876"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31784301",
                    "offsetInBeginSection": 1016,
                    "offsetInEndSection": 1198,
                    "text": "The CRC incidence was decreased by circulating 25(OH)D (RR: 0.67, 95% CI: 0.59-0.77), vitamin D intake (RR: 0.85, 95% CI: 0.78-0.93) and calcium intake (RR: 0.75, 95% CI: 0.70-0.79).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31784301",
                    "offsetInBeginSection": 1881,
                    "offsetInEndSection": 2006,
                    "text": "A significant dose-response relationship was observed between intake of vitamin D or calcium and colorectal tumour incidence.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31784301",
                    "offsetInBeginSection": 2007,
                    "offsetInEndSection": 2191,
                    "text": "Vitamin D and calcium play additively chemopreventive roles in colorectal adenoma incidence, malignant transformation and progression, especially for women and left-sided CRC patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18843026",
                    "offsetInBeginSection": 564,
                    "offsetInEndSection": 859,
                    "text": "In a multivariate analysis adjusting for potential confounding variables, calcium intake was significantly, inversely associated with colorectal cancer risk (P for trend=0.01); the odds ratio for the highest versus lowest quintile of calcium intake was 0.64 (95% confidence interval, 0.45-0.93).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18843026",
                    "offsetInBeginSection": 1394,
                    "offsetInEndSection": 1514,
                    "text": "These results add to support for a joint action of calcium and vitamin D in the prevention of colorectal carcinogenesis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10511318",
                    "offsetInBeginSection": 1637,
                    "offsetInEndSection": 1816,
                    "text": "These combined data suggest that administration of supplemental calcium or low-fat dairy foods may have a significant effect upon colonic polyp and perhaps colon cancer incidence.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12708719",
                    "offsetInBeginSection": 1323,
                    "offsetInEndSection": 1414,
                    "text": "Our results support the hypothesis that calcium modestly reduces risk of colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16236494",
                    "offsetInBeginSection": 615,
                    "offsetInEndSection": 817,
                    "text": "Overall, individuals with >or=1000IU/day oral Vitamin D (p<0.0001) or >or=33ng/ml (82nmol/l) serum 25-hydroxyvitamin D (p<0.01) had 50% lower incidence of colorectal cancer compared to reference values.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16236494",
                    "offsetInBeginSection": 818,
                    "offsetInEndSection": 964,
                    "text": "Intake of 1000IU/day of Vitamin D, half the safe upper intake established by the National Academy of Sciences, was associated with 50% lower risk.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17215380",
                    "offsetInBeginSection": 1179,
                    "offsetInEndSection": 1311,
                    "text": "The findings support the hypothesis of protective roles for calcium, vitamin D, and dairy products in the risk of colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Can calcium dietary supplementation reduce the risk of colorectal cancer?",
            "type": "yesno",
            "id": "662fc0bc187cba990d000011",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36440509",
                "http://www.ncbi.nlm.nih.gov/pubmed/24100172",
                "http://www.ncbi.nlm.nih.gov/pubmed/23465656",
                "http://www.ncbi.nlm.nih.gov/pubmed/7981593",
                "http://www.ncbi.nlm.nih.gov/pubmed/25937795",
                "http://www.ncbi.nlm.nih.gov/pubmed/22386707",
                "http://www.ncbi.nlm.nih.gov/pubmed/8872469",
                "http://www.ncbi.nlm.nih.gov/pubmed/24279481",
                "http://www.ncbi.nlm.nih.gov/pubmed/3248768",
                "http://www.ncbi.nlm.nih.gov/pubmed/29306518"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36440509",
                    "offsetInBeginSection": 1136,
                    "offsetInEndSection": 1284,
                    "text": "The global prevalence of intellectual developmental disorder (IDD) was 8% in Becker muscular dystrophy and 22% in Duchenne muscular dystrophy (DMD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36440509",
                    "offsetInBeginSection": 655,
                    "offsetInEndSection": 765,
                    "text": "The prevalence of IDD in BMD was 8.0% (95% confidence interval 5.0-11.0), and in DMD it was 22.0% (18.0-27.0).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24100172",
                    "offsetInBeginSection": 1395,
                    "offsetInEndSection": 1504,
                    "text": "Almost half of the patients show cognitive impairment (26% learning disability, 17% intellectual disability).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23465656",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 114,
                    "text": "Cognitive and behavioral difficulties occur in approximately a third of patients with Duchenne muscular dystrophy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36440509",
                    "offsetInBeginSection": 1285,
                    "offsetInEndSection": 1369,
                    "text": "The global prevalence of IDD in DMD was 12%, 29%, and 84% in participants with Dp427",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7981593",
                    "offsetInBeginSection": 122,
                    "offsetInEndSection": 307,
                    "text": "General intelligence assessment showed 31% of patients with Wechsler full intelligence quotient (FIQ) lower than 75 (normal values: 100 +/- 14), and only 24% with appropriate FIQ level.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25937795",
                    "offsetInBeginSection": 744,
                    "offsetInEndSection": 934,
                    "text": "In 37 patients with an estimated full scale intelligence quotient (FSIQ), six (16.22%) had borderline intelligence (70<FSIQ 85), while seven (18.92%) were intellectually impaired (FSIQ <70).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22386707",
                    "offsetInBeginSection": 660,
                    "offsetInEndSection": 712,
                    "text": "Thirty-seven percent displayed cognitive impairment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8872469",
                    "offsetInBeginSection": 87,
                    "offsetInEndSection": 173,
                    "text": "A significant proportion of DMD affected children suffer also from mental retardation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24279481",
                    "offsetInBeginSection": 113,
                    "offsetInEndSection": 284,
                    "text": "DMD is a fatal X-linked recessive disorder with an estimated prevalence of 1 in 3,500 male live births. This disease has long been associated with intellectual impairment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the prevalence of intellectual developmental disorders in Duchenne Muscular Dystrophy?",
            "type": "factoid",
            "id": "66300ee7187cba990d00001c",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19055515",
                "http://www.ncbi.nlm.nih.gov/pubmed/19211452",
                "http://www.ncbi.nlm.nih.gov/pubmed/29137605",
                "http://www.ncbi.nlm.nih.gov/pubmed/14757613",
                "http://www.ncbi.nlm.nih.gov/pubmed/15054679",
                "http://www.ncbi.nlm.nih.gov/pubmed/22084361",
                "http://www.ncbi.nlm.nih.gov/pubmed/20496537",
                "http://www.ncbi.nlm.nih.gov/pubmed/26369678",
                "http://www.ncbi.nlm.nih.gov/pubmed/37756582",
                "http://www.ncbi.nlm.nih.gov/pubmed/26404953"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19055515",
                    "offsetInBeginSection": 888,
                    "offsetInEndSection": 1227,
                    "text": "We found that the relative risks of any adenoma (when compared with the placebo group) were 0.859 in the high dose of aspirin groups (95% confidence interval (CI), 0.756-0.976, P = 0.019), 0.826 in the low dose of aspirin groups (95% CI 0.706-0.965, P = 0.016) and 0.836 in the both aspirin combined groups (95% CI 0.746-0.937, P = 0.002).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19055515",
                    "offsetInBeginSection": 1419,
                    "offsetInEndSection": 1552,
                    "text": "This meta-analysis suggests that aspirin prevents recurrent colorectal adenomas among patients with a history of colorectal adenomas.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19211452",
                    "offsetInBeginSection": 2016,
                    "offsetInEndSection": 2126,
                    "text": "Aspirin is effective for the prevention of colorectal adenomas in individuals with a history of these lesions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29137605",
                    "offsetInBeginSection": 977,
                    "offsetInEndSection": 1242,
                    "text": "In patients with a previous history of colorectal cancer or adenomas, low-dose aspirin (80-160 mg/day) compared to placebo taken for 2 to 4 years reduces the risk of recurrent colorectal adenomas (relative risk (RR), 0.80 [95% CI (confidence interval), 0.70-0.92]).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14757613",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "text": "Randomized, double-blind, placebo-controlled trials have established that regular aspirin use reduces the risk for recurrent colorectal adenoma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15054679",
                    "offsetInBeginSection": 874,
                    "offsetInEndSection": 1179,
                    "text": "From the combined results of three trials, significantly fewer patients in the aspirin group developed recurrent sporadic colorectal adenomas (relative risk, 0.77 (95 percent confidence interval, 0.61, 0.96), number needed to treat 12.5 (95 percent confidence interval, 7.7, 25)) after one to three years.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15054679",
                    "offsetInBeginSection": 1579,
                    "offsetInEndSection": 1716,
                    "text": "There is combined evidence from three randomized trials that aspirin significantly reduced the recurrence of sporadic adenomatous polyps.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22084361",
                    "offsetInBeginSection": 568,
                    "offsetInEndSection": 803,
                    "text": "A separate metaanalysis of nearly 3,000 patients with a history of colorectal adenoma or cancer in four randomized adenoma prevention trials showed that aspirin reduced the occurrence of advanced adenomas by 28% and any adenoma by 17%.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20496537",
                    "offsetInBeginSection": 313,
                    "offsetInEndSection": 492,
                    "text": "Aspirin is the best studied chemopreventive agent for CRC, with randomized trials demonstrating its efficacy in reducing recurrence of colorectal adenomas in higher risk patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26369678",
                    "offsetInBeginSection": 440,
                    "offsetInEndSection": 687,
                    "text": "Moreover, prospective randomized controlled trials of colorectal polyp recurrence and in patients with hereditary CRC syndromes have shown that aspirin can produce regression of existing colorectal adenomas and prevent the formation of new polyps.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is treatment with acetyl salicylic acid indicated to prevent colorectal adenomas?",
            "type": "yesno",
            "id": "660999bffdcbea915f00001b",
            "ideal_answer": "",
            "exact_answer": ""
        }
    ]
}